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comes will constitute the primary basis for preparing recom-
mendations in these guidelines.
The ACC/AHA Task Force on Practice Guidelines makes
every effort to avoid any actual, potential, or perceived con-
flicts of interest that might arise as a result of an outside rela-
tionship or personal interest of a member of the writing com-
mittee. Specifically, all members of the writing committee,
as well as peer reviewers of the document, are asked to pro-
vide disclosure statements of all such relationships that
might be perceived as real or potential conflicts of interest.
These statements are reviewed by the parent task force,
reported orally to all members of the writing panel at each
meeting, and updated and reviewed by the writing commit-
tee as changes occur. Please see Appendix I for author rela-
tionships with industry and Appendix II for peer reviewer
relationships with industry.
The practice guidelines produced are intended to assist
healthcare providers in clinical decision making by describ-
ing a range of generally acceptable approaches for the diag-
nosis, management, or prevention of specific diseases or
conditions. These guidelines attempt to define practices that
meet the needs of most patients in most circumstances. These
guideline recommendations reflect a consensus of expert
opinion after a thorough review of the available, current sci-
entific evidence and are intended to improve patient care. If
these guidelines are used as the basis for regulatory/payer
decisions, the ultimate goal is quality of care and serving the
patient’s best interests. The ultimate judgment regarding care
of a particular patient must be made by the healthcare
provider and patient in light of all of the circumstances pre-
sented by that patient. 
These guidelines were approved for publication by the gov-
erning bodies of the ACC and the AHA and have been offi-
cially endorsed by the American College of Chest
Physicians, the International Society for Heart and Lung
Transplantation, and the Heart Rhythm Society. The guide-
lines will be reviewed annually by the ACC/AHA Task Force
on Practice Guidelines and will be considered current unless
they are updated, revised, or withdrawn from publication.
The summary article including recommendations is pub-
lished in the September 20, 2005 issues of both the Journal
of the American College of Cardiology and Circulation. The
full-text guideline is posted on the World Wide Web sites of
the ACC (www.acc.org) and the AHA (www.my.american-
heart.org). Copies of the full text and the summary article are
available from both organizations. 
Elliott M. Antman, MD, FACC, FAHA
Chair, ACC/AHA Task Force on Practice Guidelines
1. INTRODUCTION
Heart failure (HF) is a major and growing public health prob-
lem in the United States. Approximately 5 million patients in
this country have HF, and over 550 000 patients are diag-
nosed with HF for the first time each year (1). The disorder
is the primary reason for 12 to 15 million office visits and 6.5
million hospital days each year (2). From 1990 to 1999, the
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PREAMBLE
It is important that the medical profession play a significant
role in critically evaluating the use of diagnostic procedures
and therapies as they are introduced and tested in the detec-
tion, management, or prevention of disease states. Rigorous
and expert analysis of the available data documenting rela-
tive benefits and risks of those procedures and therapies can
produce helpful guidelines that improve the effectiveness of
care, optimize patient outcomes, and favorably affect the
overall cost of care by focusing resources on the most effec-
tive strategies. 
The American College of Cardiology (ACC) and the
American Heart Association (AHA) have jointly engaged in
the production of such guidelines in the area of cardiovascu-
lar disease since 1980. This effort is directed by the
ACC/AHA Task Force on Practice Guidelines, whose charge
is to develop and revise practice guidelines for important car-
diovascular diseases and procedures. Experts in the subject
under consideration are selected from both organizations and
charged with examining subject-specific data and writing or
updating these guidelines. The process includes additional
representatives from other medical practitioner and specialty
groups where appropriate. Writing groups are specifically
charged to perform a formal literature review, weigh the
strength of evidence for or against a particular treatment or
procedure, and include estimates of expected health out-
comes where data exist. Patient-specific modifiers, comor-
bidities, and issues of patient preference that might influence
the choice of particular tests or therapies are considered, as
are frequency of follow-up and cost-effectiveness. When
available, information from studies on cost will be consid-
ered; however, review of data on efficacy and clinical out-
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annual number of hospitalizations has increased from
approximately 810 000 to over 1 million for HF as a primary
diagnosis and from 2.4 to 3.6 million for HF as a primary or
secondary diagnosis (3). In 2001, nearly 53000 patients died
of HF as a primary cause. The number of HF deaths has
increased steadily despite advances in treatment, in part
because of increasing numbers of patients with HF due to
better treatment and “salvage” of patients with acute myocar-
dial infarctions (MIs) earlier in life (1). 
Heart failure is primarily a condition of the elderly (4), and
thus the widely recognized “aging of the population” also
contributes to the increasing incidence of HF. The incidence
of HF approaches 10 per 1000 population after age 65 (1),
and approximately 80% of patients hospitalized with HF are
more than 65 years old (5). Heart failure is the most common
Medicare diagnosis-related group (i.e., hospital discharge
diagnosis), and more Medicare dollars are spent for the diag-
nosis and treatment of HF than for any other diagnosis (6). It
has been estimated that in 2005, the total direct and indirect
cost of HF in the US will be equal to $27.9 billion (1).
The ACC and the AHA first published guidelines for the
evaluation and management of HF in 1995 and published
revised guidelines in 2001 (7). Since that time, a great deal
of progress has been made in the development of both phar-
macological and nonpharmacological approaches to treat-
ment for this common, costly, disabling, and potentially fatal
disorder. The number of available treatments has increased,
but this increase has rendered clinical decision making far
more complex. The timing and sequence of initiating treat-
ments and the appropriateness of prescribing them in combi-
nation are uncertain. The increasing recognition of the exis-
tence of clinical HF in patients with a normal ejection frac-
tion (EF) (see Section 4.3.2.1) has also led to heightened
awareness of the limitations of evidence-based therapy for
this important group of patients. For these reasons, the 2
organizations believed that it was appropriate to reassess and
update these guidelines, fully recognizing that the optimal
therapy of HF remains a work in progress and that future
advances will require that the guideline be updated again. 
The writing committee was composed of 15 members who
represented the ACC and AHA, as well as invited partici-
pants from the American College of Chest Physicians, the
Heart Failure Society of America, the International Society
for Heart and Lung Transplantation, the American Academy
of Family Physicians, and the American College of
Physicians. Both the academic and private practice sectors
were represented. This document was reviewed by 3 official
reviewers nominated by the ACC, 3 official reviewers nomi-
nated by the AHA, 1 reviewer nominated by the American
Academy of Family Physicians, 2 reviewers nominated by
the American College of Chest Physicians, 1 reviewer nom-
inated by the American College of Physicians, 4 reviewers
nominated by the Heart Failure Society of America, and 1
reviewer nominated by the International Society for Heart
and Lung Transplantation. In addition, 9 content reviewers
and the following committees reviewed the document:
ACC/AHA Committee to Develop Performance Measures
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for Heart Failure, ACC/AHA Committee to Revise
Guidelines for the Management of Patients With Acute
Myocardial Infarction, ACC/AHA/ESC Committee to
Update Guidelines on the Management of Patients with
Atrial Fibrillation, ACC/AHA Committee to Update
Guidelines on Coronary Artery Bypass Graft Surgery, ACC
Committee to Develop Data Standards on Heart Failure,
AHA Quality of Care and Outcomes Research
Interdisciplinary Working Group Steering Committee, and
AHA Council on Clinical Cardiology Committee on Heart
Failure and Transplantation.
The full-text guidelines are available in 2 versions on the
ACC and AHA Web sites: a version that highlights the
change in recommendations (i.e., deleted text is struck
through; new text is underlined) from the 2001 guideline to
the 2005 guideline and a “clean” version that incorporates all
changes in the recommendations. (The “track changes” ver-
sion only highlights changes to the recommendations; it does
not show changes to supporting text, tables, or figures.) 
In formulating the 2001 document, the writing committee
developed a new approach to the classification of HF, one
that emphasized both the development and progression of the
disease. In doing so, the 2001 document identified 4 stages
involved in the development of the HF syndrome. The first 2
stages (A and B) are clearly not HF but are an attempt to help
healthcare providers with the early identification of patients
who are at risk for developing HF. Stages A and B patients
are best defined as those with risk factors that clearly predis-
pose toward the development of HF. For example, patients
with coronary artery disease, hypertension, or diabetes mel-
litus who do not yet demonstrate impaired left ventricular
(LV) function, hypertrophy, or geometric chamber distortion
would be considered Stage A, whereas patients who are
asymptomatic but demonstrate LV hypertrophy (LVH)
and/or impaired LV function would be designated as Stage B.
Stage C then denotes patients with current or past symptoms
of HF associated with underlying structural heart disease (the
bulk of patients with HF), and Stage D designates patients
with truly refractory HF who might be eligible for special-
ized, advanced treatment strategies, such as mechanical cir-
culatory support, procedures to facilitate fluid removal, con-
tinuous inotropic infusions, or cardiac transplantation or
other innovative or experimental surgical procedures, or for
end-of-life care, such as hospice.
This classification recognizes that there are established risk
factors and structural prerequisites for the development of
HF and that therapeutic interventions introduced even before
the appearance of LV dysfunction or symptoms can reduce
the population morbidity and mortality of HF. This classifi-
cation system is intended to complement but in no way to
replace the New York Heart Association (NYHA) functional
classification, which primarily gauges the severity of symp-
toms in patients who are in Stage C or Stage D. It has been
recognized for many years that the NYHA functional classi-
fication reflects a subjective assessment by a healthcare
provider and can change frequently over short periods of
time. It has also been recognized that the treatments used
e4
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and a manual search of selected articles. References selected
and published in this document are representative but not all-
inclusive. Recommendations relevant to a class of drugs
specify the use of the drugs shown to be effective in clinical
trials unless there is reason to believe that such drugs have a
broad class effect.
The committee elected to focus this document on the pre-
vention of HF and on the diagnosis and management of
chronic HF in the adult patient with normal or low LVEF. It
specifically did not consider acute HF, which might merit a
separate set of guidelines and is addressed in part in the
ACC/AHA Guidelines for the Management of Patients With
ST-Elevation Myocardial Infarction (8) and the ACC/AHA
2003 Update of the Guidelines for the Management of
Unstable Angina and Non-ST Elevation Myocardial
Infarction (9). We have also excluded HF in children, both
because the underlying causes of HF in children differ from
those in adults and because none of the controlled trials of
treatments for HF have included children. We have not con-
sidered the management of HF due to primary valvular dis-
ease [see ACC/AHA Guidelines on the Management of
Patients With Valvular Heart Disease (10)] or congenital
malformations, and we have not included recommendations
for the treatment of specific myocardial disorders (e.g.,
hemochromatosis, sarcoidosis, or amyloidosis). 
These practice guidelines are intended to assist healthcare
providers in clinical decision making by describing a range
of generally acceptable approaches for the prevention, diag-
nosis, and management of HF. The guidelines attempt to
define practices that meet the needs of most patients under
most circumstances. However, the ultimate judgment regard-
ing the care of a particular patient must be made by the
healthcare provider in light of all of the circumstances that
are relevant to that patient. These guidelines do not address
cost-effectiveness from a societal perspective. The guide-
lines are not meant to assist policy makers faced with the
necessity to make decisions regarding the allocation of finite
healthcare resources. In fact, these guidelines assume no
resource limitation. They do not provide policy makers with
sufficient information to be able to choose wisely between
options for resource allocation. The various therapeutic
strategies described in this document can be viewed as a
checklist to be considered for each patient in an attempt to
individualize treatment for an evolving disease process.
Every patient is unique, not only in terms of his or her cause
and course of HF, but also in terms of his or her personal and
cultural approach to the disease. Guidelines can only provide
an outline for evidence-based decisions or recommendations
for individual care; these guidelines are meant to provide that
outline. 
2. CHARACTERIZATION OF HF AS A
CLINICAL SYNDROME
2.1. Definition of HF
Heart failure is a complex clinical syndrome that can result
from any structural or functional cardiac disorder that
may not differ significantly across the classes. Therefore, the
committee believed that a staging system was needed that
would reliably and objectively identify patients during the
course of their developing disease and that would be linked
to treatments uniquely appropriate at each stage of illness.
According to this new staging approach, patients would only
be expected to either not advance at all or to advance from
one stage to the next, unless progression of the disease was
slowed or stopped by treatment, and spontaneous reversal of
this progression would be considered unusual. For instance,
although symptoms (NYHA class) might vary widely over
time (in response to therapy or to progression of disease) in
a patient who has already developed the clinical syndrome of
HF (Stage C), the patient could never return to Stage B
(never had HF), and therapies recommended for Stage C will
be appropriate even if this patient is in NYHA class I. This
new classification scheme adds a useful dimension to our
thinking about HF that is similar to that achieved by staging
or risk assessment systems for other disorders (e.g., those
used in the approach to cancer).
Classification of Recommendations and Level of Evidence
are expressed in the ACC/AHA format as follows and
described in more detail in Table 1.
Classification of Recommendations
Class I: Conditions for which there is evidence and/or
general agreement that a given procedure or
treatment is beneficial, useful, and effective.
Class II: Conditions for which there is conflicting evi-
dence and/or a divergence of opinion about
the usefulness/efficacy of a procedure or treat-
ment.
Class IIa: Weight of evidence/opinion is in
favor of usefulness/efficacy.
Class IIb: Usefulness/efficacy is less well
established by evidence/opinion.
Class III: Conditions for which there is evidence and/or
general agreement that a procedure/treat-
ment is not useful/effective and in some cases
may be harmful.
Level of Evidence
• Level of Evidence A: Data derived from multiple random-
ized clinical trials or meta-analyses.
• Level of Evidence B: Data derived from a single random-
ized trial, or nonrandomized studies.
• Level of Evidence C: Only consensus opinion of experts,
case studies, or standard-of-care.
The recommendations listed in this document are evidence-
based whenever possible. Pertinent medical literature in the
English language was identified through a series of comput-
erized literature searches (including Medline and EMBASE)
e5
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impairs the ability of the ventricle to fill with or eject blood.
The cardinal manifestations of HF are dyspnea and fatigue,
which may limit exercise tolerance, and fluid retention,
which may lead to pulmonary congestion and peripheral
edema. Both abnormalities can impair the functional capaci-
ty and quality of life of affected individuals, but they do not
necessarily dominate the clinical picture at the same time.
Some patients have exercise intolerance but little evidence of
fluid retention, whereas others complain primarily of edema
and report few symptoms of dyspnea or fatigue. Because not
all patients have volume overload at the time of initial or sub-
sequent evaluation, the term “heart failure” is preferred over
the older term “congestive heart failure.”
The clinical syndrome of HF may result from disorders of
the pericardium, myocardium, endocardium, or great vessels,
but the majority of patients with HF have symptoms due to
an impairment of LV myocardial function. Heart failure may
be associated with a wide spectrum of LV functional abnor-
malities, which may range from patients with normal LV size
and preserved EF to those with severe dilatation and/or
markedly reduced EF. In most patients, abnormalities of sys-
tolic and diastolic dysfunction coexist, regardless of EF.
Patients with normal EF may have a different natural history
and may require different treatment strategies than patients
with reduced EF, although such differences remain contro-
versial (see Section 4.3.2.1). 
Coronary artery disease, hypertension, and dilated car-
diomyopathy are the causes of HF in a substantial proportion
of patients in the Western world. As many as 30% of patients
with dilated cardiomyopathy may have a genetic cause (11).
Valvular heart disease is still a common cause of HF. In fact,
nearly any form of heart disease may ultimately lead to the
HF syndrome. 
It should be emphasized that HF is not equivalent to car-
diomyopathy or to LV dysfunction; these latter terms
describe possible structural or functional reasons for the
development of HF. Instead, HF is defined as a clinical syn-
drome that is characterized by specific symptoms (dyspnea
and fatigue) in the medical history and signs (edema, rales)
on the physical examination. There is no single diagnostic
test for HF because it is largely a clinical diagnosis that is
based on a careful history and physical examination. 
2.2. Heart Failure as a Symptomatic Disorder
The approach that is most commonly used to quantify the
degree of functional limitation imposed by HF is one first
developed by the NYHA. This system assigns patients to 1 of
4 functional classes, depending on the degree of effort need-
ed to elicit symptoms: patients may have symptoms of HF at
rest (class IV), on less-than-ordinary exertion (class III), on
ordinary exertion (class II), or only at levels of exertion that
would limit normal individuals (class I). Although the func-
tional class tends to deteriorate over periods of time, most
patients with HF do not typically show an uninterrupted and
inexorable worsening of symptoms. Instead, the severity of
symptoms characteristically fluctuates even in the absence of
changes in medications, and changes in medications and diet
can have either favorable or adverse effects on functional
capacity in the absence of measurable changes in ventricular
function. Some patients may demonstrate remarkable recov-
ery, sometimes associated with improvement in structural
and functional abnormalities. Usually, sustained improve-
ment is associated with drug therapy, and that therapy should
be continued indefinitely. 
The mechanisms responsible for the exercise intolerance of
patients with chronic HF have not been defined clearly.
Although HF is generally regarded as a hemodynamic disor-
der, many studies have indicated that there is a poor relation
between measures of cardiac performance and the symptoms
produced by the disease. Patients with a very low EF (see
Section 4.3.2.1) may be asymptomatic, whereas patients with
preserved LVEF may have severe disability. The apparent
discordance between EF and the degree of functional
impairment is not well understood but may be explained in
part by alterations in ventricular distensibility, valvular
regurgitation, pericardial restraint, cardiac rhythm, conduc-
tion abnormalities, and right ventricular function (11). In
addition, in ambulatory patients, many noncardiac factors
may contribute substantially to exercise intolerance. These
factors include but are not limited to changes in peripheral
vascular function, skeletal muscle physiology, pulmonary
dynamics, neurohormonal and reflex autonomic activity, and
renal sodium handling. The existence of these noncardiac
factors may explain why the hemodynamic improvement
produced by therapeutic agents in patients with chronic HF
may not be immediately or necessarily translated into clini-
cal improvement. Although pharmacological interventions
may produce rapid changes in hemodynamic variables, signs
and symptoms may improve slowly over weeks or months or
not at all.
2.3. Heart Failure as a Progressive Disorder
Left ventricular dysfunction begins with some injury to, or
stress on, the myocardium and is generally a progressive
process, even in the absence of a new identifiable insult to
the heart. The principal manifestation of such progression is
a change in the geometry and structure of the LV, such that
the chamber dilates and/or hypertrophies and becomes more
spherical—a process referred to as cardiac remodeling. This
change in chamber size and structure not only increases the
hemodynamic stresses on the walls of the failing heart and
depresses its mechanical performance but may also increase
regurgitant flow through the mitral valve. These effects, in
turn, serve to sustain and exacerbate the remodeling process.
Cardiac remodeling generally precedes the development of
symptoms (occasionally by months or even years), continues
after the appearance of symptoms, and contributes substan-
tially to worsening of symptoms despite treatment.
Progression of coronary artery disease, diabetes mellitus,
hypertension, or the onset of atrial fibrillation may also con-
tribute to the progression of HF. The development of struc-
tural abnormalities can have 1 of 3 outcomes: 1) patients die
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coronary artery disease, has established risk factors and
structural prerequisites; that the development of HF has
asymptomatic and symptomatic phases; and that specific
treatments targeted at each stage can reduce the morbidity
and mortality of HF (Figure 1). 
3. INITIAL AND SERIAL CLINICAL
ASSESSMENT OF PATIENTS 
PRESENTING WITH HF
Recommendations for the Initial Clinical Assessment of
Patients Presenting With HF
Class I
1. A thorough history and physical examination should
be obtained/performed in patients presenting with HF
to identify cardiac and noncardiac disorders or
behaviors that might cause or accelerate the develop-
ment or progression of HF. (Level of Evidence: C)
2. A careful history of current and past use of alcohol,
illicit drugs, current or past standard or “alternative
therapies,” and chemotherapy drugs should be
obtained from patients presenting with HF. (Level of
Evidence: C)
before developing symptoms (in Stage A or B) , 2) patients
develop symptoms controlled by treatment, or 3) patients die
of progressive HF. Sudden death can interrupt this course at
any time.
Although several factors can accelerate the process of LV
remodeling, there is substantial evidence that the activation
of endogenous neurohormonal systems plays an important
role in cardiac remodeling and thereby in the progression of
HF. Patients with HF have elevated circulating or tissue lev-
els of norepinephrine, angiotensin II, aldosterone, endothe-
lin, vasopressin, and cytokines, which can act (alone or in
concert) to adversely affect the structure and function of the
heart. These neurohormonal factors not only increase the
hemodynamic stresses on the ventricle by causing sodium
retention and peripheral vasoconstriction but may also exert
direct toxic effects on cardiac cells and stimulate myocardial
fibrosis, which can further alter the architecture and impair
the performance of the failing heart. Neurohormonal activa-
tion also has direct deleterious effects on the myocytes and
interstitium, altering the performance and phenotype of these
cells.
The development of HF can be appropriately characterized
by considering 4 stages of the disease, as described in the
Introduction. This staging system recognizes that HF, like
 
STAGE A
At high risk for HF 
but without structural 
heart disease or 
symptoms of HF.
At Risk for Heart Failure Heart Failure
STAGE B
Structural heart 
disease but without 
signs or  symptoms of 
HF.
STAGE D
Refractory HF
requiring specialized
interventions.
STAGE C
Structural heart disease 
with prior or current 
symptoms of HF.
e.g.: Patients with :
-hypertension
-atherosclerotic disease
-diabetes
-obesity
-metabolic syndrome
or
Patients
-using cardiotoxins
-with FHx CM
e.g.: Patients with :
-previous MI
-LV remodeling 
including LVH and
low EF
-asymptomatic 
valvular disease
e.g.: Patients with :
-known structural  
heart disease 
and
-shortness of 
breath and fatigue, 
reduced exercise
tolerance
e.g.: Patients
who have marked 
symptoms at rest 
despite maximal 
medical therapy 
(e.g., those who are 
recurrently 
hospitalized or 
cannot be safely 
discharged from the 
hospital without 
specialized 
interventions)
Structural 
heart 
disease
Development 
of symptoms 
of HF
Refractory 
symptoms of 
HF at rest
THERAPY
GOALS
-Treat hypertension
-Encourage smoking
cessation
-Treat lipid disorders
-Encourage regular 
exercise
-Discourage alcohol 
intake, illicit drug use
-Control metabolic 
syndrome
DRUGS
-ACEI or ARB in 
appropriate patients 
(see text)  for vascular
disease or diabetes
THERAPY
GOALS
-All measures under Stage A
DRUGS
-ACEI or ARB in appropriate 
patients (see text)
- Beta-blockers in 
appropriate patients  
(see text)
THERAPY
GOALS
-All measures under Stages A and B
-Dietary salt restriction
DRUGS FOR
ROUTINE USE
-Diuretics for fluid retention
-ACEI 
-Beta-blockers
DRUGS IN 
SELECTED PATIENTS
-Aldosterone antagonist
-ARBs
-Digitalis
-Hydralazine/nitrates
DEVICES IN 
SELECTED PATIENTS
-Biventricular pacing
-Implantable defibrillators
THERAPY
GOALS
-Appropriate measures 
under Stages A, B, C
-Decision re: appropriate 
level of care
OPTIONS
-Compassionate end -of-
life care/hospice
-Extraordinary measures
• heart transplant
• chronic inotropes
• permanent  
mechanical support
• experimental 
surgery or drugs
Figure 1. Stages in the development of heart failure/recommended therapy by stage. FHx CM indicates family history of cardiomy-
opathy; ACEI, angiotensin converting enzyme inhibitors; and ARB, angiotensin receptor blocker.
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6. Screening for hemochromatosis, sleep-disturbed
breathing, or human immunodeficiency virus is rea-
sonable in selected patients who present with HF.
(Level of Evidence: C)
7. Diagnostic tests for rheumatologic diseases, amyloido-
sis, or pheochromocytoma are reasonable in patients
presenting with HF in whom there is a clinical suspi-
cion of these diseases. (Level of Evidence: C)
8. Endomyocardial biopsy can be useful in patients pre-
senting with HF when a specific diagnosis is suspected
that would influence therapy. (Level of Evidence: C)
9. Measurement of B-type natriuretic peptide (BNP)*
can be useful in the evaluation of patients presenting
in the urgent care setting in whom the clinical diagno-
sis of HF is uncertain. (Level of Evidence: A)
Class IIb
1. Noninvasive imaging may be considered to define the
likelihood of coronary artery disease in patients with
HF and LV dysfunction. (Level of Evidence: C)
2. Holter monitoring might be considered in patients
presenting with HF who have a history of MI and are
being considered for electrophysiologic study to docu-
ment VT inducibility. (Level of Evidence: C)
Class III
1. Endomyocardial biopsy should not be performed in
the routine evaluation of patients with HF. (Level of
Evidence: C)
2. Routine use of signal-averaged electrocardiography is
not recommended for the evaluation of patients pre-
senting with HF. (Level of Evidence: C)
3. Routine measurement of circulating levels of neuro-
hormones (e.g., norepinephrine or endothelin) is not
recommended for patients presenting with HF. (Level
of Evidence: C)
Recommendations for Serial Clinical Assessment of
Patients Presenting With HF
Class I
1. Assessment should be made at each visit of the ability
of a patient with HF to perform routine and desired
activities of daily living. (Level of Evidence: C)
2. Assessment should be made at each visit of the volume
status and weight of a patient with HF. (Level of
Evidence: C)
3. Careful history of current use of alcohol, tobacco,
illicit drugs, “alternative therapies,” and chemothera-
py drugs, as well as diet and sodium intake, should be
obtained at each visit of a patient with HF. (Level of
Evidence: C)
3. In patients presenting with HF, initial assessment
should be made of the patient’s ability to perform rou-
tine and desired activities of daily living. (Level of
Evidence: C)
4. Initial examination of patients presenting with HF
should include assessment of the patient’s volume sta-
tus, orthostatic blood pressure changes, measurement
of weight and height, and calculation of body mass
index. (Level of Evidence: C)
5. Initial laboratory evaluation of patients presenting
with HF should include complete blood count, urinal-
ysis, serum electrolytes (including calcium and mag-
nesium), blood urea nitrogen, serum creatinine, fast-
ing blood glucose (glycohemoglobin), lipid profile,
liver function tests, and thyroid-stimulating hormone.
(Level of Evidence: C)
6. Twelve-lead electrocardiogram and chest radiograph
(PA and lateral) should be performed initially in all
patients presenting with HF. (Level of Evidence: C)
7. Two-dimensional echocardiography with Doppler
should be performed during initial evaluation of
patients presenting with HF to assess LVEF, LV size,
wall thickness, and valve function. Radionuclide ven-
triculography can be performed to assess LVEF and
volumes. (Level of Evidence: C)
8. Coronary arteriography should be performed in
patients presenting with HF who have angina or sig-
nificant ischemia unless the patient is not eligible for
revascularization of any kind. (Level of Evidence: B)
Class IIa
1. Coronary arteriography is reasonable for patients
presenting with HF who have chest pain that may or
may not be of cardiac origin who have not had evalu-
ation of their coronary anatomy and who have no con-
traindications to coronary revascularization. (Level of
Evidence: C)
2. Coronary arteriography is reasonable for patients
presenting with HF who have known or suspected
coronary artery disease but who do not have angina
unless the patient is not eligible for revascularization
of any kind. (Level of Evidence: C)
3. Noninvasive imaging to detect myocardial ischemia
and viability is reasonable in patients presenting with
HF who have known coronary artery disease and no
angina unless the patient is not eligible for revascular-
ization of any kind. (Level of Evidence: B)
4. Maximal exercise testing with or without measure-
ment of respiratory gas exchange and/or blood oxygen
saturation is reasonable in patients presenting with
HF to help determine whether HF is the cause of exer-
cise limitation when the contribution of HF is uncer-
tain. (Level of Evidence: C)
5. Maximal exercise testing with measurement of respi-
ratory gas exchange is reasonable to identify high-risk
patients presenting with HF who are candidates for
cardiac transplantation or other advanced treat-
ments. (Level of Evidence: B)
*Note in proof: The writing committee intended BNP to indicate B-
type natriuretic peptide rather than a specific type of assay. Assessment
can be made using assays for BNP or N-terminal proBNP. The two
types of assays yield clinically similar information.
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Class IIa
Repeat measurement of EF and the severity of struc-
tural remodeling can provide useful information in
patients with HF who have had a change in clinical
status or who have experienced or recovered from a
clinical event or received treatment that might have
had a significant effect on cardiac function. (Level of
Evidence: C)
Class IIb
The value of serial measurements of BNP to guide
therapy for patients with HF is not well established.
(Level of Evidence: C)
3.1. Initial Evaluation of Patients
3.1.1. Identification of Patients
In general, patients with LV dysfunction or HF present to the
healthcare provider in 1 of 3 ways: 
(1) With a syndrome of decreased exercise tolerance.
Most patients with HF seek medical attention with com-
plaints of a reduction in their effort tolerance due to dyspnea
and/or fatigue. These symptoms, which may occur at rest or
during exercise, may be attributed inappropriately by the
patient and/or healthcare provider to aging, other physiolog-
ical abnormalities (e.g., deconditioning), or other medical
disorders (e.g., pulmonary disease). Therefore, in a patient
whose exercise capacity is limited by dyspnea or fatigue, the
healthcare provider must determine whether the principal
cause is HF or another abnormality. Elucidation of the pre-
cise reason for exercise intolerance can be difficult because
several disorders may coexist in the same patient. A clear dis-
tinction can sometimes be made only by measurements of
gas exchange or blood oxygen saturation or by invasive
hemodynamic measurements during graded levels of exer-
cise [see ACC/AHA 2002 Guideline Update for Exercise
Testing (12)]. 
(2) With a syndrome of fluid retention. Patients may
present with complaints of leg or abdominal swelling as their
primary (or only) symptom. In these patients, the impairment
of exercise tolerance may occur so gradually that it may not
be noted unless the patient is questioned carefully and specif-
ically about a change in activities of daily living. 
(3) With no symptoms or symptoms of another cardiac
or noncardiac disorder. During their evaluation for a disor-
der other than HF (e.g., abnormal heart sounds or abnormal
electrocardiogram or chest X-ray, hypertension or hypoten-
sion, diabetes mellitus, an acute MI, an arrhythmia, or a pul-
monary or systemic thromboembolic event), patients may be
found to have evidence of cardiac enlargement or dysfunc-
tion. 
3.1.2. Identification of a Structural and
Functional Abnormality
A complete history and physical examination are the first
steps in evaluating the structural abnormality or cause
responsible for the development of HF. Direct inquiry may
reveal prior or current evidence of MI, valvular disease, or
congenital heart disease, whereas examination of the heart
may suggest the presence of cardiac enlargement, murmurs,
or a third heart sound. Although the history and physical
examination may provide important clues about the nature of
the underlying cardiac abnormality, identification of the
structural abnormality leading to HF generally requires inva-
sive or noninvasive imaging of the cardiac chambers or great
vessels. 
The single most useful diagnostic test in the evaluation of
patients with HF is the comprehensive 2-dimensional
echocardiogram coupled with Doppler flow studies to deter-
mine whether abnormalities of myocardium, heart valves, or
pericardium are present and which chambers are involved.
Three fundamental questions must be addressed: 1) is the
LVEF preserved or reduced, 2) is the structure of the LV nor-
mal or abnormal, and 3) are there other structural abnormal-
ities such as valvular, pericardial, or right ventricular abnor-
malities that could account for the clinical presentation? This
information should be quantified with a numerical estimate
of EF, measurement of ventricular dimensions and/or vol-
umes, measurement of wall thickness, and evaluation of
chamber geometry and regional wall motion. 
Right ventricular size and systolic performance should be
assessed. Atrial size should also be determined semiquantita-
tively and left atrial dimensions and/or volumes measured.
All valves should be evaluated for anatomic and flow abnor-
malities to exclude the presence of primary valve disease.
Secondary changes in valve function, particularly the sever-
ity of mitral and tricuspid valve insufficiency, should be
determined. 
Noninvasive hemodynamic data acquired at the time of
echocardiography are an important additional correlate for
patients with preserved or reduced EF. Combined quantifica-
tion of the mitral valve inflow pattern, pulmonary venous
inflow pattern, and mitral annular velocity provides data
about characteristics of LV filling and left atrial pressure.
Evaluation of the tricuspid valve regurgitant gradient cou-
pled with measurement of inferior vena caval dimension and
its response during respiration provides an estimate of sys-
tolic pulmonary artery pressure and central venous pressure.
Stroke volume may be determined with combined dimension
measurement and pulsed Doppler in the LV outflow tract
(13). However, abnormalities can be present in any of these
parameters in the absence of HF. No one of these necessari-
ly correlates specifically with HF; however, a totally normal
filling pattern argues against clinical HF.
A comprehensive echocardiographic evaluation is impor-
tant, because it is common for patients to have more than 1
cardiac abnormality that contributes to the development of
HF. Furthermore, the study may serve as a baseline for com-
parison, because measurement of EF and the severity of
structural remodeling can provide useful information in
patients who have had a change in clinical status or who have
experienced or recovered from a clinical event or received
treatment that might have had a significant effect on cardiac
function.
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The physical examination should document specific signs of
right or left HF, with particular attention to the presence of
elevated jugular venous pressure and a third heart sound,
because these have been shown to have prognostic signifi-
cance (16). 
A detailed family history should be obtained not only to
determine whether there is a familial predisposition to ather-
osclerotic disease but also to identify relatives with car-
diomyopathy, sudden unexplained death, conduction system
disease, and skeletal myopathies. Recent studies suggest that
as many as 30% of cases of idiopathic dilated cardiomyopa-
thy may be familial, and polymorphisms in genes encoding
cardiac proteins may provide important prognostic informa-
tion (17). However, the cost-effectiveness of family screen-
ing has not been established, and determination of the geno-
type of patients with familial cardiomyopathies or investiga-
tion of genetic polymorphisms is not routinely performed.
Instead, an electrocardiogram and echocardiogram should be
considered in first-degree relatives of patients with a dilated
cardiomyopathy, and families with multiple cases of dilated
cardiomyopathy should be referred to a center with expertise
in genetic analysis and counseling. 
3.1.3.2. Laboratory Testing
Laboratory testing may reveal the presence of disorders or
conditions that can lead to or exacerbate HF. The initial eval-
uation of patients with HF should include a complete blood
Other tests may be used to provide information regarding
the nature and severity of the cardiac abnormality.
Radionuclide ventriculography can provide highly accurate
measurements of LV function and right ventricular ejection
fraction, but it is unable to directly assess valvular abnor-
malities or cardiac hypertrophy. Magnetic resonance imaging
or computed tomography may be useful in evaluating cham-
ber size and ventricular mass, detecting right ventricular dys-
plasia, or recognizing the presence of pericardial disease, as
well as in assessing cardiac function and wall motion (14).
Magnetic resonance imaging may also be used to identify
myocardial viability and scar tissue (15). Chest radiography
can be used to estimate the degree of cardiac enlargement
and pulmonary congestion or to detect the presence of pul-
monary disease. A 12-lead electrocardiogram may demon-
strate evidence of prior MI, LVH, cardiac conduction abnor-
mality (e.g., left bundle-branch block), or a cardiac arrhyth-
mia. However, because of their low sensitivity and specifici-
ty, neither the chest X-ray nor the electrocardiogram should
form the primary basis for determining the specific cardiac
abnormality responsible for the development of HF.
3.1.3. Evaluation of the Cause of HF
Identification of the condition responsible for the cardiac
structural and/or functional abnormalities may be important,
because some conditions that lead to LV dysfunction are
potentially treatable and/or reversible. Efforts to identify a
cause frequently allow the detection of coexistent conditions
that may contribute to or exacerbate the severity of symp-
toms. However, it may not be possible to discern the cause of
HF in many patients presenting with this syndrome, and in
others, the underlying condition may not be amenable to
treatment. Hence, clinicians should focus their efforts on
diagnoses that have implications for therapy.
3.1.3.1. History and Physical Examination
Evaluation of potential causative factors begins with a thor-
ough history and careful physical examination (see Table 2).
Healthcare providers should inquire about a history of hyper-
tension; diabetes mellitus; dyslipidemia; tobacco use; coro-
nary, valvular, or peripheral vascular disease; rheumatic
fever; heart murmur or congenital heart disease; personal or
family history of myopathy; mediastinal irradiation; sleep-
disturbed breathing; and exposure to cardiotoxic agents,
including ephedra, and antineoplastic agents such as anthra-
cyclines, trastuzumab (Herceptin, an antibody for the treat-
ment of breast cancer), or high-dose cyclophosphamide.
Heart failure may occur years after exposure to anthracy-
clines or mediastinal irradiation. Patients should be ques-
tioned carefully about illicit drug use, current and past alco-
hol consumption, symptoms suggestive of sleep-disturbed
breathing, and exposure to sexually transmitted diseases. The
history and physical evaluation should include specific con-
sideration of noncardiac diseases such as collagen vascular
disease, bacterial or parasitic infection, obesity, thyroid
excess or deficiency, amyloidosis, and pheochromocytoma.
Table 2. Evaluation of the Cause of Heart Failure: The History
History to include inquiry regarding:
Hypertension
Diabetes
Dyslipidemia
Valvular heart disease
Coronary or peripheral vascular disease
Myopathy
Rheumatic fever
Mediastinal irradiation
History or symptoms of sleep-disordered breathing
Exposure to cardiotoxic agents
Current and past alcohol consumption
Smoking
Collagen vascular disease
Exposure to sexually transmitted diseases
Thyroid disorder
Pheochromocytoma
Obesity
Family history to include inquiry regarding:
Predisposition to atherosclerotic disease
(Hx of MIs, strokes, PAD)
Sudden cardiac death
Myopathy
Conduction system disease (need for pacemaker)
Tachyarrhythmias
Cardiomyopathy (unexplained HF)
Skeletal myopathies
HF indicates heart failure; Hx, history; MI, myocardial infarction; and PAD, peripheral
arterial disease.
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count, urinalysis, serum electrolytes (including calcium and
magnesium), glycohemoglobin, and blood lipids, as well as
tests of both renal and hepatic function, a chest radiograph,
and a 12-lead electrocardiogram. Thyroid-function tests
(especially thyroid-stimulating hormone) should be meas-
ured, because both hyperthyroidism and hypothyroidism can
be a primary or contributory cause of HF. A fasting transfer-
rin saturation is useful to screen for hemochromatosis; sev-
eral mutated alleles for this disorder are common in individ-
uals of Northern European descent, and affected patients
may show improvement in LV function after treatment with
phlebotomy and chelating agents. Magnetic resonance imag-
ing of the heart or liver may be needed to confirm the pres-
ence of iron overload. Screening for human immunodefi-
ciency virus (HIV) is recommended by some healthcare
providers and should be considered in patients who are at
high risk, although the majority of patients who have car-
diomyopathy due to HIV do not present with symptoms of
HF until other clinical signs of HIV infection are apparent.
Serum titers of antibodies developed in response to infec-
tious organisms are occasionally measured in patients with a
recent onset of HF (especially in those with a recent viral
syndrome), but the yield of such testing is low, and the ther-
apeutic implications of a positive result are uncertain. Assays
for connective tissue diseases and for pheochromocytoma
should be performed if these diagnoses are suspected, and
serum titers of Chagas disease antibodies should be checked
in patients with nonischemic cardiomyopathy who have trav-
eled in or immigrated from an endemic region. 
Several recent assays have been developed for BNP and
related peptides. Several of the natriuretic peptides are syn-
thesized by and released from the heart. Elevated plasma
BNP levels have been associated with reduced LVEF (18),
LVH, elevated LV filling pressures, and acute MI and
ischemia, although they can occur in other settings, such as
pulmonary embolism and chronic obstructive pulmonary dis-
ease. They are sensitive to other biological factors, such as
age, sex, weight, and renal function (19).  Elevated levels
lend support to a diagnosis of abnormal ventricular function
or hemodynamics causing symptomatic HF (20). Trials with
this diagnostic marker suggest utility in the urgent-care set-
ting, where it has been used in combination with clinical
evaluation to differentiate dyspnea due to HF from dyspnea
of other causes (21), and suggest that its use may reduce both
the time to hospital discharge and the cost of treatment (22).
B-type natriuretic peptide levels tend to be less elevated in
HF with preserved EF than in HF with low EF and are lower
in obese patients (23, 24). Levels of BNP may be elevated
meaningfully in women and in people over 60 years of age
who do not have HF, and thus BNP levels should be inter-
preted cautiously in such individuals when distinguishing
between cardiac and noncardiac causes of dyspnea. Elevated
BNP levels may lend weight to a suspected diagnosis of HF
or trigger consideration of HF when the diagnosis is
unknown but should not be used in isolation to confirm or
exclude the presence of HF (22, 25).
3.1.3.3. Evaluation of the Possibility of 
Coronary Artery Disease
Coronary artery disease is believed to be the underlying
cause in approximately two thirds of patients with HF and
low EF and also contributes to the progression of HF through
mechanisms that include endothelial dysfunction, ischemia,
and infarction. Recent cohort studies suggest that there is less
often a history of prior MI in patients with HF and preserved
EF, although coronary artery disease is often evident on
angiography or at autopsy (26-28). Therefore, it may be use-
ful to define the presence, anatomic characteristics, and func-
tional significance of coronary artery disease in selected
patients who present with this syndrome. 
PATIENTS WITH CORONARY ARTERY DISEASE AND ANGINA.
Coronary artery bypass grafting has been shown to improve
symptoms and survival in patients with modestly reduced EF
(variably defined in clinical trials) and angina, although
patients with HF or markedly reduced EFs were not includ-
ed in these studies (21). An ongoing National Institutes of
Health–funded trial is evaluating the utility of surgical revas-
cularization in such patients. Because revascularization is
recommended in individuals with significant ischemic chest
pain regardless of the degree of ischemia or viability, there
would appear to be little role for noninvasive cardiac testing
in such patients. Clinicians should proceed directly to coro-
nary angiography in patients who have angina and impaired
ventricular function (29).
PATIENTS WITH CORONARY ARTERY DISEASE AND NO ANGINA.
Controlled trials have not addressed the issue of whether
coronary revascularization can improve clinical outcomes in
patients with HF who do not have angina. Nevertheless, the
ACC/AHA 2004 Guideline Update for Coronary Artery
Bypass Graft Surgery (29) recommends revascularization in
patients with a significant left main stenosis and in patients
who have large areas of noninfarcted but hypoperfused and
hypocontractile myocardium on noninvasive testing.
Observational studies have shown that revascularization can
favorably affect LV function in some patients with impaired
yet viable myocardium, but it is not clear how such patients
should be identified because the sensitivity and specificity of
an abnormal imaging test have not been validated in patients
with HF (30). Additional studies are needed to determine
whether the possibility of myocardial ischemia or viability
should be evaluated routinely to assess the contribution of
coronary artery disease in patients with HF and reduced
LVEF who do not have angina [see the ACC/AHA/ASE
2003 Guideline Update for the Clinical Application of
Echocardiography (31) and the ACC/AHA/ASNC
Guidelines for Clinical Use of Cardiac Radionuclide
Imaging (32)]. 
PATIENTS IN WHOM THE POSSIBILITY OF CORONARY ARTERY
DISEASE HAS NOT BEEN EVALUATED. Up to one third of
patients with nonischemic cardiomyopathy complain of
chest pain, which may resemble angina or may be atypical in
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fibrosis), and it has not been established conclusively how
biopsy findings (even when positive) affect patient manage-
ment (35). For example, an endomyocardial biopsy might
detect inflammatory cell infiltrates attributed to viral
myocarditis in some patients with acute or even chronic HF.
Nevertheless, many patients with biopsy-proven myocarditis
improve with supportive care only, without specific antiviral
or anti-inflammatory treatment; the prognosis of these
patients has not been influenced clearly by immunosuppres-
sion (36). Similarly, an endomyocardial biopsy can be used
to make a diagnosis of sarcoidosis and amyloidosis, but
changes characteristic of these disorders are often missed on
histological evaluation, and there is no conclusive evidence
that treatment can favorably affect the course of these dis-
eases. 
Examples of cases in which a biopsy might be helpful usu-
ally occur in a setting in which the cause of the cardiomy-
opathy is already suspected because of other supportive data.
Tissue obtained by biopsy can be used to make the diagnosis
of hemochromatosis, endocardial fibroelastosis, and
Loeffler’s syndrome in patients in whom these disorders are
suspected on clinical grounds. Biopsy tissue may also be
used to assess the risk of continued anthracycline therapy in
patients with cancer, especially when combined with imag-
ing of ventricular function (37, 38). Biopsies can confirm the
presence of cardiac disorders that often might weigh against
eligibility for heart transplantation (e.g., amyloidosis).
Finally, the biopsy can be used to identify patients with
giant-cell myocarditis, who generally progress rapidly to
death and are unresponsive to treatment and who thus may be
considered for mechanical circulatory support or immediate
heart transplantation (39). 
However, endomyocardial biopsy is not indicated in the
routine evaluation of cardiomyopathy. Although the risk of a
serious complication is less than 1% in centers experienced
in this technique, biopsies should be performed only when
there is a strong reason to believe that the results will have a
meaningful effect on subsequent therapeutic decisions or
prognosis and only by operators experienced in its perform-
ance. 
3.2. Ongoing Evaluation of Patients
Once the nature and cause of the structural abnormalities
leading to the development of HF have been defined, health-
care providers should focus on the clinical assessment of
patients, both during the initial presentation and during sub-
sequent visits. This clinical assessment should identify
symptoms and their functional consequences and should
evaluate the short- and long-term risks of disease progression
and death whenever appropriate. This ongoing review of the
patient’s clinical status is critical to the appropriate selection
and monitoring of treatments. 
3.2.1. Assessment of Functional Capacity
During the initial and subsequent visits, healthcare providers
should inquire about the type, severity, and duration of symp-
nature. Because coronary revascularization would play a role
in the management of these patients if their chest pain were
related to the presence of coronary artery disease, coronary
angiography is generally recommended in these circum-
stances to define the presence or absence of large-vessel
coronary obstructions. Although many healthcare providers
perform noninvasive testing before coronary angiography in
these patients, inhomogeneous nuclear images and abnormal
wall-motion patterns are common in patients with a nonis-
chemic cardiomyopathy. Hence, in most situations, clinicians
should proceed directly to coronary angiography in patients
who have HF and chest pain. 
How should healthcare providers evaluate patients with HF
due to LV dysfunction who do not have chest pain and who
do not have a history of coronary artery disease? The use of
coronary angiography appears reasonable in young patients
to exclude the presence of congenital coronary anomalies. In
older patients, however, efforts to detect the presence of
coronary artery disease may not be worthwhile, because
revascularization has not been shown to improve clinical
outcomes in patients without angina (29). Nevertheless, the
observation that revascularization might have a favorable
effect on LV function has led some experts to suggest that
coronary artery disease should be excluded whenever possi-
ble, especially in patients with diabetes mellitus or other
states associated with silent myocardial ischemia. Only coro-
nary arteriography can reliably demonstrate or exclude the
presence of obstructed coronary vessels, because perfusion
deficits and segmental wall-motion abnormalities suggestive
of coronary artery disease are commonly present in patients
with a nonischemic cardiomyopathy on noninvasive imag-
ing. In patients in whom coronary artery disease has been
excluded previously as the cause of LV dysfunction, repeat-
ed invasive or noninvasive assessment for ischemia is gener-
ally not indicated unless there is a change in clinical status
that suggests the interim development of ischemic disease. 
3.1.3.4. Evaluation of the Possibility of 
Myocardial Disease
One half of patients with HF and low EF have normal or
near-normal coronary arteries on coronary angiography, and
myocardial disorders are responsible for the development of
cardiomyopathy in most such individuals (33). Most patients
with a cardiomyopathy have no identifiable causative factor
(i.e., idiopathic dilated cardiomyopathy), but in some
patients, the cardiomyopathy is related to a systemic disorder
(e.g., hypertension, diabetes mellitus, hyperthyroidism,
hemochromatosis, or hypocalcemia), exposure to a car-
diotoxic agent (alcohol, cocaine, methamphetamine, anthra-
cycline, or trastuzumab), or the presence of myocardial
inflammation or infiltration.
Although some of these conditions may be detected by
endomyocardial biopsy, the overall usefulness of endomy-
ocardial biopsy in the evaluation of patients with a car-
diomyopathy of unknown cause is not clear (34). Most
patients with a nonischemic cardiomyopathy show nonspe-
cific changes on biopsy (including hypertrophy, cell loss, and
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toms that occur during activities of daily living and that may
impair the patient’s functional capacity. Questions regarding
the ability to perform specific tasks may provide greater
insight than general inquiries about what symptoms the
patient is experiencing, because many patients curtail their
activities to limit discomfort. Patients with modest limita-
tions of activity should be asked about their participation in
sports or their ability to perform strenuous exercise, whereas
patients with substantial limitations of activity should be
asked about their ability to get dressed without stopping, take
a shower or bath, climb stairs, or perform specific routine
household chores. A useful approach is to ask patients to
describe activities that they would like to do but can no
longer perform, because changes in the ability to perform
specific tasks are generally related to important changes in
clinical status or course. Ideally, these inquiries should be
coupled with direct observations of the patient during a walk
around the clinic or up the stairs. 
A variety of approaches have been used to quantify the
degree of functional limitation imposed by HF. The most
widely used scale is the NYHA functional classification (40),
but this system is subject to considerable interobserver vari-
ability and is insensitive to important changes in exercise
capacity. These limitations may be overcome by formal tests
of exercise tolerance. Measurement of the distance that a
patient can walk in 6 minutes may have prognostic signifi-
cance and may help to assess the level of functional impair-
ment in the very sick, but serial changes in walking distance
may not parallel changes in clinical status. Maximal exercise
testing, with measurement of peak oxygen uptake, has been
used to identify appropriate candidates for cardiac transplan-
tation, to determine disability, and to assist in the formulation
of an exercise prescription, but its role in the general man-
agement of patients with HF has not been defined.
3.2.2. Assessment of Volume Status
It is critically important for healthcare providers to evaluate
the fluid or volume status of patients with HF during the ini-
tial visit and each follow-up examination. This assessment
plays a pivotal role in determining the need for diuretic ther-
apy and in detecting sodium excesses or deficiencies that
may limit efficacy and decrease the tolerability of drugs used
to treat HF. The physical examination is the primary step in
evaluating the presence and severity of fluid retention in
patients with HF. At each visit, healthcare providers should
record the patient’s body weight and sitting and standing
blood pressures and determine the degree of jugular venous
distension and its response to abdominal pressure, the pres-
ence and severity of organ congestion (pulmonary rales and
hepatomegaly), and the magnitude of peripheral edema in the
legs, abdomen, presacral area, and scrotum, as well as ascites
in the abdomen.
The most reliable sign of volume overload is jugular
venous distention (41-43). Right-sided filling pressures are
elevated in the basal state or with abdominal compression
(hepatojugular reflux) in many patients with chronically ele-
vated left-sided filling pressures (44). Most patients with
peripheral edema should also be considered to have volume
overload, but the possibility of noncardiac causes for edema
may limit the utility of this sign in some patients. In contrast,
most patients with chronic HF do not have rales. This is true
even in patients with end-stage disease who have markedly
elevated left-sided filling pressures. The presence of rales
generally reflects the rapidity of onset of HF rather than the
degree of volume overload. Indeed, many patients with
chronic HF have elevated intravascular volume in the
absence of peripheral edema or rales. Studies using 131I-
tagged albumin have demonstrated plasma volume expan-
sion in more than 50% of patients in whom clinical volume
overload was not recognized (45). Short-term changes in
fluid status are best assessed by measuring changes in body
weight; however, changes in body weight may be less reli-
able during long periods of follow-up, because many patients
may gain nonfluid weight and others may lose skeletal mus-
cle mass and body fat as HF progresses due to the develop-
ment of cardiac cachexia. 
The majority of patients with clinical evidence of volume
overload do not exhibit hypoperfusion, even though cardiac
performance may be severely depressed. Clinical signs of
hypoperfusion become most apparent when cardiac output
declines markedly or abruptly. Clues that suggest the pres-
ence of such a marked reduction in cardiac output include
narrow pulse pressure, cool extremities, altered mentation,
Cheyne-Stokes respiration, resting tachycardia, and a dispro-
portionate elevation of blood urea nitrogen relative to serum
creatinine. Renal dysfunction in HF is poorly understood and
appears to be mediated by interactions between the heart and
kidney beyond those primarily due to depressed cardiac out-
put (19).
3.2.3. Laboratory Assessment
Serum electrolytes and renal function should be monitored
routinely in patients with HF. Of particular importance is the
serial measurement of serum potassium concentration,
because hypokalemia is a common adverse effect of treat-
ment with diuretics and may cause fatal arrhythmias and
increase the risk of digitalis toxicity, whereas hyperkalemia
may complicate therapy with angiotensin converting enzyme
(ACE) inhibitors, angiotensin receptor blockers (ARBs), and
aldosterone antagonists. Worsening renal function may
require adjustment of the doses of diuretics, renin-
angiotensin-aldosterone system antagonists, digoxin, and
noncardiac medications. Development of hyponatremia or
anemia may be a sign of disease progression and is associat-
ed with impaired survival.
Serum BNP levels have been shown to parallel the clinical
severity of HF as assessed by NYHA class in broad popula-
tions. Levels are higher in hospitalized patients and tend to
decrease during aggressive therapy for decompensation (see
Section 3.1.3.2 on BNP) (20). However, it cannot be
assumed that BNP levels can be used effectively as targets
for adjustment of therapy in individual patients. Many
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information for patients and their families to help them
appropriately plan for their futures. It also identifies patients
in whom cardiac transplantation or mechanical device thera-
py should be considered. 
Multivariate analysis of clinical variables has helped to
identify the most significant predictors of survival, and prog-
nostic models have been developed and validated (48).
Decreasing LVEF, worsening NYHA functional status,
degree of hyponatremia, decreasing peak exercise oxygen
uptake, decreasing hematocrit, widened QRS on 12-lead
electrocardiogram, chronic hypotension, resting tachycardia,
renal insufficiency, intolerance to conventional therapy, and
refractory volume overload are all generally recognized key
prognostic parameters, although the actual prognostic mod-
els incorporating them are not widely used in clinical prac-
tice (49, 50). Although elevated circulating levels of neuro-
hormonal factors have also been associated with high mor-
tality rates, the routine assessment of neurohormones such as
norepinephrine or endothelin is neither feasible nor helpful
in clinical management. .Likewise, elevated BNP levels pre-
dict higher risk of HF and other events after MI, whereas
marked elevation in BNP levels during hospitalization for
HF may predict rehospitalization and death. Nonetheless, the
BNP measurement has not been clearly shown to supplement
careful clinical assessment. 
Because treatment of HF has improved over the past 10
years, the older prognostic models need to be revalidated
(51), and newer prognostic models may have to be devel-
oped. Outcomes have been improved for most high-risk
patients, which has resulted in a shift in the selection process
for patients referred for heart transplantation (51). Routine
use of ambulatory electrocardiographic monitoring, T-wave
alternans analysis, heart rate variability measurement, and
signal-averaged electrocardiography have not been shown to
provide incremental value in assessing overall prognosis,
although ambulatory electrocardiographic monitoring can be
useful in decision making regarding placement of
implantable cardioverter-defibrillators (ICDs) (52).
4. THERAPY
4.1. Patients at High Risk for Developing HF
(Stage A)
RECOMMENDATIONS
Class I
1. In patients at high risk for developing HF, systolic and
diastolic hypertension should be controlled in accor-
dance with contemporary guidelines. (Level of
Evidence: A)
2. In patients at high risk for developing HF, lipid disor-
ders should be treated in accordance with contempo-
rary guidelines. (Level of Evidence: A)
3. For patients with diabetes mellitus (who are all at high
risk for developing HF), blood sugar should be con-
trolled in accordance with contemporary guidelines.
(Level of Evidence: C)
patients taking optimal doses of medications continue to
show markedly elevated levels of BNP, and some patients
demonstrate BNP levels within the normal range despite
advanced HF. The use of BNP measurements to guide the
titration of drug doses has not been shown to improve out-
comes more effectively than achievement of the target doses
of drugs shown in clinical trials to prolong life (46). Ongoing
trials will help to determine the role of serial BNP measure-
ments in both diagnosis and management of HF. 
Serial chest radiographs are not recommended in the man-
agement of chronic HF. Although the cardiothoracic ratio is
commonly believed to reflect the cardiac dilatation that is
characteristic of HF, enlargement of the cardiac silhouette
primarily reflects changes in right ventricular volume rather
than LV function, because the right ventricle forms most of
the border of dilated hearts on radiographs. Similarly,
changes in the radiographic assessment of pulmonary vascu-
lar congestion are too insensitive to detect any but the most
extreme changes in fluid status (47). 
Repeat assessment of EF may be most useful when the
patient has demonstrated a major change in clinical status.
Both improvement and deterioration may have important
implications for future care, although the recommended
medical regimen should be continued in most cases.
Improvement may reflect recovery from a previous condi-
tion, such as viral myocarditis or hypothyroidism, or may
occur after titration of recommended therapies for chronic
HF. Deterioration may reflect gradual disease progression or
a new event, such as recurrent MI. Routine assessment of EF
at frequent, regular, or arbitrary intervals is not recommend-
ed. 
There has been no established role for periodic invasive or
noninvasive hemodynamic measurements in the manage-
ment of HF. Most drugs used for the treatment of HF are pre-
scribed on the basis of their ability to improve symptoms or
survival rather than their effect on hemodynamic variables.
Moreover, the initial and target doses of these drugs are
selected on the basis of experience in controlled trials and are
not based on the changes they may produce in cardiac output
or pulmonary wedge pressure. Nevertheless, invasive hemo-
dynamic measurements may assist in the determination of
volume status and in distinguishing HF from other disorders
that may cause circulatory instability, such as pulmonary dis-
eases and sepsis. Measurements of cardiac output and pul-
monary wedge pressure through a pulmonary artery catheter
have also been used in patients with refractory HF to assess
pulmonary vascular resistance, a determinant of eligibility
for heart transplantation. Cardiac output can also be meas-
ured by noninvasive methods.
3.2.4. Assessment of Prognosis
Although both healthcare providers and patients may be
interested in defining the prognosis of an individual patient
with HF, the likelihood of survival can be determined reli-
ably only in populations and not in individuals. However,
some attempt at prognostication in HF may provide better
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4.1.1. Control of Risk
4.1.1.1. Treatment of Hypertension
Elevated levels of diastolic and especially systolic blood
pressure are major risk factors for the development of HF
(53, 54), and long-term treatment of both systolic and dias-
tolic hypertension has been shown to reduce the risk of HF
(55-57). A number of large, controlled studies have quite uni-
4. Patients at high risk for developing HF should be
counseled to avoid behaviors that may increase the
risk of HF (e.g., smoking, excessive alcohol consump-
tion, and illicit drug use). (Level of Evidence: C)
5. Ventricular rate should be controlled or sinus rhythm
restored in patients with supraventricular tachy-
arrhythmias who are at high risk for developing HF.
(Level of Evidence: B)
6. Thyroid disorders should be treated in accordance
with contemporary guidelines in patients at high risk
for developing HF. (Level of Evidence: C)
7. Healthcare providers should perform periodic evalu-
ation for signs and symptoms of HF in patients at high
risk for developing HF. (Level of Evidence: C)
8. In patients at high risk for developing HF who have
known atherosclerotic vascular disease, healthcare
providers should follow current guidelines for second-
ary prevention. (Level of Evidence: C)
9. Healthcare providers should perform a noninvasive
evaluation of LV function (i.e., LVEF) in patients with
a strong family history of cardiomyopathy or in those
receiving cardiotoxic interventions. (Level of
Evidence: C)
Class IIa
1. Angiotensin converting enzyme inhibitors can be use-
ful to prevent HF in patients at high risk for develop-
ing HF who have a history of atherosclerotic vascular
disease, diabetes mellitus, or hypertension with associ-
ated cardiovascular risk factors. (Level of Evidence:
A)
2. Angiotensin II receptor blockers can be useful to pre-
vent HF in patients at high risk for developing HF
who have a history of atherosclerotic vascular disease,
diabetes mellitus, or hypertension with associated car-
diovascular risk factors. (Level of Evidence: C)
Class III
Routine use of nutritional supplements solely to pre-
vent the development of structural heart disease
should not be recommended for patients at high risk
for developing HF. (Level of Evidence: C)
Table 3 describes cardiovascular medications useful for
treatment of various stages of HF. 
Many conditions or behaviors that are associated with an
increased risk of structural heart disease can be identified
before patients show any evidence of structural abnormali-
ties. Because early modification of many of these factors can
reduce the risk of HF, the recommendation of appropriate
medical interventions to patients with these risk factors pro-
vides the earliest opportunity to reduce the impact of HF on
public and individual health.
Table 3. Cardiovascular Medications Useful for Treatment of Various
Stages* of Heart Failure
Drug Stage A Stage B Stage C
Ace Inhibitors
Benazepril H — —
Captopril H, DN Post MI HF
Enalapril H, DN Asymptomatic HF
LVSD
Fosinopril H — HF
Lisinopril H, DN Post MI HF
Moexipril H — —
Perindopril H, CV Risk — —
Quinapril H — HF
Ramipril H, CV Risk Post MI Post MI
Trandolapril H Post MI Post MI
Angiotensin Receptor Blockers
Candesartan H — HF
Eprosartan H — —
Irbesartan H, DN — —
Losartan H, DN CV Risk —
Olmesartan H — —
Telmisartan H — —
Valsartan H, DN Post MI Post MI, HF
Aldosterone  Blockers
Eplerenone H Post MI Post MI
Spironolactone H — HF
Beta Blockers
Acebutolol H — —
Atenolol H Post MI —
Betaxolol H — —
Bisoprolol H — HF
Carteolol H — —
Carvedilol H Post MI HF, Post MI
Labetalol H — —
Metoprolol succinate H — HF
Metoprolol tartrate H Post MI —
Nadolol H — —
Penbutolol H — —
Pindolol H — —
Propranolol H Post MI —
Timolol H Post MI —
Digoxin — — HF
*See Figure 1 for explanation of stages of heart failure.
AsymptomaticLVSD indicates asymptomatic left-ventricular systolic dysfunction; CV
Risk, reduction in future cardiovascular events; DN, diabetic nephropathy; H, hyperten-
sion; HF, heart failure and asymptomatic left venricular dysfunction; Post MI, reduction in
heart failureor other cardiac events following myocardial infarction.
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50 years of age who had urinary albumin greater than 20 mg
per liter, 4% of patients developed HF over the study period,
of whom 36% died (76). The occurrence of HF represents a
major and adverse prognostic turn in a diabetic patient’s life.
There is a differential gender effect associated with this risk;
diabetes mellitus only modestly increases the risk of HF for
men, but it increases the relative risk of HF more than 3-fold
among women (53). Healthcare providers should make every
effort to control hyperglycemia, although such control has
not yet been shown to reduce the subsequent risk of HF. In
addition, ACEIs or ARBs can prevent the development of
end-organ disease and the occurrence of clinical events in
diabetic patients, even in those who do not have hypertension
(66, 77). Long-term treatment with several ACEIs or ARBs
has been shown to decrease the risk of renal disease in dia-
betic patients (78, 79), and prolonged therapy with the ACEI
ramipril has been shown to lower the likelihood of cardio-
vascular death, MI, and HF (66). Likewise, the use of ARBs
in patients with diabetes mellitus and hypertension or LVH
has been shown to reduce the incidence of first hospitaliza-
tion for HF, in addition to having other beneficial effects on
renal function (68, 69, 80).
4.1.1.3. Management of the Metabolic Syndrome
The clustering of cardiovascular risk factors in individual
patients, termed the metabolic syndrome or syndrome X,
includes any 3 of the following criteria: abdominal adiposity,
hypertriglyceridemia, low high-density lipoprotein, hyper-
tension, and fasting hyperglycemia. It is estimated that the
prevalence of the metabolic syndrome in the United States
exceeds 20% of individuals who are at least 20 years of age
and 40% of the population over 40 years of age (81). The
major adverse consequence of the metabolic syndrome is
cardiovascular disease in general and may include an
increased incidence of new HF (82). As noted previously, the
appropriate treatment of hypertension, diabetes mellitus, and
dyslipidemia (83) as they occur in isolation can significantly
reduce the development of HF. A number of trials are cur-
rently in progress to determine the most effective interven-
tion for patients with the metabolic syndrome.
4.1.1.4. Management of Atherosclerotic Disease
Patients with known atherosclerotic disease (e.g., of the
coronary, cerebral, or peripheral blood vessels) are likely to
develop HF, and healthcare providers should seek to control
vascular risk factors in such patients according to recom-
mended guidelines (70). In one large-scale trial, long-term
treatment with an ACEI decreased the risk of the primary end
point of cardiovascular death, MI, and stroke in patients with
established vascular disease who were without evidence of
HF or reduced LVEF at the time of randomization but the
incidence of new HF was not a primary or secondary end-
point, although it was improved (66). Among patients with
established coronary artery disease and no HF, another ACEI
significantly reduced incidence of death, MI, or cardiac
arrest, but again the incidence of new HF was neither a pri-
formly demonstrated that optimal blood pressure control
decreases the risk of new HF by approximately 50% (58).
Because approximately one fourth of the American popula-
tion is hypertensive, and the lifetime risk of developing
hypertension in the United States exceeds 75% (59), strate-
gies to control hypertension are certainly a vital part of any
effort to prevent HF. The subsequent structural abnormalities
that occur in patients with hypertension, including LVH or
MI (e.g., Stage B HF), portend an even higher number of
adverse cardiovascular outcomes. Left ventricular hypertro-
phy is an independent cardiovascular risk factor that is as
potent as age or systolic blood pressure in predicting MI,
stroke, sudden death, or HF (60). In the Framingham Heart
Study, hypertension accounted for 39% of HF cases in men
and 59% in women (53). In addition, the benefits of treating
hypertension in patients who have had a prior MI (Stage B)
are even more dramatic, with an 81% reduction in the inci-
dence of HF (56). 
Healthcare providers should lower both systolic and dias-
tolic blood pressure in accordance with the recommendations
provided in published guidelines, including the most recent-
ly published report of the Joint National Committee on
Prevention, Detection, Evaluation, and Treatment of High
Blood Pressure (61); target levels of blood pressure are lower
in patients with associated major cardiovascular risk factors,
especially those with diabetes mellitus (62, 63). When an
antihypertensive regimen is devised, optimal control of
blood pressure should remain as the primary goal, with the
choice of drugs determined by the concomitant medical
problems (e.g., coronary artery disease, diabetes, or renal
disease). Diuretic-based antihypertensive therapy has repeat-
edly been shown to prevent HF in a wide range of target pop-
ulations (64). ACE inhibitors (ACEIs) and beta-blockers are
also effective in the prevention of HF (61), whereas calcium
antagonists and alpha-blockers are less effective in prevent-
ing HF syndrome (65). However, ACEIs and beta-blockers,
as single therapies, are not superior to other antihypertensive
drug classes in the reduction of all cardiovascular outcomes.
Nevertheless, among patients with diabetes or other cardio-
vascular complications (66, 67), ACEIs have been most
notable with respect to a reduction in the onset of HF and
new-onset diabetes. Likewise, compared with placebo, the
ARBs losartan (68) and irbesartan (69) significantly reduced
the incidence of HF in patients with type 2 diabetes mellitus
and nephropathy. Ultimately, an appropriate antihypertensive
regimen frequently consists of several drugs used in combi-
nation. Although prevention of HF is the focus of these
guidelines, overall cardiovascular preventative strategies
have also been the subject of published guidelines (70).
4.1.1.2. Treatment of Diabetes
Obesity and insulin resistance are important risk factors for
the development of HF (71, 72). The presence of clinical dia-
betes mellitus markedly increases the likelihood of HF in
patients without structural heart disease (73) and adversely
affects the outcomes of patients with established HF (74, 75).
In a study of patients with type 2 diabetes mellitus more than
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mary or secondary endpoint (67). A more recent large trial of
ACEI versus placebo failed to show a reduction in the pri-
mary composite endpoint, although a post hoc analysis did
show some reduction in HF hospitalization (83a). The com-
mittee, in reviewing the accruing data, decided to change the
level of recommendation for the use of ACEI for Stage A
patients from Class I in the 2001 document to Class IIa in
this document. Treatment of hyperlipidemia (in accordance
with published guidelines) has been shown to reduce the
likelihood of death and of HF in patients with a history of MI
(83, 84, 84a, 84b).
4.1.1.5. Control of Conditions That May Cause
Cardiac Injury
Many therapeutic and recreational agents can exert important
cardiotoxic effects, and patients should be strongly advised
about the hazards of smoking, as well as the use of alcohol,
cocaine, amphetamines, and other illicit drugs. Several epi-
demiological studies have revealed no correlation between
the amount of alcohol ingested and the subsequent develop-
ment of HF; nevertheless, the Writing Committee strongly
believed that any patient with a history of alcohol abuse or
with current substantial routine alcohol consumption and
new-onset HF without other obvious cause should be coun-
seled to become abstinent. Many HF programs limit alco-
holic beverage consumption to no more than 1 alcoholic bev-
erage serving daily for all patients with LV dysfunction,
regardless of cause (85, 86). Several interventions used in the
treatment of cancer can injure the heart and lead to the devel-
opment of HF, even in patients with no other cardiovascular
risk factors. Such treatments include ionizing radiation that
involves the mediastinum (87) and chemotherapeutic agents
such as anthracyclines, immunotherapy such as trastuzumab,
or high-dose cyclophosphamide (88-90). Patients who take
trastuzumab in combination with anthracyclines are at par-
ticular risk of HF. Heart failure may occur years after initial
exposure to anthracyclines or mediastinal radiotherapy. Use
of ephedra, formerly a common ingredient in over-the-
counter weight loss preparations, may contribute to the
development of HF as well (91). 
4.1.1.6. Other Measures
There is no direct evidence that control of dietary sodium or
participation in regular exercise can prevent the development
of HF; however, in patients with hypertension or other vas-
cular disease, these efforts may have other health benefits
and may enhance a general sense of well-being. There is also
no evidence that routine use of nutritional supplements can
prevent dysfunction of or injury to the heart. 
4.1.2. Early Detection of Structural Abnormalities
Asymptomatic patients with ventricular dilatation and
reduced LVEF carry substantially higher risk for subsequent
morbidity and mortality than the general population. It would
be desirable to construct cost-effective strategies to identify
such patients in the interest of reducing their subsequent risk.
Limited information is available to support the cost-effec-
tiveness of broad population screening. Brain natriuretic pep-
tide levels represent a potential tool for this purpose (92). An
analysis of the implications of elevated BNP has suggested
that the screening of asymptomatic people over the age of 60
years with this blood test could yield cost-effective improve-
ment in clinical outcomes across the population (93). Certain
patients are appropriate targets for more aggressive screen-
ing on the basis of characteristics that denote an increase in
the risk for structural heart disease. Healthcare professionals
should perform echocardiographic evaluation in selected
patients without apparent structural heart disease who are at
very high risk of a cardiomyopathy (e.g., those with a strong
family history of cardiomyopathy or those receiving car-
diotoxic interventions) (94, 95). Routine periodic assessment
of LV function in other patients is not recommended.
4.2. Patients With Cardiac Structural
Abnormalities or Remodeling Who Have Not
Developed HF Symptoms (Stage B)
RECOMMENDATIONS
Class I
1. All Class I recommendations for Stage A should apply
to patients with cardiac structural abnormalities who
have not developed HF. (Levels of Evidence: A, B, and
C as appropriate)
2. Beta-blockers and ACEIs should be used in all
patients with a recent or remote history of MI regard-
less of EF or presence of HF (see Table 3). (Level of
Evidence: A)
3. Beta-blockers are indicated in all patients without a
history of MI who have a reduced LVEF with no HF
symptoms (see Table 3 and text). (Level of Evidence:
C)
4. Angiotensin converting enzyme inhibitors should be
used in patients with a reduced EF and no symptoms
of HF, even if they have not experienced MI. (Level of
Evidence: A)
5. An ARB should be administered to post-MI patients
without HF who are intolerant of ACEIs and have a
low LVEF. (Level of Evidence: B)
6. Patients who have not developed HF symptoms should
be treated according to contemporary guidelines after
an acute MI. (Level of Evidence: C)
7. Coronary revascularization should be recommended
in appropriate patients without symptoms of HF in
accordance with contemporary guidelines (see
ACC/AHA Guidelines for the Management of
Patients With Chronic Stable Angina). (Level of
Evidence: A)
8. Valve replacement or repair should be recommended
for patients with hemodynamically significant valvu-
lar stenosis or regurgitation and no symptoms of HF
in accordance with contemporary guidelines. (Level of
Evidence: B)
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4.2.1. Prevention of Cardiovascular Events
4.2.1.1. Patients With an Acute MI
In patients who are experiencing an acute MI, the infusion of
a fibrinolytic agent or the use of percutaneous coronary inter-
vention can decrease the risk of developing HF (101), and
these interventions can reduce the risk of death, especially in
patients with a prior myocardial injury (102, 103). Patients
with an acute infarction also benefit from the administration
of both a beta-blocker and either an ACEI or ARB, which can
decrease the risk of reinfarction or death when initiated with-
in days after the ischemic event, especially in patients whose
course is complicated by HF (104-110). Combined neuro-
hormonal blockade (beta-blocker and ACEI or ARB) pro-
duces additive benefits (111). For recommendations on the
treatment of patients with MI, see the ACC/AHA Guidelines
for the Management of Patients With ST-Elevation
Myocardial Infarction (8).
4.2.1.2. Patients With a History of MI 
but Normal LVEF
Both hypertension and hyperlipidemia should be treated vig-
orously in patients with a history of MI, because the benefits
of treating these coronary risk factors are particularly marked
in patients with a prior ischemic event (55, 56). Patients with
a recent MI should also receive treatment with ACEIs and
beta-blockers (104, 105, 108, 109, 111), which have been
shown to reduce the risk of death when initiated days or
weeks after an ischemic cardiac event. Evidence from 2
large-scale studies indicates that prolonged therapy with an
ACEI can also reduce the risk of a major cardiovascular
event, even when treatment is initiated months or years after
MI (66, 67). 
4.2.1.3. Patients With Hypertension and LVH
See Section 4.1.1.1.
4.2.1.4. Patients With Chronic Reduction of LVEF
but No Symptoms
Long-term treatment with an ACEI has been shown to delay
the onset of HF symptoms and decrease the risk of death and
hospitalization for HF in asymptomatic patients with reduced
LVEF, whether due to a remote ischemic injury or to a non-
ischemic cardiomyopathy (97, 112). Although a recent trial
investigated patients with low EF and HF at the time of MI,
there are no studies that specifically address use of ARBs in
asymptomatic patients with reduced LVEF. Given results of
studies in symptomatic patients with low EF, ARBs may be
an appropriate alternative, particularly in patients who can-
not tolerate an ACEI. Furthermore, although controlled clin-
ical trials are lacking, the use of beta-blockers in patients
with a low EF and no symptoms (especially those with coro-
nary artery disease) is also recommended (107, 111). In such
cases, the same beta-blockers should be used that were
employed in the large HF trials. 
Class IIa
1. Angiotensin converting enzyme inhibitors or ARBs
can be beneficial in patients with hypertension and
LVH and no symptoms of HF. (Level of Evidence B)
2. Angiotensin II receptor blockers can be beneficial in
patients with low EF and no symptoms of HF who are
intolerant of ACEIs. (Level of Evidence: C)
3. Placement of an ICD is reasonable in patients with
ischemic cardiomyopathy who are at least 40 days
post-MI, have an LVEF of 30% or less, are NYHA
functional class I on chronic optimal medical therapy,
and have reasonable expectation of survival with a
good functional status for more than 1 year.  (Level of
Evidence: B)
Class IIb
Placement of an ICD might be considered in patients
without HF who have nonischemic cardiomyopathy
and an LVEF less than or equal to 30% who are in
NYHA functional class I with chronic optimal medical
therapy and have a reasonable expectation of survival
with good functional status for more than 1 year.
(Level of Evidence: C)
Class III
1. Digoxin should not be used in patients with low EF,
sinus rhythm, and no history of HF symptoms,
because in this population, the risk of harm is not bal-
anced by any known benefit. (Level of Evidence: C)
2. Use of nutritional supplements to treat structural
heart disease or to prevent the development of symp-
toms of HF is not recommended. (Level of Evidence:
C)
3. Calcium channel blockers with negative inotropic
effects may be harmful in asymptomatic patients with
low LVEF and no symptoms of HF after MI (see text
in Stage C). (Level of Evidence: C)
Patients without HF symptoms but who have had an MI or
who have evidence of LV remodeling are at considerable risk
of developing HF (96, 97). In such patients, the incidence of
HF can be decreased by reducing the risk of additional injury
and by retarding the evolution and progression of LV remod-
eling. Initial appropriate measures include those listed as
class I recommendations for patients in Stage A (also see
Section 5). 
As is the case with patients who have no structural heart
disease, there is no evidence that the use of nutritional sup-
plements can prevent the development of HF in patients with
a recent or remote MI with or without LV remodeling. The
aldosterone antagonist eplerenone has been shown to reduce
morbidity and mortality in a population of patients with low
EF and no HF after MI that has already been treated with
ACEIs and beta-blockers (98, 99). Other preventive meas-
ures have been addressed in related guidelines (100).
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imize structural changes in the ventricle and thereby possibly
delay the need for surgical intervention; however, these
drugs are often poorly tolerated in this setting, and no trial
has shown that these vasodilators can reduce the risk of HF
or death [see ACC/AHA Guidelines for the Management of
Patients With Valvular Heart Disease (117)]. There are no
long-term studies of vasodilator therapy in patients with
severe asymptomatic mitral regurgitation.
4.2.2. Early Detection of HF
As noted, the symptoms and signs of HF are often difficult to
identify because they are frequently confused with other dis-
orders or are attributed to aging, obesity, or lack of condi-
tioning. Limitations of exercise tolerance can occur so grad-
ually that patients may adapt their lifestyles (consciously or
subconsciously) to minimize symptoms and thus fail to
report them to healthcare providers. Hence, patients at risk
should be advised to inform their healthcare providers about
limitations of exercise tolerance or unexplained fatigue, and
healthcare providers should intensify their vigilance for the
signs and symptoms of HF in such individuals.
4.3. Patients With Current or Prior Symptoms of
HF (Stage C) 
4.3.1. Patients With Reduced LVEF
RECOMMENDATIONS
Class I
1. Measures listed as Class I recommendations for
patients in stages A and B are also appropriate for
patients in Stage C. (Levels of Evidence: A, B, and C as
appropriate)
2. Diuretics and salt restriction are indicated in patients
with current or prior symptoms of HF and reduced
LVEF who have evidence of fluid retention (see Table
4). (Level of Evidence: C)
3. Angiotensin converting enzyme inhibitors are recom-
mended for all patients with current or prior symp-
toms of HF and reduced LVEF, unless contraindicat-
ed (see Table 3 and text). (Level of Evidence: A)
4. Beta-blockers (using 1 of the 3 proven to reduce mor-
tality, i.e., bisoprolol, carvedilol, and sustained release
metoprolol succinate) are recommended for all stable
patients with current or prior symptoms of HF and
reduced LVEF, unless contraindicated (see Table 3
and text). (Level of Evidence: A)
5. Angiotensin II receptor blockers approved for the
treatment of HF (see Table 3) are recommended in
patients with current or prior symptoms of HF and
reduced LVEF who are ACEI-intolerant (see text for
information regarding patients with angioedema).
(Level of Evidence: A)
6. Drugs known to adversely affect the clinical status of
patients with current or prior symptoms of HF and
reduced LVEF should be avoided or withdrawn when-
ever possible (e.g., nonsteroidal anti-inflammatory
The use of ICD therapy in patients with chronic reduction
of LVEF but no symptoms has been evaluated in one large
trial including only patients with ischemic cardiomyopathy.
The trials assessing ICD for primary prophylaxis in non-
ischemic cardiomyopathy have not included functional class
I patients and the efficacy of ICDs in this population as a
whole is unknown (112a). The trial involving patients with
ischemic cardiomyopathy included a subset of asymptomatic
patients post-MI with LVEF 30% or less and there was
demonstrated benefit of ICD placement (MADIT-II) in that
subset. The findings potentially apply to large numbers of
patients and the number needed to treat to have benefit would
be great. The writing committee struggled with this issue
since guidelines are meant to summarize current science and
not take into account economic issues or the societal impact
of making a recommendation. However, the committee rec-
ognizes that economic impact and societal issues will clear-
ly modulate how these recommendations are implemented.  
In contrast, there are no data to recommend the use of
digoxin in patients with asymptomatic reduction of LVEF,
except in those with atrial fibrillation. Because the only rea-
son to treat such patients is to prevent the progression of HF,
and because digoxin has a minimal effect on disease pro-
gression in symptomatic patients (113), it is unlikely that the
drug would be beneficial in those with no symptoms.
Likewise, there are no data to recommend the routine use of
calcium channel blockers in patients with asymptomatic
reduction of LVEF, but they have not been shown to have
adverse effects and may be helpful for concomitant condi-
tions such as hypertension. However, the use of calcium
channel blockers with negative inotropic effects is not rec-
ommended in asymptomatic patients with EF less than 40%
after MI (114). 
Healthcare providers should pay particular attention to
patients whose cardiomyopathy is associated with a rapid
arrhythmia of supraventricular origin (e.g., atrial flutter or
atrial fibrillation). Although healthcare providers frequently
consider such tachycardias to be the result of an impairment
of ventricular function, these rhythm disorders may lead to or
exacerbate the development of a cardiomyopathy (115, 116).
Therefore, in patients with a reduced LVEF, every effort
should be made to control the ventricular response to these
tachyarrhythmias or to restore sinus rhythm (see Section
5.0). 
4.2.1.5. Patients With Severe Valvular Disease 
but No Symptoms
Valve replacement or repair surgery should be considered for
patients with severe aortic or mitral valve stenosis or regur-
gitation, even when ventricular function is impaired (117-
120). Long-term treatment with a systemic vasodilator drug
may be considered for those with severe aortic regurgitation
who are deemed to be poor candidates for surgery. Several
studies (121, 122) have suggested that prolonged therapy
with hydralazine and nifedipine in patients with severe aor-
tic regurgitation and preserved LV function might act to min-
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11. Patients with LVEF less than or equal to 35%, sinus
rhythm, and NYHA functional class III or ambulato-
ry class IV symptoms despite recommended, optimal
medical therapy and who have cardiac dyssynchrony,
which is currently defined as a QRS duration greater
than 0.12 ms, should receive cardiac resynchroniza-
tion therapy unless contraindicated. (Level of
Evidence: A)
12.Addition of an aldosterone antagonist is reasonable in
selected patients with moderately severe to severe
symptoms of HF and reduced LVEF who can be care-
fully monitored for preserved renal function and nor-
mal potassium concentration. Creatinine should be
less than or equal to 2.5 mg/dL in men or less than or
equal to 2.0 mg/dL in women and potassium should be
less than 5.0 mEq/L. Under circumstances where
monitoring for hyperkalemia or renal dysfunction is
not anticipated to be feasible, the risks may outweigh
the benefits of aldosterone antagonists. (Level of
Evidence: B)
Class IIa
1. Angiotensin II receptor blockers are reasonable to use
as alternatives to ACEIs as first-line therapy for
patients with mild to moderate HF and reduced
LVEF, especially for patients already taking ARBs for
other indications. (Level of Evidence: A)
2. Digitalis can be beneficial in patients with current or
prior symptoms of HF and reduced LVEF to decrease
hospitalizations for HF. (Level of Evidence: B)
3. The addition of a combination of hydralazine and a
nitrate is reasonable for patients with reduced LVEF
drugs, most antiarrhythmic drugs, and most calcium
channel blocking drugs; see text). (Level of Evidence:
B)
7. Exercise training is beneficial as an adjunctive
approach to improve clinical status in ambulatory
patients with current or prior symptoms of HF and
reduced LVEF. (Level of Evidence: B)
8. An implantable cardioverter-defibrillator is recom-
mended as secondary prevention to prolong survival
in patients with current or prior symptoms of HF and
reduced LVEF who have a history of cardiac arrest,
ventricular fibrillation, or hemodynamically destabi-
lizing ventricular tachycardia. (Level of Evidence: A)
9. Implantable cardioverter-defibrillator therapy is rec-
ommended for primary prevention to reduce total
mortality by a reduction in sudden cardiac death in
patients with ischemic heart disease who are at least
40 days post-MI, have an LVEF less than or equal to
30%, with NYHA functional class II or III symptoms
while undergoing chronic optimal medical therapy,
and have reasonable expectation of survival with a
good functional status for more than 1 year. (Level of
Evidence: A)
10. Implantable cardioverter-defibrillator therapy is rec-
ommended for primary prevention to reduce total
mortality by a reduction in sudden cardiac death in
patients with nonischemic cardiomyopathy who have
an LVEF less than or equal to 30%, with NYHA func-
tional class II or III symptoms while undergoing
chronic optimal medical therapy, and who have rea-
sonable expectation of survival with a good functional
status for more than 1 year. (Level of Evidence: B)
Table 4. Oral Diuretics Recommended for Use in the Treatment of Fluid Retention in Chronic Heart Failure
Initial Maximum Total
Drug Daily Dose(s) Daily Dose Duration of Action
Loop diuretics
Bumetanide 0.5 to 1.0 mg once or twice 10 mg 4 to 6 hours
Furosemide 20 to 40 mg once or twice 600 mg 6 to 8 hours
Torsemide 10 to 20 mg once 200 mg 12 to 16 hours
Thiazide diuretics
Chlorothiazide 250 to 500 mg once or twice 1000 mg 6 to 12 hours
Chlorthalidone 12.5 to 25 mg once 100 mg 24 to 72 hours
Hydrochlorothiazide 25 mg once or twice 200 mg 6 to 12 hours
Indapamide 2.5 once 5 mg 36 hours
Metolazone 2.5 mg once 20 mg 12 to 24 hours
Potassium-sparing diuretics
Amiloride 5 mg once 20 mg 24 hours
Spironolactone 12.5 to 25 mg once 50 mg* 2 to 3 days
Triamterene 50 to 75 mg twice 200 mg 7 to 9 hours
Sequential nephron blockade
Metolazone 2.5 to 10 mg once plus loop diuretic
Hydrochlorothiazide 25 to 100 mg once or twice plus loop diuretic
Chlorothiazide (IV) 500 to 1000 mg once plus loop diuretic 
mg indicates milligrams; IV, intravenous.
*Higher doses may occasionally be used with close monitoring.
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who are already taking an ACEI and beta-blocker for
symptomatic HF and who have persistent symptoms.
(Level of Evidence: A)
4. Placement of an implantable cardioverter-defibrilla-
tor is reasonable in patients with LVEF of 30% to
35% of any origin with NYHA functional class II or
III symptoms who are taking chronic optimal medical
therapy and who have reasonable expectation of sur-
vival with good functional status of more than 1 year.
(Level of Evidence: B)
Class IIb
1. A combination of hydralazine and a nitrate might be
reasonable in patients with current or prior symptoms
of HF and reduced LVEF who cannot be given an
ACEI or ARB because of drug intolerance, hypoten-
sion, or renal insufficiency. (Level of Evidence: C)
2. The addition of an ARB may be considered in persist-
ently symptomatic patients with reduced LVEF who
are already being treated with conventional therapy.
(Level of Evidence: B)
Class III
1. Routine combined use of an ACEI, ARB, and aldos-
terone antagonist is not recommended for patients
with current or prior symptoms of HF and reduced
LVEF. (Level of Evidence: C)
2. Calcium channel blocking drugs are not indicated as
routine treatment for HF in patients with current or
prior symptoms of HF and reduced LVEF. (Level of
Evidence: A)
3. Long-term use of an infusion of a positive inotropic
drug may be harmful and is not recommended for
patients with current or prior symptoms of HF and
reduced LVEF, except as palliation for patients with
end-stage disease who cannot be stabilized with stan-
dard medical treatment (see recommendations for
Stage D). (Level of Evidence: C)
4. Use of nutritional supplements as treatment for HF is
not indicated in patients with current or prior symp-
toms of HF and reduced LVEF. (Level of Evidence: C)
5. Hormonal therapies other than to replete deficiencies
are not recommended and may be harmful to patients
with current or prior symptoms of HF and reduced
LVEF. (Level of Evidence: C)
4.3.1.1. General Measures
Measures listed as class I recommendations for patients in
stages A or B are also appropriate for patients with current or
prior symptoms of HF (also see Section 5.0). In addition,
moderate sodium restriction, along with daily measurement
of weight, is indicated to permit effective use of lower and
safer doses of diuretic drugs, even if overt sodium retention
can be controlled by the use of diuretics. Immunization with
influenza and pneumococcal vaccines may reduce the risk of
a respiratory infection. Although most patients should not
participate in heavy labor or exhaustive sports, physical
activity should be encouraged (except during periods of
acute exacerbation of the signs and symptoms of HF, or in
patients with suspected myocarditis), because restriction of
activity promotes physical deconditioning, which may
adversely affect clinical status and contribute to the exercise
intolerance of patients with HF (123-126). 
Three classes of drugs can exacerbate the syndrome of HF
and should be avoided in most patients: 
1) Antiarrhythmic agents (127) can exert important car-
diodepressant and proarrhythmic effects. Of available
agents, only amiodarone and dofetilide (128) have been
shown not to adversely affect survival. 
2) Calcium channel blockers can lead to worsening HF and
have been associated with an increased risk of cardiovascu-
lar events (129). Of available calcium channel blockers, only
the vasoselective ones have been shown not to adversely
affect survival (130, 131). 
3) Nonsteroidal anti-inflammatory drugs can cause sodium
retention and peripheral vasoconstriction and can attenuate
the efficacy and enhance the toxicity of diuretics and ACEIs
(132-135). A discussion of the use of aspirin as a unique
agent is found later in this section (see Section 4.3.1.2.2.1).
Patients with HF should be monitored carefully for changes
in serum potassium, and every effort should be made to pre-
vent the occurrence of either hypokalemia or hyperkalemia,
both of which may adversely affect cardiac excitability and
conduction and may lead to sudden death (136). Activation
of both the sympathetic nervous system and renin-
angiotensin systems can lead to hypokalemia (137, 138), and
most drugs used for the treatment of HF can alter serum
potassium (139). Even modest decreases in serum potassium
can increase the risks of using digitalis and antiarrhythmic
drugs (136, 140), and even modest increases in serum potas-
sium may prevent the utilization of treatments known to pro-
long life (141). Hence, many experts believe that serum
potassium concentrations should be targeted in the 4.0 to 5.0
mmol per liter range. In some patients, correction of potassi-
um deficits may require supplementation of magnesium and
potassium (142). In others (particularly those taking ACEIs
alone or in combination with aldosterone antagonists), the
routine prescription of potassium salts may be unnecessary
and potentially deleterious. 
Of the general measures that should be used in patients
with HF, possibly the most effective yet least utilized is close
attention and follow-up. Nonadherence with diet and med-
ications can rapidly and profoundly affect the clinical status
of patients, and increases in body weight and minor changes
in symptoms commonly precede by several days the occur-
rence of major clinical episodes that require emergency care
or hospitalization. Patient education and close supervision,
which includes surveillance by the patient and his or her fam-
ily, can reduce the likelihood of nonadherence and lead to the
detection of changes in body weight or clinical status early
enough to allow the patient or a healthcare provider an
opportunity to institute treatments that can prevent clinical
deterioration. Supervision need not be performed by a physi-
cian and may ideally be accomplished by a nurse or physi-
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When using diuretics in patients with HF, healthcare
providers should keep several points in mind: 
1) Diuretics produce symptomatic benefits more rapidly
than any other drug for HF. They can relieve pulmonary and
peripheral edema within hours or days, whereas the clinical
effects of digitalis, ACEIs, or beta-blockers may require
weeks or months to become apparent (155, 156).
2) Diuretics are the only drugs used for the treatment of HF
that can adequately control the fluid retention of HF.
Although both digitalis and low doses of ACEIs can enhance
urinary sodium excretion (101,102), few patients with HF
and a history of fluid retention can maintain sodium balance
without the use of diuretic drugs. Attempts to substitute
ACEIs for diuretics can lead to pulmonary and peripheral
congestion (154). 
3) Diuretics should not be used alone in the treatment of
Stage C HF. Even when diuretics are successful in control-
ling symptoms and fluid retention, diuretics alone are unable
to maintain the clinical stability of patients with HF for long
periods of time (154). The risk of clinical decompensation
can be reduced, however, when diuretics are combined with
an ACEI and a beta-blocker (157).
4) Appropriate use of diuretics is a key element in the suc-
cess of other drugs used for the treatment of HF. The use of
inappropriately low doses of diuretics will result in fluid
retention, which can diminish the response to ACEIs and
increase the risk of treatment with beta-blockers (158).
Conversely, the use of inappropriately high doses of diuret-
ics will lead to volume contraction, which can increase the
risk of hypotension with ACEIs and vasodilators (158, 159)
and the risk of renal insufficiency with ACEIs and ARBs
(160). Optimal use of diuretics is the cornerstone of any suc-
cessful approach to the treatment of HF.
PRACTICAL USE OF DIURETIC THERAPY. Selection of patients.
Diuretics should be prescribed to all patients who have evi-
dence of, and to most patients with a prior history of, fluid
retention. Diuretics should generally be combined with an
ACEI and a beta-blocker. Few patients with HF will be able
to maintain dry weight without the use of diuretics. 
PRACTICAL USE OF DIURETIC THERAPY. Initiation and mainte-
nance. The most commonly used loop diuretic for the treat-
ment of HF is furosemide, but some patients respond favor-
ably to other agents in this category (such as torsemide)
because of superior absorption and longer duration of action
(161, 162). In outpatients with HF, therapy is commonly ini-
tiated with low doses of a diuretic, and the dose is increased
until urine output increases and weight decreases, generally
by 0.5 to 1.0 kg daily. Further increases in the dose or fre-
quency (i.e., twice-daily dosing) of diuretic administration
may be required to maintain an active diuresis and sustain the
loss of weight. The ultimate goal of diuretic treatment is to
eliminate clinical evidence of fluid retention, such as jugular
venous pressure elevation and peripheral edema. Diuretics
are generally combined with moderate dietary sodium
restriction (3 to 4 g daily). 
cian assistant with special training in the care of patients with
HF. Such an approach has been reported to have significant
clinical benefits (143-146). 
4.3.1.2. Drugs Recommended for Routine Use
Most patients with HF should be routinely managed with a
combination of 3 types of drugs: a diuretic, an ACEI or an
ARB, and a beta-blocker (147). The value of these drugs has
been established by the results of numerous large-scale clin-
ical trials, and the evidence supporting a central role for their
use is compelling and persuasive. Patients with evidence of
fluid retention should take a diuretic until a euvolemic state
is achieved, and diuretic therapy should be continued to pre-
vent the recurrence of fluid retention. Even if the patient has
responded favorably to the diuretic, treatment with both an
ACEI and a beta-blocker should be initiated and maintained
in patients who can tolerate them because they have been
shown to favorably influence the long-term prognosis of HF.
Therapy with digoxin as a fourth agent may be initiated at
any time to reduce symptoms, prevent hospitalization, con-
trol rhythm, and enhance exercise tolerance.
4.3.1.2.1. DIURETICS. Diuretics interfere with the sodium
retention of HF by inhibiting the reabsorption of sodium or
chloride at specific sites in the renal tubules. Bumetanide,
furosemide, and torsemide act at the loop of Henle (thus,
they are called loop diuretics), whereas thiazides, metola-
zone, and potassium-sparing agents (e.g., spironolactone) act
in the distal portion of the tubule (148, 149). These 2 classes
of diuretics differ in their pharmacological actions. The loop
diuretics increase sodium excretion up to 20% to 25% of the
filtered load of sodium, enhance free water clearance, and
maintain their efficacy unless renal function is severely
impaired. In contrast, the thiazide diuretics increase the frac-
tional excretion of sodium to only 5% to 10% of the filtered
load, tend to decrease free water clearance, and lose their
effectiveness in patients with impaired renal function (creati-
nine clearance less than 40 ml per min). Consequently, the
loop diuretics have emerged as the preferred diuretic agents
for use in most patients with HF; however, thiazide diuretics
may be preferred in hypertensive HF patients with mild fluid
retention because they confer more persistent antihyperten-
sive effects.
Effect of Diuretics in the Management of HF. Controlled tri-
als have demonstrated the ability of diuretic drugs to increase
urinary sodium excretion and decrease physical signs of fluid
retention in patients with HF (150, 151). In these short-term
studies, diuretic therapy has led to a reduction in jugular
venous pressures, pulmonary congestion, peripheral edema,
and body weight, all of which were observed within days of
initiation of therapy. In intermediate-term studies, diuretics
have been shown to improve cardiac function, symptoms,
and exercise tolerance in patients with HF (152-154). There
have been no long-term studies of diuretic therapy in HF, and
thus, their effects on morbidity and mortality are not known. 
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markedly enhanced when 2 diuretics are used in combina-
tion. The loss of electrolytes is related to enhanced delivery
of sodium to distal sites in the renal tubules and the exchange
of sodium for other cations, a process that is potentiated by
activation of the renin-angiotensin-aldosterone system (149).
Potassium deficits can be corrected by the short-term use of
potassium supplements or, if severe, by the addition of mag-
nesium supplements (174). Concomitant administration of
ACEIs alone or in combination with potassium-retaining
agents (such as spironolactone) can prevent electrolyte
depletion in most patients with HF who are taking a loop
diuretic. When these drugs are prescribed, long-term oral
potassium supplementation frequently is not needed and may
be deleterious. 
Excessive use of diuretics can decrease blood pressure and
impair renal function and exercise tolerance (158-160, 175),
but hypotension and azotemia may also occur as a result of
worsening HF, which may be exacerbated by attempts to
reduce the dose of diuretics. If there are no signs of fluid
retention, hypotension and azotemia are likely to be related
to volume depletion and may resolve after a reduction in
diuretic dose. The signs of fluid retention, hypotension and
azotemia, are likely to reflect worsening HF and a decline in
effective peripheral perfusion. This is an ominous clinical
scenario and necessitates considering the measures discussed
under Stage D HF.
Tables 4 and 5 illustrate oral and intravenous diuretics rec-
ommended for use in the treatment of chronic HF.
4.3.1.2.2. INHIBITORS OF THE RENIN-ANGIOTENSIN-ALDOS-
TERONE SYSTEM. Inhibition of the renin-angiotensin-aldos-
terone system can take place at multiple sites: at the level of
the enzyme that converts angiotensin I to angiotensin II
(ACEIs), at the angiotensin receptor (ARBs), or at the recep-
tor for aldosterone, which is under control of both the renin-
angiotensin system and other systemic and local influences
(aldosterone antagonists). Angiotensin converting enzyme
inhibitors are the best studied class of agents in HF, with
multiple mechanisms of benefit for both HF, coronary dis-
ease, and other atherosclerotic vascular disease, as well as
diabetic nephropathy. During chronic therapy with ACEIs,
the renin-angiotensin system demonstrates partial “escape”
from inhibition with “normalization” of angiotensin levels,
in part owing to alternative local pathways for production of
angiotensin. This leaves the potential for benefit from addi-
tional therapy with ARBs and with the aldosterone antago-
nists. 
4.3.1.2.2.1. Angiotensin Converting Enzyme Inhibitors:
Angiotensin Converting Enzyme Inhibitors in the Manage-
ment of HF. It is not clear whether the effects of ACEIs can
be explained solely by the suppression of angiotensin II pro-
duction, because ACE inhibition not only interferes with the
renin-angiotensin system but also enhances the action of
kinins and augments kinin-mediated prostaglandin produc-
tion (176-178). In experimental models of HF, ACEIs modi-
fy cardiac remodeling more favorably than ARBs (179-182),
If electrolyte imbalances are seen, these should be treated
aggressively and the diuresis continued. If hypotension or
azotemia is observed before the goals of treatment are
achieved, the physician may elect to slow the rapidity of
diuresis, but diuresis should nevertheless be maintained until
fluid retention is eliminated, even if this strategy results in
mild or moderate decreases in blood pressure or renal func-
tion, as long as the patient remains asymptomatic. Excessive
concern about hypotension and azotemia can lead to the
underutilization of diuretics and a state of refractory edema.
Persistent volume overload not only contributes to the per-
sistence of symptoms but may also limit the efficacy and
compromise the safety of other drugs used for the treatment
of HF (163). 
Once fluid retention has resolved, treatment with the
diuretic should be maintained to prevent the recurrence of
volume overload. Patients are commonly prescribed a fixed
dose of diuretic, but the dose of these drugs frequently may
need adjustment. In many cases, this adjustment can be
accomplished by having patients record their weight each
day and make changes in their diuretic dosage if the weight
increases or decreases beyond a specified range. 
The response to a diuretic is dependent on the concentra-
tion of the drug and the time course of its entry into the urine
(148, 149). Patients with mild HF respond favorably to low
doses because they absorb diuretics rapidly from the bowel
and deliver these drugs rapidly to the renal tubules. However,
as HF advances, the absorption of the drug may be delayed
by bowel edema or intestinal hypoperfusion, and the delivery
of the drug and the response to a given intratubular concen-
tration may be impaired by a decline in renal perfusion and
function (164-166). Consequently, the clinical progression of
HF is characterized by the need for increasing doses of
diuretics. 
Patients may become unresponsive to high doses of diuret-
ic drugs if they consume large amounts of dietary sodium,
are taking agents that can block the effects of diuretics (e.g.,
nonsteroidal anti-inflammatory drugs, including cyclo-oxy-
genase-2 inhibitors) (133, 134, 167), or have a significant
impairment of renal function or perfusion (161). Diuretic
resistance can generally be overcome by the intravenous
administration of diuretics (including the use of continuous
infusions) (168), the use of 2 or more diuretics in combina-
tion (e.g., furosemide and metolazone) (169-172), or the use
of diuretics together with drugs that increase renal blood
flow (e.g., positive inotropic agents) (172). 
PRACTICAL USE OF DIURETIC THERAPY. Risks of treatment.
The principal adverse effects of diuretics include electrolyte
and fluid depletion, as well as hypotension and azotemia.
Diuretics may also cause rashes and hearing difficulties, but
these are generally idiosyncratic or are seen with the use of
very large doses, respectively.
Diuretics can cause the depletion of important cations
(potassium and magnesium), which can predispose patients
to serious cardiac arrhythmias, particularly in the presence of
digitalis therapy (173). The risk of electrolyte depletion is
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scribed without diuretics in patients with a current or recent
history of fluid retention, because diuretics are needed to
maintain sodium balance and prevent the development of
peripheral and pulmonary edema (154). Angiotensin con-
verting enzyme inhibitors are often preferred over ARBs or
direct-acting vasodilators (194, 196) because of the greater
experience and weight of evidence in support of their effec-
tiveness.
Patients should not be given an ACEI if they have experi-
enced life-threatening adverse reactions (angioedema or
anuric renal failure) during previous exposure to the drug or
if they are pregnant. They should take an ACEI with caution
if they have very low systemic blood pressures (systolic
blood pressure less than 80 mm Hg), markedly increased
serum levels of creatinine (greater than 3 mg per dL), bilat-
eral renal artery stenosis, or elevated levels of serum potassi-
um (greater than 5.5 mmol per liter). Finally, treatment with
an ACEI should not be initiated in hypotensive patients who
are at immediate risk of cardiogenic shock. Such patients
should first receive other forms of treatment for their HF and
then be re-evaluated for ACE inhibition once stability has
been achieved.
PRACTICAL USE OF ACE INHIBITORS. Initiation and mainte-
nance. Although most of the evidence that supports an effect
of ACEIs on the survival of patients with HF is derived from
experience with enalapril, the available data suggest that
there are no differences among available ACEIs in their
effects on symptoms or survival (183). Although some have
suggested that drugs in this class may differ in their ability to
inhibit tissue ACE, no trial has shown that tissue ACE-
inhibiting agents are superior to other ACEIs in any clinical
aspect of HF. Nevertheless, in selecting among ACEIs, it is
recommended that preference be given to ACEIs that have
been shown to reduce morbidity and mortality in clinical tri-
and this advantage of ACEIs is abolished by the coadminis-
tration of a kinin receptor blocker (179, 181). Angiotensin
converting enzyme inhibitors have been evaluated in more
than 7000 patients with HF who participated in more than 30
placebo-controlled clinical trials (183). All of these trials
enrolled patients with reduced LVEF (EF less than 35% to
40%) who were treated with diuretics, with or without digi-
talis. These trials recruited many types of patients, including
women and the elderly, as well as patients with a wide range
of causes and severity of LV dysfunction. However, patients
with preserved systolic function, low blood pressure (less
than 90 mm Hg systolic), or impaired renal function (serum
creatinine greater than 2.5 mg per mL) were not recruited or
represented a small proportion of patients who participated
in these studies. 
Analysis of this collective experience indicates that ACEIs
can alleviate symptoms, improve clinical status, and enhance
the overall sense of well-being of patients with HF (184-
195). In addition, ACEIs can reduce the risk of death and the
combined risk of death or hospitalization (193-195). These
benefits of ACE inhibition were seen in patients with mild,
moderate, or severe symptoms and in patients with or with-
out coronary artery disease. 
PRACTICAL USE OF ACE INHIBITORS. Selection of patients.
Angiotensin converting enzyme inhibitors should be pre-
scribed to all patients with HF due to LV systolic dysfunction
with reduced LVEF unless they have a contraindication to
their use or have been shown to be unable to tolerate treat-
ment with these drugs. Because of their favorable effects on
survival, treatment with an ACEI should not be delayed until
the patient is found to be resistant to treatment with other
drugs. 
In general, ACEIs are used together with a beta-blocker.
Angiotensin converting enzyme inhibitors should not be pre-
Table 5. Intravenous Diuretic Medications Useful for the Treatment of Severe Heart Failure
Maximum 
Drug Initial Dose Single Dose
Loop diuretics
Bumetanide 1.0 mg 4 to 8 mg
Furosemide 40 mg 160 to 200 mg
Torsemide 10 mg 100 to 200 mg
Thiazide diuretics
Chlorothiazide 500 mg 1000 mg
Sequential nephron blockade
Chlorothiazide 500 to 1000 mg IV once or twice 
plus loop diuretics once; multiple doses per day
Metolazone (as Zaroxolyn or Diulo) 2.5 to 5 mg PO once or twice daily 
with loop diuretic
Intravenous infusions
Bumetanide 1-mg IV load, then 0.5 to 2 mg per hour infusion
Furosemide 40-mg IV load, then 10 to 40 mg per hour infusion
Torsemide 20-mg IV load, then 5 to 20 mg per hour infusion
mg indicates milligrams; IV, intravenous.
*Higher doses may occasionally be used with close monitoring.
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als in HF or post-MI populations (captopril, enalapril, lisino-
pril, perindopril, ramipril, and trandolapril), because these
studies have clearly defined a dose that is effective in modi-
fying the natural history of the disease. Such information is
generally lacking for ACEIs that have not been shown to be
effective in large-scale studies. 
Treatment with an ACEI should be initiated at low doses
(see Table 5), followed by gradual increments in dose if
lower doses have been well tolerated. Renal function and
serum potassium should be assessed within 1 to 2 weeks of
initiation of therapy and periodically thereafter, especially in
patients with pre-existing hypotension, hyponatremia, dia-
betes mellitus, or azotemia or in those taking potassium sup-
plements. Because fluid retention can blunt the therapeutic
effects and fluid depletion can potentiate the adverse effects
of ACE (160, 163), healthcare providers should ensure that
patients are being given appropriate doses of diuretics before
and during treatment with these drugs. Most patients (85% to
90%) with HF can tolerate short- and long-term therapy with
these drugs (193-195). 
What dose of an ACEI should physicians try to achieve in
patients with HF? In controlled clinical trials that were
designed to evaluate survival, the dose of the ACEI was not
determined by a patient’s therapeutic response but was
increased until a target dose was reached (193-195).
However, these drugs are commonly prescribed in clinical
practice at much lower doses that are similar to those recom-
mended for initiation rather than maintenance of therapy.
Which approach should be followed? In the controlled clini-
cal trials of ACEIs, low or intermediate doses were com-
monly prescribed if higher doses could not be tolerated. In
controlled trials with newer agents for HF, intermediate
doses rather than high doses of ACEIs were generally used as
background therapy. Higher doses of an ACEI were better
than low doses in reducing the risk of hospitalization, but
they showed similar effects on symptoms and mortality (197,
198). Clinicians should attempt to use doses that have been
shown to reduce the risk of cardiovascular events in clinical
trials. If these target doses of an ACEI cannot be used or are
poorly tolerated, intermediate doses should be used with the
expectation that there are likely to be only small differences
in efficacy between low and high doses. More importantly,
clinicians should not delay the institution of beta-blockers in
patients because of a failure to reach target ACEI doses.
Once the drug has been titrated to the appropriate dose,
patients can generally be maintained on long-term therapy
with an ACEI with little difficulty. Although symptoms may
improve in some patients within the first 48 hours of therapy
with an ACEI, the clinical responses to these drugs are gen-
erally delayed and may require several weeks, months, or
more to become apparent (155, 184). Even if symptoms do
not improve, long-term treatment with an ACEI should be
maintained to reduce the risk of death or hospitalization.
Abrupt withdrawal of treatment with an ACEI can lead to
clinical deterioration and should be avoided (199) in the
absence of life-threatening complications (e.g., angioedema). 
Every effort should be made to minimize the occurrence of
sodium retention or depletion during long-term treatment
with an ACEI, because changes in salt and water balance can
exaggerate or attenuate the cardiovascular and renal effects
of treatment (160, 163). Fluid retention can minimize the
symptomatic benefits of ACE inhibition, whereas fluid loss
increases the risk of hypotension and azotemia. The use of an
ACEI can also minimize or eliminate the need for long-term
potassium supplementation. Nonsteroidal anti-inflammatory
drugs can block the favorable effects and enhance the
adverse effects of ACEIs in patients with HF and should be
avoided (135, 137). 
Clinical experience in patients who are hemodynamically
or clinically unstable suggests that the hypotensive effects of
ACE inhibition may attenuate the natriuretic response to
diuretics and antagonize the pressor response to intravenous
vasoconstrictors (200, 201). As a result, in such patients (par-
ticularly those who are responding poorly to diuretic drugs),
it may be prudent to interrupt treatment with the ACEI tem-
porarily until the clinical status of the patient stabilizes. 
Retrospective analyses of large-scale clinical trials have
suggested that aspirin might interfere with the benefits of
ACE inhibition in patients with HF by inhibiting kinin-medi-
ated prostaglandin synthesis. In short-term hemodynamic
and maximal-exercise studies, aspirin can attenuate the
hemodynamic actions of ACEIs in patients with HF (202,
203), an effect not seen with nonaspirin antiplatelet agents
(e.g., clopidogrel) (204). 
In several multicenter trials, concomitant use of aspirin was
associated with a diminution of the effect of ACEIs on sur-
vival and on cardiovascular morbidity (205, 206). A recent
comprehensive systematic overview of 22 060 patients from
6 long-term randomized trials of ACEIs re-evaluated the
issue of the potential detrimental effect of combining aspirin
with ACEI therapy. When all of these trials were considered
together, the effects of ACEIs were significantly beneficial in
patients with and without aspirin therapy. The composite risk
reduction was 20% for patients taking aspirin and 29% for
those not taking aspirin, a difference that did not reach sta-
tistical significance (207). A second retrospective review
subsequently also reported no adverse effect of concomitant
aspirin use with ACEIs on long-term survival (208). Given
these retrospective results, many physicians believe the data
justify prescribing aspirin and ACEIs together when there is
an indication for use of aspirin. However, these large
overviews are subject to varying interpretation. Other physi-
cians would consider not combining aspirin with an ACEI
because there are no data to indicate that it can reduce the
risk of ischemic events in patients with HF (209, 210), or
they might consider the use of an alternative antiplatelet
agent such as clopidogrel, which does not interact with
ACEIs and which may have superior effects in preventing
ischemic events (211). However, clopidogrel does not have
an indication for the primary prevention of ischemic events.
There may be an important interaction between aspirin and
ACEIs, but there is controversy regarding this point, and it
requires further study. 
PRACTICAL USE OF ACE INHIBITORS. Risks of treatment. Most
of the adverse reactions of ACEIs can be attributed to the 2
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3. POTASSIUM RETENTION
Hyperkalemia can occur during ACE inhibition in patients
with HF and may be sufficiently severe to cause cardiac con-
duction disturbances. In general, hyperkalemia is seen in
patients whose renal function deteriorates or who are taking
oral potassium supplements or potassium-sparing diuretics,
or aldosterone antagonists, especially if they have diabetes
mellitus (218).
Adverse effects related to kinin potentiation.
1. COUGH
Cough related to the use of ACEIs is the most common rea-
son for the withdrawal of long-term treatment with these
drugs (219); the frequency of cough is approximately 5% to
10% in white patients of European descent and rises to near-
ly 50% in Chinese patients (220). It is characteristically non-
productive, is accompanied by a persistent and annoying
"tickle" in the back of the throat, usually appears within the
first months of therapy, disappears within 1 to 2 weeks of
discontinuing treatment, and recurs within days of rechal-
lenge. Other causes of cough, especially pulmonary conges-
tion, should always be considered, and the ACEI should be
implicated only after these have been excluded.
Demonstration that the cough disappears after drug with-
drawal and recurs after rechallenge with another ACEI
strongly suggests that ACE inhibition is the cause of the
cough. In a number of studies of ACEI cough, it was found
that this symptom did not recur with rechallenge and proba-
bly was a coincidental finding. Because of the long-term
benefits of ACEIs, physicians should encourage patients to
continue taking these drugs if the cough is not severe. Only
if the cough proves to be persistent and troublesome should
the physician consider withdrawal of the ACEI and the use of
alternative medications (e.g., an ARB).
2. ANGIOEDEMA
Angioedema occurs in fewer than 1% of patents taking an
ACEI but is more frequent in blacks. Because its occurrence
may be life-threatening, the clinical suspicion of this reaction
justifies subsequent avoidance of all ACEIs for the lifetime
of the patient (219). Angiotensin converting enzyme
inhibitors should not be initiated in any patient with a histo-
ry of angioedema. Although ARBs may be considered as
alternative therapy for patients who have developed
angioedema while taking an ACEI, there are a number of
patients who have also developed angioedema with ARBs
and extreme caution is advised when substituting an ARB in
a patient who has had angioedema associated with ACEI use
(221-223, 223a).
4.3.1.2.2.2. Angiotensin Receptor Blockers. Agents that
block these receptors were developed on the rationale that 1)
angiotensin II production continues in the presence of ACE
inhibition, driven through alternative enzyme pathways, and
2) interference with the renin-angiotensin system without
principal pharmacological actions of these drugs: those relat-
ed to angiotensin suppression and those related to kinin
potentiation. Other types of side effects may also occur (e.g.,
rash and taste disturbances).
Adverse effects related to angiotensin suppression.
1. HYPOTENSION
The most common adverse effects of ACE inhibition in
patients with HF are hypotension and dizziness. Blood pres-
sure declines without symptoms in nearly every patient treat-
ed with an ACEI, so hypotension is generally a concern only
if it is accompanied by postural symptoms, worsening renal
function, blurred vision, or syncope. Hypotension is seen
most frequently during the first few days of initiation of
increments in therapy, particularly in patients with hypov-
olemia, a recent marked diuresis, or severe hyponatremia
(serum sodium concentration less than 130 mmol per liter)
(212). 
Should symptomatic hypotension occur with the first
doses, it may not recur with repeated administration of the
same doses of the drug. However, it is prudent under such
circumstances to reduce the activation of and dependence on
the renin-angiotensin system by reducing the dose of diuret-
ics, liberalizing salt intake, or both, provided the patient does
not have significant fluid retention. The doses of other
hypotensive agents (especially vasodilators) can be reduced
or staggered so their peak effect does not coincide with that
of the ACEI. Most patients who experience early sympto-
matic hypotension remain excellent candidates for long-term
ACE inhibition if appropriate measures are taken to mini-
mize recurrent hypotensive reactions.
2. WORSENING RENAL FUNCTION
In states characterized by reduced renal perfusion (such as
HF), glomerular filtration is critically dependent on
angiotensin-mediated efferent arteriolar vasoconstriction
(213), and ACE inhibition may cause functional renal insuf-
ficiency (160). Because the decline in glomerular filtration is
related to the withdrawal of the actions of angiotensin II, the
risk of azotemia is highest in patients who are most depend-
ent on the renin-angiotensin system for support of renal
homeostasis (i.e., class IV or hyponatremic patients) (214). A
significant increase in serum creatinine (e.g., greater than 0.3
mg per dL) with the use of ACEIs is observed in 15% to 30%
of patients with severe HF (215), but in only 5% to 15% of
patients with mild to moderate symptoms (216). The risks
are substantially greater if patients have bilateral renal artery
stenosis or are taking nonsteroidal anti-inflammatory drugs
(134, 137, 217). Renal function usually improves after a
reduction in the dose of concomitantly administered diuret-
ics, and thus, these patients can generally be managed with-
out the need to withdraw treatment with the ACEI (160).
However, if the dose of diuretic cannot be reduced because
the patient has fluid retention, the physician and patient may
need to tolerate mild to moderate degrees of azotemia to
maintain therapy with the ACEI.
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inhibition of kininase would produce all of the benefits of
ACEIs while minimizing the risk of their adverse reactions
(224). However, it is now known that some of the benefits
may be related to the accumulation of kinins (225) rather
than to the suppression of angiotensin II formation, whereas
some of the side effects of ACEIs in HF are related to the
suppression of angiotensin II formation (179-181). Table 6
lists the inhibitors of the renin-angiotensin-aldosterone sys-
tem and beta-blockers that are commonly used for the treat-
ment of patients with HF with low ejection fraction.
Several ARBs (e.g., candesartan, eprosartan, irbesartan,
losartan, telmisartan, olmesartan, and valsartan) are avail-
able for clinical use. Experience with these drugs in con-
trolled clinical trials of patients with HF is considerably less
than that with ACEIs. Nevertheless, in several placebo-con-
trolled studies, long-term therapy with ARBs produced
hemodynamic, neurohormonal, and clinical effects consis-
tent with those expected after interference with the renin-
angiotensin system (226-231). In patients with evidence of
LV dysfunction early after MI, a recent trial demonstrated
that ARBs had a benefit that was not inferior to that of
ACEIs without an advantage in terms of tolerability (110).
However, the addition of an ARB to an ACEI did not
improve outcomes and resulted in more side effects. 
For patients unable to tolerate ACEIs because of cough or
angioedema, the ARBs valsartan and candesartan (223, 232)
have demonstrated benefit by reducing hospitalizations and
mortality. The combination of an ACEI and ARBs may pro-
duce more reduction of LV size than either agent alone
(233). The addition of ARBs to chronic ACEI therapy
caused a modest decrease in hospitalization in 2 studies,
with a trend to decreased total mortality in one and no
impact on mortality in another (232-234).
Recommendations Concerning ARBs.
Angiotensin converting enzyme inhibitors remain the first
choice for inhibition of the renin-angiotensin system in
chronic HF, but ARBs can now be considered a reasonable
alternative. Candesartan improved outcomes in patients with
preserved LVEF who were intolerant of ACEIs in the
Candesartan in Heart Failure Assessment of Reduction in
Mortality and Morbidity (CHARM) Preserved trial (235).
Angiotensin receptor blockers are as likely to produce
hypotension, worsening renal function, and hyperkalemia as
ACEIs. Although angioedema is much less frequent with
ARBs, there are cases of patients who developed angioede-
ma to both ACEIs and later to ARBs (223). There is little
information available about the addition of ARBs to therapy
with both ACEIs and aldosterone antagonists, but risks of
renal dysfunction and hyperkalemia would be further
increased. Until further information is available, the routine
combined use of all 3 inhibitors of the renin-angiotensin sys-
tem cannot be recommended.
Table 6. Inhibitors of the Renin-Angiotensin-Aldosterone System and Beta-Blockers Commonly Used
for the Treatment of Patients With Heart Failure With Low Ejection Fraction
Initial Maximum 
Drug Daily Dose(s) Dose(s)
ACE inhibitors
Captopril 6.25 mg 3 times 50 mg 3 times
Enalapril 2.5 mg  twice 10 to 20 mg twice
Fosinopril 5 to 10 mg once 40 mg once
Lisinopril 2.5 to 5 mg once 20 to 40 mg once
Perindopril 2 mg once 8 to 16 mg once
Quinapril 5 mg twice 20 mg twice
Ramipril 1.25 to 2.5 mg once 10 mg once
Trandolapril 1 mg once 4 mg once
Angiotensin receptor blockers
Candesartan 4 to 8 mg once 32 mg once
Losartan 25 to 50 mg once 50 to 100 mg once
Valsartan 20 to 40 mg twice 160 mg twice
Aldosterone antagonists
Spironolactone 12.5 to 25 mg once 25 mg once or twice
Eplerenone 25 mg once 50 mg once
Beta-blockers
Bisoprolol 1.25 mg once 10 mg once
Carvedilol 3.125 mg twice 25 mg twice
50 mg twice for patients over 85 kg
Metoprolol succinate 12.5 to 25 mg once 200 mg once
extended release 
(metoprolol CR/XL)
ACE indicates angiotensin converting enzyme; mg, milligrams; and kg, kilograms.
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with LV dysfunction early after MI. These recommendations
are based on the strong data demonstrating reduced death
and rehospitalization in 2 clinical trial populations (98,141).
The entry criteria for these trials describe a broader popula-
tion than was actually enrolled, such that the favorable effi-
cacy/toxicity ratio may not be as applicable to patients at the
margins of trial eligibility. For both of these major trials,
patients were excluded for a serum creatinine level in excess
of 2.5 mg per dL, but few patients were actually enrolled
with serum creatinine levels over 1.5 mg per dL. In the trial
of patients after MI, there was a significant interaction
between serum creatinine and benefit of eplerenone. The
average serum creatinine of enrolled patients was 1.1 mg per
dL, above which there was no demonstrable benefit for sur-
vival. 
To minimize the risk of life-threatening hyperkalemia in
patients with low LVEF and symptoms of HF, patients
should have initial serum creatinine less than 2.0 to 2.5 mg
per dL without recent worsening and serum potassium less
than 5.0 mEq per dL without a history of severe hyper-
kalemia. In view of the consistency of evidence for patients
with low LVEF early after MI and patients with recent
decompensation and severe symptoms, it may be reasonable
to consider addition of aldosterone antagonists to loop
diuretics for some patients with mild to moderate symptoms
of HF; however, the Writing Committee strongly believes
that there are insufficient data or experience to provide a spe-
cific or strong recommendation. Because the safety and effi-
cacy of aldosterone antagonist therapy has not been shown in
the absence of loop diuretic therapy, it is not currently rec-
ommended that such therapy be given without other con-
comitant diuretic therapy in chronic HF. Although 17% of
patients in the CHARM add-on trial were receiving spirono-
lactone, the safety of the combination of ACEIs, ARBs, and
aldosterone antagonists has not been explored adequately,
and this combination cannot be recommended.
PRACTICAL USE OF ALDOSTERONE ANTAGONISTS. Selection of
patients. Decisions regarding the selection of patients for
aldosterone antagonists reflect the balance between potential
benefit to decrease death and hospitalization from HF and
potential risks of life-threatening hyperkalemia. Despite this,
patients who meet recommended criteria from formal trials
may need to be excluded in practice for a recent history of
renal dysfunction characterized by higher creatinine,
markedly elevated blood urea nitrogen, or hyperkalemia,
particularly in the presence of insulin-requiring diabetes mel-
litus. Serum creatinine levels often underestimate renal dys-
function, particularly in the elderly, in whom estimated crea-
tinine clearance less than 50 mL per min should trigger a
reduction of the initial dose of spironolactone to 12.5 mg
daily or of eplerenone to 25 mg daily, and aldosterone antag-
onists should not be given when clearance is less than 30 mL
per minute (Table 7). Patients chronically requiring high
doses of diuretics without potassium replacement should be
evaluated closely, because potassium handling may be
impaired.
PRACTICAL USE OF ARBS. Initiation and maintenance. When
used, angiotensin receptor antagonists should be initiated
with the starting doses shown in Table 6. Many of the con-
siderations with ARB are similar to those with initiation of
an ACEI, as discussed above. Blood pressure (including pos-
tural blood pressure changes), renal function, and potassium
should be reassessed within 1 to 2 weeks after initiation and
followed closely after changes in dose. Patients with systolic
blood pressure below 80 mm Hg, low serum sodium, dia-
betes mellitus, and impaired renal function merit particular
surveillance during therapy with inhibitors of the renin-
angiotensin-aldosterone system. Titration is generally
achieved by doubling doses. For stable patients, it is reason-
able to add therapy with beta-blocking agents before full tar-
get doses of either ACEIs or ARBs are reached. 
The risks of treatment with ARBs are those attributed to
suppression of angiotensin stimulation, as discussed above
for ACEIs. These risks of hypotension, renal dysfunction,
and hyperkalemia are greater when combined with another
inhibitor of this axis, such as ACEIs or aldosterone antago-
nists.
4.3.1.2.2.3. Aldosterone Antagonists. Although short-term
therapy with both ACEIs and ARBs can lower circulating
levels of aldosterone, such suppression may not be sustained
during long-term treatment (236). The lack of long-term sup-
pression may be important, because experimental data sug-
gest that aldosterone exerts adverse effects on the structure
and function of the heart, independently of and in addition to
the deleterious effects produced by angiotensin II (237-243). 
Spironolactone is the most widely used aldosterone antag-
onist. In a large-scale, long-term trial (141), low doses of
spironolactone (starting at 12.5 mg daily) were added to
ACEI therapy for patients with NYHA class IV HF symp-
toms or class III symptoms and recent hospitalization. The
risk of death was reduced from 46% to 35% (30% relative
risk reduction) over 2 years, with a 35% reduction in HF hos-
pitalization and an improvement in functional class. Initial
creatinine levels were below 2.0 mg per dL in the dose-rang-
ing pilot trial and below 2.5 mg per dL in the main trial.
Potassium replacements were stopped at trial entry, and
serum potassium and renal function were followed very
closely. 
A recent trial investigated the newer aldosterone antagonist
eplerenone in patients with LVEF less than or equal to 40%
and clinical evidence of HF or diabetes mellitus within 14
days of MI. Mortality was decreased from 13.6% to 11.8% at
1 year. Hyperkalemia occurred in 5.5% of patients treated
with eplerenone compared with 3.9% of those given placebo
overall and in up to 10.1% versus 4.6% of patients with esti-
mated creatinine clearance less than 50 mL per min (98).
Recommendations Concerning Aldosterone
Antagonists.
The addition of low-dose aldosterone antagonists should be
considered in carefully selected patients with moderately
severe or severe HF symptoms and recent decompensation or
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there is a great increase in evidence of toxicity when the trial
results are applied to the general population.
Although aldosterone antagonists usually have a relatively
weak diuretic effect, some patients may experience marked
potentiation of other diuretic therapy after the addition of
aldosterone antagonists. Fluid depletion can occur, which
further increases the risk of renal dysfunction and hyper-
kalemia. During chronic therapy after initial stabilization,
hyperkalemia may occur in the setting of other conditions
that cause volume depletion, such as gastroenteritis.
Gynecomastia or other antiandrogen effects that can occur
during therapy with spironolactone are not generally seen
with the newer aldosterone antagonist eplerenone (98).
PRACTICAL USE OF ALDOSTERONE ANTAGONISTS. Initiation
and Monitoring. Spironolactone should be initiated at a dose
of 12.5 to 25 mg daily, or occasionally on alternate days.
Eplerenone was used after MI in one study (98) at doses of
25 mg per day, increasing to 50 mg daily. Potassium supple-
mentation is generally stopped after the initiation of aldos-
terone antagonists, and patients should be counseled to avoid
high potassium–containing foods. However, patients who
have required large amounts of potassium supplementation
may need to continue receiving supplementation, albeit at a
lower dose, particularly when previous episodes of
hypokalemia have been associated with ventricular arrhyth-
mias. On the other hand, potassium supplementation
required during vigorous therapy of fluid overload is often
no longer necessary once the goal is to maintain even fluid
balance. Patients should be cautioned to avoid the addition of
nonsteroidal anti-inflammatory agents and cyclo-oxygenase-
2 inhibitors, which can lead to worsening renal function and
hyperkalemia. Potassium levels and renal function should be
rechecked within 3 days and again at 1 week after initiation
of an aldosterone antagonist. Subsequent monitoring should
be dictated by the general clinical stability of renal function
and fluid status but should occur at least monthly for the first
3 months and every 3 months thereafter. The addition or an
increase in dosage of ACEIs or ARBs should trigger a new
cycle of monitoring. In view of the potential risk for hyper-
kalemia, the Writing Committee recommends that the routine
triple combination of ACEIs, ARBs, and an aldosterone
antagonist be avoided.
The development of potassium levels in excess of 5.5 mEq
per liter should generally trigger discontinuation or dose
reduction of the aldosterone antagonist unless patients have
been receiving potassium supplementation, which should
then be stopped. The development of worsening renal func-
tion should lead to careful evaluation of the entire medical
regimen and consideration for stopping the aldosterone
antagonist. Patients should be instructed specifically to stop
the aldosterone antagonist during an episode of diarrhea or
while loop diuretic therapy is interrupted.
4.3.1.2.3. BETA-ADRENERGIC RECEPTOR BLOCKERS. Beta-
blockers act principally to inhibit the adverse effects of the
sympathetic nervous system in patients with HF, and these
effects far outweigh their well-known negative inotropic
PRACTICAL USE OF ALDOSTERONE ANTAGONISTS. Risks of
Aldosterone Antagonists. The major risk of aldosterone
antagonists is hyperkalemia due to inhibition of potassium
excretion. Renal dysfunction may be aggravated, which fur-
ther impairs potassium excretion. The positive results of a
recent trial led to wider use of spironolactone in HF regi-
mens. The subsequent incidence of hyperkalemia was
reported to be as high as 24% in one series (312), in which
half of the subjects with hyperkalemia had potassium levels
in excess of 6 mEq per liter. Similar results were reported
from Norway (245). Although this far exceeded the 2% inci-
dence in the large trial, it is comparable to the 13% observed
in the preceding pilot trial with a 25-mg dose and 20% with
a 50-mg dose. 
The potential impact on the overall HF population is sug-
gested by a population-based analysis in Ontario, Canada of
more than 30 000 patients taking ACEIs after a hospitaliza-
tion for HF. After publication of these trial results in 1999,
prescriptions for spironolactone in this geographic area more
than tripled, the rate of hospitalization for hyperkalemia
increased from 2.4 to 11 patients per thousand, and the asso-
ciated mortality increased from 0.3 to 2 per thousand (246).
These observations lead to a strong recommendation for cau-
tion in the selection and monitoring of patients to be given
aldosterone antagonists, because the observations make it
clear that clinical trial populations are highly selected, and
Table 7. Guidelines for Minimizing the Risk of Hyperkalemia in
Patients Treated With Aldosterone Antagonists
1. Impaired renal function is a risk factor for hyperkalemia during
treatment with aldosterone antagonists. The risk of hyperkalemia
increases progressively when serum creatinine exceeds 1.6 mg per
dL.* In elderly patients or others with low muscle mass in whom
serum creatinine does not accurately reflect glomerular filtration
rate, determination that glomerular filtration rate or creatinine
clearance exceeds 30 mL per min is recommended.
2. Aldosterone antagonists should not be administered to patients with
baseline serum potassium in excess of 5.0 mEq per liter.
3. An initial dose of spironolactone 12.5 mg or eplerenone 25 mg is
recommended, after which the dose may be increased to spirono-
lactone 25 mg or eplerenone 50 mg if appropriate.
4. The risk of hyperkalemia is increased with concomitant use of high-
er doses of ACEIs (captopril greater than or equal to 75 mg daily;
enalapril or lisinopril greater than or equal to 10 mg daily).
5. Nonsteroidal anti-inflammatory drugs and cyclo-oxygenase-2
inhibitors should be avoided.
6. Potassium supplements should be discontinued or reduced.
7. Close monitoring of serum potassium is required; potassium levels
and renal function should be checked in 3 days and at 1 week after
initiation of therapy and at least monthly for the first 3 months.
8. Diarrhea or other causes of dehydration should be addressed emer-
gently.
ACEI indicates angiotensin converting enzyme inhibitor.
*Although the entry criteria for the trials of aldosterone antagonists included creatinine
greater than 2.5 mg per dL, the majority of patients had creatinine much lower; in 1 trial
(98), 95% of patients had creatinine less than or equal to 1.7 mg per dL.
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types of patients, including women and the elderly, as well as
patients with a wide range of causes and severity of LV dys-
function, but patients with preserved systolic function, low
heart rates (less than 65 beats per min), or low systolic blood
pressure (less than 85 mm Hg) and those who were hospital-
ized or who had class IV HF were not recruited or represent-
ed a small proportion of the patients who participated in
these published studies. An exception was one trial with
carvedilol that enrolled clinically stable patients with NYHA
class III and IV symptoms who were free of edema. That trial
also demonstrated a reduction in mortality similar to the tri-
als of patients with less advanced disease (263). 
This collective experience indicates that long-term treat-
ment with beta-blockers can lessen the symptoms of HF,
improve the clinical status of patients, and enhance the
patient’s overall sense of well-being (266-273). In addition,
like ACEIs, beta-blockers can reduce the risk of death and
the combined risk of death or hospitalization (255, 260, 262,
263, 274). These benefits of beta-blockers were seen in
patients with or without coronary artery disease and in
patients with or without diabetes mellitus, as well as in
women and black patients. The favorable effects of beta-
blockers were also observed in patients already taking
ACEIs, which suggests that combined blockade of the 2 neu-
rohormonal systems can produce additive effects.
PRACTICAL USE OF BETA-BLOCKERS. Selection of patients.
Beta-blockers should be prescribed to all patients with stable
HF due to reduced LVEF unless they have a contraindication
to their use or have been shown to be unable to tolerate
treatment with these drugs. Because of the favorable effects
of beta-blockers on survival and disease progression, treat-
ment with a beta-blocker should be initiated as soon as LV
dysfunction is diagnosed. Even when symptoms are mild or
have responded to other therapies, beta-blocker therapy is
important and should not be delayed until symptoms return
or disease progression is documented during treatment with
other drugs. Therefore, even if patients do not benefit symp-
tomatically because they have little disability, they should
receive treatment with a beta-blocker to reduce the risk of
disease progression, future clinical deterioration, and sudden
death (255, 260, 262, 273, 274).
Patients need not be taking high doses of ACEIs before
being considered for treatment with a beta-blocker, because
most patients enrolled in the beta-blocker trials were not tak-
ing high doses of ACEIs. Furthermore, in patients taking a
low dose of an ACEI, the addition of a beta-blocker produces
a greater improvement in symptoms and reduction in the risk
of death than an increase in the dose of the ACEI, even to the
target doses used in clinical trials (197, 275). In patients with
current or recent history of fluid retention, beta-blockers
should not be prescribed without diuretics, because diuretics
are needed to maintain sodium and fluid balance and prevent
the exacerbation of fluid retention that can accompany the
initiation of beta-blocker therapy (276-278). 
Which patients are sufficiently stable to be considered for
treatment with a beta-blocker? Regardless of the severity of
symptoms, patients should not be hospitalized in an intensive
care unit, should have no or minimal evidence of fluid over-
effects. Whereas cardiac adrenergic drive initially supports
the performance of the failing heart, long-term activation of
the sympathetic nervous system exerts deleterious effects
that can be antagonized by the use of beta-blockers.
Sympathetic activation can increase ventricular volumes and
pressure by causing peripheral vasoconstriction (247) and by
impairing sodium excretion by the kidneys (248).
Norepinephrine can also induce cardiac hypertrophy but
restrict the ability of the coronary arteries to supply blood to
the thickened ventricular wall, leading to myocardial
ischemia (215, 249, 250). Activation of the sympathetic
nervous system can also provoke arrhythmias by increasing
the automaticity of cardiac cells, increasing triggered activi-
ty in the heart, and promoting the development of
hypokalemia (138, 251-253). Norepinephrine can also
increase heart rate and potentiate the activity and actions of
other neurohormonal systems. Finally, by stimulating growth
and oxidative stress in terminally differentiated cells, norep-
inephrine can trigger programmed cell death or apoptosis
(254). These deleterious effects are mediated through actions
on alpha-1–, beta-1–, and beta-2–adrenergic receptors (138,
215, 247-254). 
Three beta-blockers have been shown to be effective in
reducing the risk of death in patients with chronic HF: biso-
prolol (255) and sustained-release metoprolol (succinate)
(256), which selectively block beta-1–receptors, and
carvedilol (263, 264), which blocks alpha-1–, beta-1–, and
beta-2–receptors. Positive findings with these 3 agents, how-
ever, should not be considered indicative of a beta-blocker
class effect, as shown by the lack of effectiveness of bucin-
dolol and the lesser effectiveness of short-acting metoprolol
in clinical trials (257-259). Patients who have Stage C HF
should be treated with 1 of these 3 beta-blockers.
The relative efficacy among these 3 agents is not known,
but available evidence does suggest that beta-blockers can
differ in their effects on survival (257). In one trial (259),
carvedilol (target dose 25 mg twice daily) was compared
with immediate-release metoprolol tartrate (target dose 50
mg twice daily). In that trial, carvedilol was associated with
a significantly reduced mortality compared with metoprolol
tartrate. Although both the dose and the formulation of meto-
prolol (metoprolol tartrate) used in the above-referenced trial
are commonly prescribed by physicians for the treatment of
HF, they were neither the dose nor the formulation used in
the controlled trial (256) that showed that sustained-release
metoprolol (metoprolol succinate) reduces the risk of death
(260). There have been no trials to explore whether the sur-
vival benefits of carvedilol are greater than those of sus-
tained-released metoprolol when both are used at the target
doses.
Effect of Beta-Blockers in the Management of HF. Beta-
blockers have now been evaluated in more than 20 000
patients with HF who participated in more than 20 published
placebo-controlled clinical trials (72, 76, 255, 260-265). All
trials enrolled patients with reduced LVEF (EF less than 35%
to 45%) who had already been treated with diuretics and an
ACEI, with or without digitalis. These trials recruited many
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the subsequent risk of clinical decompensation.
Consequently, if patients develop fluid retention, with or
without mild symptoms, it is reasonable to continue the beta-
blocker while the dose of diuretic is increased (281).
However, if the deterioration in clinical status is character-
ized by hypoperfusion or requires the use of intravenous pos-
itive inotropic drugs, it may be prudent to halt or significant-
ly reduce treatment with beta-blockers temporarily until the
status of the patient stabilizes. In such patients, positive
inotropic agents whose effects are mediated independently of
the beta-receptor (e.g., a phosphodiesterase inhibitor such as
milrinone) may be preferred. Once stabilized, the beta-
blocker should be reintroduced to reduce the subsequent risk
of clinical deterioration.
PRACTICAL USE OF BETA-BLOCKERS. Risks of treatment.
Initiation of treatment with a beta-blocker has produced 4
types of adverse reactions that require attention and manage-
ment, as discussed below.
1. FLUID RETENTION AND WORSENING HF
Initiation of therapy with a beta-blocker can cause fluid
retention (276-278), which is usually asymptomatic and is
detected primarily by an increase in body weight but which
may become sufficiently marked to cause worsening symp-
toms of HF (282). Patients with fluid retention before treat-
ment are at greatest risk of fluid retention during treatment,
and thus, physicians should ensure that patients are not vol-
ume overloaded before a beta-blocker is initiated.
Furthermore, physicians should monitor patients closely for
increases in weight and for worsening signs and symptoms
of HF and should augment the dose of diuretic if weight
increases whether or not other signs or symptoms of worsen-
ing HF are present. The occurrence of fluid retention or
worsening HF is not generally a reason for the permanent
withdrawal of treatment. Such patients generally respond
favorably to intensification of conventional therapy, and
once treated, such patients remain excellent candidates for
long-term treatment with a beta-blocker.
2. FATIGUE
Treatment with a beta-blocker can be accompanied by feel-
ings of general fatigue or weakness. In many cases, the sense
of lassitude resolves spontaneously within several weeks
without treatment, but in some patients, it may be severe
enough to limit increments in dose or require the withdrawal
of treatment. Complaints of fatigue can generally be man-
aged by a reduction in the dose of the beta-blocker (or the
accompanying diuretic), but treatment should be discontin-
ued if the syndrome of weakness is accompanied by evi-
dence of peripheral hypoperfusion. Reinitiation at a later
time or with a different effective beta-blocker may be suc-
cessful.
3. BRADYCARDIA AND HEART BLOCK
The slowing of heart rate and cardiac conduction produced
by beta-blockers is generally asymptomatic and thus gener-
load or volume depletion, and should not have required
recent treatment with an intravenous positive inotropic agent.
Those excluded from treatment for these reasons should first
receive intensified treatment with other drugs for HF (e.g.,
diuretics) and then be re-evaluated for beta-blockade after
clinical stability has been achieved. Beta-blockers may be
considered in patients who have reactive airway disease or
asymptomatic bradycardia but should be used with great cau-
tion or not at all in patients with persistent symptoms of
either condition.
PRACTICAL USE OF BETA-BLOCKERS. Initiation and mainte-
nance. Treatment with a beta-blocker should be initiated at
very low doses (see Table 6), followed by gradual increments
in dose if lower doses have been well tolerated. Patients
should be monitored closely for changes in vital signs and
symptoms during this uptitration period. In addition, because
initiation of therapy with a beta-blocker can cause fluid
retention (276-278), physicians should ask patients to weigh
themselves daily and to manage any increase in weight by
immediately increasing the dose of concomitantly adminis-
tered diuretics until weight is restored to pretreatment levels.
Planned increments in the dose of a beta-blocker should be
delayed until any side effects observed with lower doses
have disappeared. Using such a cautious approach, most
patients (approximately 85%) enrolled in clinical trials with
beta-blockers were able to tolerate short- and long-term
treatment with these drugs and achieve the maximum
planned trial dose (255, 260, 262, 263). Recent data show
that beta-blockers can be safely started before discharge even
in patients hospitalized for HF, provided they do not require
intravenous therapy for HF (279). 
What dose of a beta-blocker should physicians try to
achieve in patients with HF? As with ACEIs, the dose of
beta-blockers in controlled clinical trials was not determined
by a patient’s therapeutic response but was increased until
the patient received a prespecified target dose. Low doses
were prescribed only if the target doses were not tolerated,
and thus, most trials did not evaluate whether low doses
would be effective. Therefore, physicians, especially cardiol-
ogists and primary care physicians, should make every effort
to achieve the target doses of the beta-blockers shown to be
effective in major clinical trials. 
Once the target dose has been achieved, patients can gen-
erally continue long-term therapy with a beta-blocker with
little difficulty. Patients should be advised that clinical
responses to the drug are generally delayed and may require
2 to 3 months to become apparent (159). Even if symptoms
do not improve, long-term treatment should be maintained to
reduce the risk of major clinical events. Abrupt withdrawal
of treatment with a beta-blocker can lead to clinical deterio-
ration and should be avoided (280).
How should clinical deterioration be managed in patients
who have been taking a beta-blocker for long periods of time
(more than 3 months)? Because long-term treatment with a
beta-blocker reduces the risk of worsening HF, discontinua-
tion of long-term treatment with these drugs after an episode
of worsening HF will not diminish and may in fact increase
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EFFECT OF DIGITALIS IN THE TREATMENT OF HF. Several place-
bo-controlled trials have shown that treatment with digoxin
for 1 to 3 months can improve symptoms, quality of life, and
exercise tolerance in patients with mild to moderate HF (157,
289-294). These benefits have been seen regardless of the
underlying rhythm (normal sinus rhythm or atrial fibrilla-
tion), cause of HF (ischemic or nonischemic cardiomyopa-
thy), or concomitant therapy (with or without ACEIs). In a
long-term trial that enrolled patients who primarily had class
II or III symptoms, treatment with digoxin for 2 to 5 years
had no effect on mortality but modestly reduced the com-
bined risk of death and hospitalization (113). 
PRACTICAL USE OF DIGITALIS IN HF. Selection of patients.
Physicians may consider adding digoxin in patients with per-
sistent symptoms of HF during therapy with diuretics, an
ACEI (or ARB), and a beta-blocker (295, 296). Digoxin may
also be added to the initial regimen in patients with severe
symptoms who have not yet responded symptomatically dur-
ing treatment with diuretics, an ACEI, and beta-blockers.
Alternatively, treatment with digoxin may be delayed until
the patient’s response to ACEIs and beta-blockers has been
defined and be used only in patients who remain sympto-
matic despite therapy with the neurohormonal antagonists.
Yet another strategy is to initiate aldosterone antagonists in
this type of symptomatic patient and delay the addition of
digoxin except in patients who do not respond or who cannot
tolerate aldosterone antagonists. If a patient is taking digox-
in but not an ACEI or a beta-blocker, treatment with digoxin
should not be withdrawn, but appropriate therapy with the
neurohormonal antagonists should be instituted. Digoxin is
prescribed routinely in patients with HF and chronic atrial
fibrillation, but beta-blockers are usually more effective
when added to digoxin in controlling the ventricular
response, particularly during exercise (297-300). Because
beta blockers improve survival and may be effective in con-
trolling rate alone, digoxin should be considered as an
adjunctive agent for rate control. 
Digoxin is not indicated as primary therapy for the stabi-
lization of patients with an acute exacerbation of HF symp-
toms, including fluid retention or hypotension. Such patients
should first receive appropriate treatment for HF (usually
with intravenous medications); therapy with digoxin may be
initiated after stabilization as part of an effort to establish a
long-term treatment strategy. 
Patients should not be given digoxin if they have signifi-
cant sinus or atrioventricular block, unless the block has been
addressed with a permanent pacemaker. The drug should be
used cautiously in patients taking other drugs that can
depress sinus or atrioventricular nodal function or affect
digoxin levels (e.g., amiodarone or a beta-blocker), even
though such patients usually tolerate digoxin without diffi-
culty. 
PRACTICAL USE OF DIGITALIS IN HF. Initiation and mainte-
nance. Although a variety of glycosides have been utilized,
digoxin is the most commonly used, and it is the only glyco-
side that has been evaluated in placebo-controlled trials.
ally requires no treatment; however, if the bradycardia is
accompanied by dizziness or lightheadedness or if second- or
third-degree heart block occurs, physicians should decrease
the dose of the beta-blocker. Physicians should also consider
the possibility of drug interactions, because other drugs can
cause bradycardia or heart block and may be discontinued.
The role of pacemaker therapy with or without cardiac resyn-
chronization therapy (CRT) to permit the use of beta-block-
er therapy is entirely unknown.
4. HYPOTENSION
Beta-blockers, especially those that also block alpha-1-
receptors, can produce hypotension, which is usually asymp-
tomatic but may produce dizziness, lightheadedness, or
blurred vision (262). For beta-blockers that also block alpha-
receptors, such as carvedilol, these vasodilatory side effects
are generally seen within 24 to 48 hours of the first dose or
the first increments in dose and usually subside with repeat-
ed dosing without any change in dose. Physicians may min-
imize the risk of hypotension by administering the beta-
blocker and ACEI at different times during the day. If this is
ineffective, the occurrence of hypotension may require a
temporary reduction in the dose of the ACEI. Hypotensive
symptoms may also resolve after a decrease in the dose of
diuretics in patients who are volume depleted, but in the
absence of such depletion, relaxation of diuretic therapy may
increase the risk or consequences of fluid retention (276-
278). If hypotension is accompanied by other clinical evi-
dence of hypoperfusion, beta-blocker therapy should be
decreased or discontinued pending further patient evaluation.
4.3.1.2.4. DIGITALIS. The digitalis glycosides exert their
effects in patients with HF by virtue of their ability to inhib-
it sodium-potassium (Na+-K+) adenosine triphosphatase
(ATPase) (283). Inhibition of this enzyme in cardiac cells
results in an increase in the contractile state of the heart, and
for many decades, the benefits of digitalis in HF were
ascribed exclusively to this positive inotropic action.
However, recent evidence suggests that the benefits of digi-
talis may be related in part to enzyme inhibition in noncar-
diac tissues. Inhibition of Na+-K+ ATPase in vagal afferent
fibers acts to sensitize cardiac baroreceptors, which in turn
reduces sympathetic outflow from the central nervous sys-
tem (284, 285). In addition, by inhibiting Na+-K+ ATPase in
the kidney, digitalis reduces the renal tubular reabsorption of
sodium (286); the resulting increase in the delivery of sodi-
um to the distal tubules leads to the suppression of renin
secretion from the kidneys (287). These observations have
led to the hypothesis that digitalis acts in HF primarily by
attenuating the activation of neurohormonal systems and not
as a positive inotropic drug (288). Although a variety of dig-
italis glycosides have been used in the treatment of HF for
the last 200 years, the most commonly used preparation in
the United States is digoxin.
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There is little reason to prescribe other cardiac glycosides for
the management of HF. 
Therapy with digoxin is commonly initiated and main-
tained at a dose of 0.125 to 0.25 mg daily. Low doses (0.125
mg daily or every other day) should be used initially if the
patient is more than 70 years old, has impaired renal func-
tion, or has a low lean body mass (301). Higher doses (e.g.,
digoxin 0.375 to 0.50 mg daily) are rarely used or needed in
the management of patients with HF. There is no reason to
use loading doses of digoxin to initiate therapy in patients
with HF. 
Doses of digoxin that achieve a concentration of drug in
plasma in the range of 0.5 to 1.0 ng per mL are suggested
given the limited evidence currently available. There has
been no prospective, randomized evaluation of the relative
efficacy or safety of different plasma concentrations of
digoxin. Retrospective analysis of 2 studies of digoxin with-
drawal found that the prevention of worsening HF by digox-
in at lower concentrations in plasma (0.5 to 0.9 ng per mL)
was as great as that achieved at higher concentrations (302).
In a retrospective analysis of the Digitalis Investigation
Group trial, risk-adjusted mortality increased as the plasma
concentrations exceeded 1.0 ng per mL (303). However, the
likelihood that reduced clearance of digoxin by renal and
hepatic P-glycoprotein transporters reflects HF severity pro-
vides an alternate explanation of the relationship of higher
plasma levels with mortality, and the most conservative
interpretation is that levels of digoxin greater than 1.0 ng per
mL were not associated with a superior outcome.
PRACTICAL USE OF DIGITALIS IN HF. Risks of treatment. When
administered with attention to dose and to factors that alter
its disposition, digoxin is well tolerated by most patients with
HF (304). The principal adverse reactions occur primarily
when digoxin is administered in large doses, but large doses
may not be needed to produce clinical benefits (305-307).
The major side effects include cardiac arrhythmias (e.g.,
ectopic and re-entrant cardiac rhythms and heart block), gas-
trointestinal symptoms (e.g., anorexia, nausea, and vomit-
ing), and neurological complaints (e.g., visual disturbances,
disorientation, and confusion). Overt digitalis toxicity is
commonly associated with serum digoxin levels greater than
2 ng per mL. However, toxicity may occur with lower digox-
in levels, especially if hypokalemia, hypomagnesemia, or
hypothyroidism coexists (308, 309). The concomitant use of
clarithromycin, erythromycin, amiodarone, itraconazole,
cyclosporine, verapamil, or quinidine can increase serum
digoxin concentrations and may increase the likelihood of
digitalis toxicity (310-312). The dose of digoxin should be
reduced if treatment with these drugs is initiated.
Spironolactone does not inhibit the disposition of digoxin
(313); cross-reactivity of some digoxin antibodies with
spironolactone confounded earlier attempts to assess the
effect of spironolactone on digoxin clearance. In addition, a
low lean body mass and impaired renal function can also ele-
vate serum digoxin levels, which may explain the increased
risk of digitalis toxicity in elderly patients. Of note, one
analysis suggested that women may not benefit from digox-
in therapy and may be at increased risk for death with such
therapy (314).
In addition to these established side effects, there is con-
cern that levels of digoxin that previously had been consid-
ered to be in the therapeutic range (up to 2 ng per mL) may
exert deleterious cardiovascular effects in the long term,
even though such levels appear to be well tolerated in the
short-term. In one major long-term trial, serum digoxin con-
centrations in the therapeutic range were associated with an
increased frequency of hospitalizations for cardiovascular
events other than HF and an increased risk of death due to
arrhythmias or MI (113). These effects neutralized any ben-
efit on survival that might otherwise have been seen as a
result of the favorable effect of the drug on HF. These obser-
vations have raised the possibility that digoxin doses and
serum digoxin concentrations that are generally considered
by physicians to be safe may adversely affect the heart (315).
Digoxin should be used with caution or not used at all in
post-MI patients, particularly if they have ongoing ischemia
(316).
The Writing Committee has re-evaluated the evidence per-
tinent to the value of digitalis therapy in patients with HF.
Although no new data or trials using digitalis have emerged
since publication of the 2001 guidelines, the Writing
Committee believes that in terms of safety and efficacy, dig-
italis does not compare favorably with such agents as the
aldosterone blockers, to which the Writing Committee has
assigned a Class IIa level of recommendation. If digitalis
were a new drug with clinical trials showing a very narrow
risk/benefit ratio (especially for potential use in the aging
population) and no mortality benefit, it would clearly not be
considered for a Class I recommendation. The Writing
Committee, therefore, decided to change the level of recom-
mendation for digitalis glycosides from Class I to Class IIa
in the current document.
4.3.1.2.5. VENTRICULAR ARRHYTHMIAS AND PREVENTION OF
SUDDEN DEATH. Patients with LV dilation and reduced LVEF
frequently manifest ventricular tachyarrhythmias, both non-
sustained ventricular tachycardia (VT) and sustained VT.
The cardiac mortality of patients with all types of ventricular
tachyarrhythmias is high. The high mortality results from
progressive HF, as well as from sudden death. Sudden death
is often equated with a primary arrhythmic event, but multi-
ple causes of sudden death have been documented and
include ischemic events such as acute MI (198), electrolyte
disturbances, pulmonary or systemic emboli, or other vascu-
lar events. Although ventricular tachyarrhythmias are the
most common rhythms associated with unexpected sudden
death, bradycardia and other pulseless supraventricular
rhythms are common in patients with advanced HF (317).
Sudden death can be decreased meaningfully by the thera-
pies that decrease disease progression, as discussed else-
where in these guidelines. For instance, clinical trials with
beta-blockers have shown a reduction in sudden death, as
well as in all-cause mortality, in both postinfarction patients
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absence of prior MI. Approximately 50% to 70% of patients
with low EF and symptomatic HF have episodes of nonsus-
tained VT on routine ambulatory electrocardiographic moni-
toring; however, it is not clear whether the occurrence of
complex ventricular arrhythmias in these patients with HF
contributes to the high frequency of sudden death or, alterna-
tively, simply reflects the underlying disease process (320-
322). Antiarrhythmic drugs to suppress premature ventricu-
lar depolarizations and nonsustained ventricular arrhythmias
have not improved survival (323, 324), although nonsus-
tained VT may play a role in triggering ventricular tach-
yarrhythmias. Furthermore, most antiarrhythmic drugs have
negative inotropic effects and can increase the risk of serious
arrhythmia; these adverse cardiovascular effects are particu-
larly pronounced in patients with low EF (127, 325, 326).
This risk is especially high with the use of Class IA agents
(quinidine and procainamide), Class IC agents (flecainide
and encainide), and some Class III agents (D-sotalol) (323,
324, 327, 328), which have increased mortality in post-MI
trials (329).
Amiodarone is a Class III antiarrhythmic agent but differs
from other drugs in this class in having a sympatholytic
effect on the heart (330). Amiodarone has been associated
with overall neutral effects on survival when given to
patients with low EF and HF (331-334). Amiodarone thera-
py may also act through mechanisms other than antiarrhyth-
mic effects, because amiodarone has been shown in some tri-
als to increase LVEF and decrease the incidence of worsen-
ing HF (332, 333). Side effects of amiodarone have included
thyroid abnormalities, pulmonary toxicity, hepatotoxicity,
neuropathy, insomnia, and numerous other reactions.
Therefore, amiodarone should not be considered as part of
the routine treatment of patients with HF, with or without fre-
quent premature ventricular depolarizations or asymptomatic
nonsustained VT; however, it remains the agent most likely
to be safe and effective when antiarrhythmic therapy is nec-
essary to prevent recurrent atrial fibrillation or symptomatic
ventricular arrhythmias. Other pharmacological antiarrhyth-
mic therapies, apart from beta-blockers, are rarely indicated
in HF but may occasionally be used to suppress recurrent
ICD shocks when amiodarone has been ineffective or dis-
continued owing to toxicity. 
The role of ICDs in the primary prevention of sudden death
in patients without prior history of symptomatic arrhythmias
has been explored recently in a number of trials. If sustained
ventricular tachyarrhythmias can be induced in the electro-
physiology laboratory in patients with previous MI or chron-
ic ischemic heart disease, the risk of sudden death in these
patients is in the range of 5% to 6% per year and can be
improved by ICD implantation (335).
The role of ICD implantation for the primary prevention of
sudden death in patients with HF and low EF and no history
of spontaneous or inducible VT has been addressed by sev-
eral large trials that used only readily available clinical data
as entry criteria (334, 336, 337). The first of these demon-
strated that ICDs, compared with standard medical therapy,
decreased the occurrence of total mortality for patients with
and patients with HF regardless of cause (104, 105, 255,
260, 262). Aldosterone antagonists decrease sudden death
and overall mortality in HF early after MI and in advanced
HF (98). Sudden unexpected death can be decreased further
by the use of implanted devices that terminate sustained
arrhythmias (318). Even when specific antiarrhythmic ther-
apy is necessary to diminish recurrent ventricular tach-
yarrhythmias and device firings, the frequency and tolerance
of arrhythmias may be improved with appropriate therapy
for HF. In some cases, definitive therapy of myocardial
ischemia or other reversible factors may prevent recurrence
of tachyarrhythmia, particularly polymorphic VT, ventricu-
lar fibrillation, and nonsustained VT. Nonetheless,
implantable defibrillators would be recommended in all
patients who have had a life-threatening tachyarrhythmia
and have otherwise good prognosis. 
The absolute frequency of sudden death is highest in
patients with severe symptoms, or Stage D HF. Many
patients with end-stage symptoms experience “sudden
death” that is nonetheless expected. Prevention of sudden
death in this population could potentially shift the mode of
death from sudden to that of progressive HF without
decreasing total mortality, as competing risks of death
emerge. On the other hand, prevention of sudden death in
mild HF may allow many years of meaningful survival. This
makes it imperative for physicians to not only assess an indi-
vidual patient’s risk for sudden death but also to assess over-
all prognosis and functional capacity before consideration of
device implantation.
Secondary Prevention of Sudden Death. Patients with previ-
ous cardiac arrest or documented sustained ventricular
arrhythmias have a high risk of recurrent events.
Implantation of an ICD has been shown to reduce mortality
in cardiac arrest survivors. An ICD is indicated for second-
ary prevention of death from ventricular tachyarrhythmias in
patients with otherwise good clinical function and progno-
sis, for whom prolongation of survival is a goal. Patients
with chronic HF and a low EF who experience syncope of
unclear origin have a high rate of subsequent sudden death
and should also be considered for placement of an ICD
(319). However, when ventricular tachyarrhythmias occur in
a patient with a progressive and irreversible downward spi-
ral of clinical HF decompensation, placement of an ICD is
not indicated to prevent recurrence of sudden death, because
death is likely imminent regardless of mode. An exception
may exist for the small minority of patients for whom defin-
itive therapy such as cardiac transplantation is planned.
Primary Prevention of Sudden Death. Patients with low EF
without prior history of cardiac arrest, spontaneous VT, or
inducible VT (positive programmed electrical stimulation
study) have a risk of sudden death that is lower than for
those who have experienced previous events, but it remains
significant. Within this group, it has not yet been possible to
identify those patients at highest risk, especially in the
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The decision regarding the balance of potential risks and
benefits of ICD implantation for an individual patient thus
remains a complex one. A decrease in incidence of sudden
death does not necessarily translate into decreased total mor-
tality, and decreased total mortality does not guarantee a pro-
longation of survival with meaningful quality of life. This
concept is particularly important in patients with limited
prognosis owing to advanced HF or other serious comorbidi-
ties, because there was no survival benefit observed from
ICD implantation until after the first year in 2 of the major
trials (334, 336). Furthermore, the average age of patients
with HF and low EF is over 70 years, a population not well
represented in any of the ICD trials. Comorbidities common
in the elderly population, such as prior stroke, chronic pul-
monary disease, and crippling arthritic conditions, as well as
nursing home residence, should be factored into discussions
regarding ICD. Atrial fibrillation, a common trigger for
inappropriate shocks, is more prevalent in the elderly popu-
lation. The gap between community and trial populations is
particularly important for a device therapy that may prolong
survival but has no positive impact on function or quality of
life. Some patients may suffer a diminished quality of life
because of device-site complications, such as bleeding,
hematoma, or infections, or after ICD discharges, particular-
ly those that are inappropriate.
Consideration of ICD implantation is thus recommended in
patients with EF less than 30% and mild to moderate symp-
toms of HF and in whom survival with good functional
capacity is otherwise anticipated to extend beyond 1 year.
Because medical therapy may substantially improve EF, con-
sideration of ICD implants should follow documentation of
sustained reduction of EF despite a course of beta-blockers
and ACEIs or ARBs; however, ICDs are not warranted in
patients with refractory symptoms of HF (Stage D) or in
patients with concomitant diseases that would shorten their
life expectancy independent of HF. The appropriate manage-
ment of patients with HF and an EF between 30% and 35%
remains controversial. Risk may be further stratified for
patients with coronary artery disease by performing a pro-
grammed electrical stimulation study to demonstrate
inducible VT. In the patient with idiopathic cardiomyopathy
and an EF of 30% to 35%, the physician might want to con-
tinue intensive medical therapy with those drugs shown to
improve EF and delay disease progression before giving con-
sideration to ICD implantation.
Before implantation, patients should be fully informed of
their cardiac prognosis, including the risk of both sudden and
nonsudden mortality; the efficacy, safety, and risks of an
ICD; and the morbidity associated with an ICD shock.
Patients and families should clearly understand that the ICD
does not improve clinical function or delay HF progression.
Most importantly, the possible reasons and process for poten-
tial future deactivation of defibrillator features should be dis-
cussed long before functional capacity or outlook for sur-
vival is severely reduced.
EF less than or equal to 30% after remote MI (336). Absolute
mortality was decreased in the ICD arm by 5.6%, a relative
decrease of 31% over 20 months. In a second trial, a survival
benefit was not demonstrated with devices implanted within
6 to 40 days after an acute MI in patients who at that time had
an EF less than 35% and abnormal heart rate variability.
Although sudden deaths were decreased, there was an
increase in other events, and ICD implantation did not con-
fer any survival benefit in this setting (337). A third trial
examining the benefit of ICD implantation for patients with
EF less than 35% and NYHA class II to III symptoms of HF
included both ischemic and nonischemic causes of HF;
absolute mortality was decreased by 7.2% over a 5-year peri-
od in the arm that received a simple “shock-box” ICD with
backup pacing at a rate of 40 beats per min. This represented
a relative mortality decrease of 23%, which was a survival
increase of 11% (334). There was no improvement in sur-
vival during the first year, with a 1.8% absolute survival ben-
efit per year averaged over the next 4 years. The
Defibrillators in Non-Ischemic Cardiomyopathy Treatment
Evaluation (DEFINITE) trial compared medical therapy
alone with medical therapy plus an ICD in patients with non-
ischemic cardiomyopathy, NYHA class I to III HF, and an
LVEF less than 36% (338). The ICD was associated with a
reduction in all-cause mortality that did not reach statistical
significance but was consistent in terms of magnitude of
effect (30%) with the findings of the Multicenter Automatic
Defibrillator Implantation Trial (MADIT II) (336) and the
Sudden Cardiac Death in Heart Failure: Trial of prophylactic
amiodarone versus implantable defibrillator therapy (SCD-
HeFT) (334). There is an intrinsic variability in measurement
of EF particularly shortly after recovery from an acute coro-
nary syndrome event.
ICDs are highly effective in preventing death due to ven-
tricular tachyarrhythmias; however, frequent shocks from an
ICD can lead to a reduced quality of life, whether triggered
appropriately by life-threatening rhythms or inappropriately
by sinus or other supraventricular tachycardia. For symptoms
from recurrent discharges triggered by ventricular arrhyth-
mias or atrial fibrillation, antiarrhythmic therapy, most often
amiodarone, may be added. For recurrent ICD discharges
from VT despite antiarrhythmic therapy, catheter ablation
may be effective (339). 
It is important to recognize that ICDs have the potential to
aggravate HF and have been associated with an increase in
HF hospitalizations (336, 340). This may result from right
ventricular pacing that produces dyssynchronous cardiac
contraction; however, the occurrence of excess nonsudden
events with ICDs placed early after MI suggests that other
factors may also limit the overall benefit from ICDs . Careful
attention to the details of ICD implantation, programming,
and pacing function is important for all patients with low EF
who are treated with an ICD. The ACC/AHA/NASPE 2002
Guideline Update for Implantation of Cardiac Pacemakers
and Antiarrhythmia Devices (341) provides further discus-
sion of the potential problem of worsening HF and LV func-
tion in all patients with right ventricular pacing. 
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ACEI produced more favorable effects on survival (194), a
benefit not evident in the subgroup of patients with class III
to IV HF. In both trials, the use of hydralazine and isosorbide
dinitrate produced frequent adverse reactions (primarily
headache and gastrointestinal complaints), and many
patients could not continue treatment at target doses. 
Of note, a post hoc retrospective analysis of both vasodila-
tor trials demonstrated particular efficacy of isosorbide dini-
trate and hydralazine in the black cohort (528). A confirma-
tory trial has been done. In that trial, which was limited to the
black population with HF, the addition of hydralazine and
isosorbide dinitrate to standard therapy with an ACEI and/or
a beta-blocker was shown to be of significant benefit (356).
The benefit was presumed to be related to enhanced nitric
oxide bioavailability. Whether this benefit is evident in other
patients with HF remains to be investigated. The combina-
tion of hydralazine and isosorbide dinitrate should not be
used for the treatment of HF in patients who have no prior
use of an ACEI and should not be substituted for ACEIs in
patients who are tolerating ACEIs without difficulty. 
Despite the lack of data with the vasodilator combination in
patients who are intolerant of ACEIs, the combined use of
hydralazine and isosorbide dinitrate may be considered as a
therapeutic option in such patients. However, compliance
with this combination has generally been poor because of the
large number of tablets required and the high incidence of
adverse reactions (194, 354). For patients with more severe
symptoms and ACEI intolerance, the combination of
hydralazine and nitrates is used frequently, particularly when
ACEI therapy is limited by hypotension or renal insufficien-
cy. There are, however, no trials addressing the use of isosor-
bide dinitrate and hydralazine specifically in the population
of patients who have persistent symptoms and intolerance to
inhibitors of the renin-angiotensin system.
4.3.1.3.4. CARDIAC RESYNCHRONIZATION THERAPY. Approx-
imately one third of patients with low EF and class III to IV
symptoms of HF manifest a QRS duration greater than 120
ms (357-359). This electrocardiographic representation of
abnormal cardiac conduction has been used to identify
patients with dyssynchronous ventricular contraction. While
imperfect, no other consensus definition of cardiac dyssyn-
chrony exists as yet, although several echocardiographic
measures appear promising. The mechanical consequences
of dyssynchrony include suboptimal ventricular filling, a
reduction in LV dP/dt (rate of rise of ventricular contractile
force or pressure), prolonged duration (and therefore greater
severity) of mitral regurgitation, and paradoxical septal wall
motion (360-362). Ventricular dyssynchrony has also been
associated with increased mortality in HF patients (363-365).
Dyssynchronous contraction can be addressed by electrical-
ly activating the right and left ventricles in a synchronized
manner with a biventricular pacemaker device. This
approach to HF therapy, commonly called cardiac resyn-
chronization therapy (CRT), may enhance ventricular con-
traction and reduce the degree of secondary mitral regurgita-
tion (366-368). In addition, the short-term use of CRT has
4.3.1.3. Interventions to Be Considered for Use in
Selected Patients
Controlled clinical trials have shown some interventions to
be useful in limited cohorts of patients with HF. Several of
these interventions are undergoing active investigation in
large-scale trials to determine whether their role in the man-
agement of HF might be justifiably expanded, and others
have already been validated as useful in specific cohorts.
4.3.1.3.1. ISOSORBIDE DINITRATE. Isosorbide dinitrate was
one of the first vasodilator agents reported to be useful for
chronic therapy of HF. Nitrate therapy may decrease symp-
toms of dyspnea at night and during exercise and may
improve exercise tolerance in patients who have persistent
limitations despite optimization of other therapies (342).
Most experience relates to the oral dinitrate and more recent-
ly the mononitrate preparations, with little information avail-
able about topical nitrate therapy in this population. Recent
evidence suggests that nitrates can inhibit abnormal myocar-
dial and vascular growth (343, 344) and may thereby attenu-
ate the process of ventricular remodeling (345) and improve
symptoms. 
The only common side effects of nitrate therapy are
headaches and hypotension. In clinical use, nitrates are fre-
quently prescribed to patients with persistent congestive
symptoms. Although the only large trial of nitrates in HF
(355) used a combination of nitrates and hydralazine, nitrates
predominantly are potent venodilators that also have effects
on arterial tone when used alone, particularly when systemic
vascular resistance is severely elevated. Because they act
through cyclic guanosine monophosphate, there is a theoret-
ical reason that they may be titrated up to facilitate weaning
of intravenous infusions that act through the same pathway. 
There is extensive literature regarding the development of
nitrate tolerance. This appears to be minimized by prescrip-
tion of a “nitrate-free interval” of at least 10 hours and by
combination with ACEIs or hydralazine.
4.3.1.3.2. HYDRALAZINE. Hydralazine is an arterial vasodila-
tor with relatively little effect on venous tone and cardiac fill-
ing pressures. The rationale for its combined use with
nitrates was to achieve both venous and arterial vasodilation
(346, 347). In addition to its direct vascular actions,
hydralazine in theory may interfere with the biochemical and
molecular mechanisms responsible for the progression of HF
(348, 349) and the development of nitrate tolerance (350-
353). There are limited data regarding the use of hydralazine
alone in HF.
4.3.1.3.3. HYDRALAZINE AND ISOSORBIDE DINITRATE. In a
large-scale trial that compared the vasodilator combination
with placebo, the use of hydralazine and isosorbide dinitrate
reduced mortality but not hospitalizations in patients with
HF treated with digoxin and diuretics but not an ACEI or
beta-blocker (354, 355). However, in another large-scale trial
that compared the vasodilator combination with an ACEI, the
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ventricular dyssynchrony that may be improved by CRT, but
no studies have addressed this situation as yet.
Recommendations regarding CRT for patients with right
bundle-branch block, atrial fibrillation, minor conduction
abnormality, and pacemaker dependence as well as inade-
quate medical therapy must await the completion of ongoing
or future trials.
Ten studies have reported on CRT peri-implant morbidity
and mortality. There were 13 deaths in 3,113 patients (0.4%).
From a pooled assessment of 3,475 patients in 17 studies, the
success rate of implantation was approximately 90% (372).
Device-related problems during the first 6 months after
implantation reported in 13 studies included lead malfunc-
tion or dislodgement in 8.5%, pacemaker problems in 6.7%,
and infection in 1.4% of cases. These morbidity and mortal-
ity data are derived from trials that used expert centers.
Results in individual clinical centers may vary considerably
and are subject to a significant learning curve for each cen-
ter; however, as implantation techniques evolve and equip-
ment improves, complication rates may also decline (372).
4.3.1.3.5. EXERCISE TRAINING. In the past, patients with HF
were advised to avoid physical exertion in the hope that bed
rest might minimize symptoms (377) and in the belief that
physical activity might accelerate the progression of LV dys-
function (378-380); however, it is now understood that a
reduction in physical activity (produced by the symptoms of
HF or prescribed by physicians treating HF) leads to a state
of physical deconditioning that contributes to the symptoms
and exercise intolerance of patients with chronic HF (123,
126). Limitations of activity not only may impair exercise
capacity but also may produce adverse psychological effects
and impair peripheral vasodilatory responses (125, 381).
These findings have led to the hypothesis that exercise train-
ing might improve the clinical status of patients with chron-
ic HF (123, 382). 
Several controlled trials have shown that exercise training
can lessen symptoms, increase exercise capacity, and
improve the quality of life of patients with chronic HF (383,
383-392). The improvement was comparable to that
achieved with pharmacological interventions (382), was in
addition to the benefits of ACEIs and beta-blockers, (384,
385), and was associated with an enhancement of endotheli-
um-dependent peripheral vasodilation and skeletal muscle
metabolism (384, 393). In these studies, physical condition-
ing was generally accomplished in the context of a formal
program, which required patients to gradually achieve work-
loads of 40% to 70% of maximal effort for 20 to 45 minutes
3 to 5 times per week for periods of 8 to12 weeks (391). 
The long-term effects of exercise training have not been
completely defined. In short-term studies, exercise training
has been accompanied by a reduction in the activation of
neurohormonal systems and attenuation of the process of
ventricular remodeling (386, 394, 395). In the experimental
setting, exercise appears to attenuate the rate of progression
of HF (396, 397). These observations suggest that exercise
training might have a favorable effect on the natural history
of HF. Only 1 study has evaluated the long-term effect of
been associated with improvements in cardiac function and
hemodynamics without an accompanying increase in oxygen
utilization (369), as well as adaptive changes in the bio-
chemistry of the failing heart (367).
To date, more than 4,000 HF patients with ventricular dys-
synchrony have been evaluated in randomized controlled tri-
als of optimal medical therapy alone versus optimal medical
therapy plus CRT with or without an ICD. Cardiac resynchro-
nization therapy, when added to optimal medical therapy in
persistently symptomatic patients, has resulted in significant
improvements in quality of life, functional class, exercise
capacity (by peak oxygen uptake) and exercise distance dur-
ing a 6-minute walk test, and EF in patients randomized to
CRT (370) or to the combination of CRT and ICD (318, 371,
372). In a meta-analysis of several CRT trials, HF hospital-
izations were reduced by 32% and all-cause mortality by
25%. The effect on mortality in this meta-analysis became
apparent after approximately 3 months of therapy (372). In
one study, subjects were randomized to optimal pharmaco-
logical therapy alone, optimal medical therapy plus CRT
alone, or optimal medical therapy plus the combination of
CRT and an ICD. Compared with optimal medical therapy
alone, both device arms significantly decreased the combined
risk of all-cause hospitalization and all-cause mortality by
approximately 20%, whereas the combination of a CRT and
an ICD decreased all-cause mortality significantly by 36%
(373). More recently, in a randomized controlled trial com-
paring optimal medical therapy alone with optimal medical
therapy plus CRT alone (without a defibrillator), CRT signif-
icantly reduced the combined risk of death of any cause or
unplanned hospital admission for a major cardiovascular
event (analyzed as time to first event) by 37% (374). In that
trial, all-cause mortality was significantly reduced by 36%
and HF hospitalizations by 52% with the addition of CRT.
Thus, there is strong evidence to support the use of CRT to
improve symptoms, exercise capacity, quality of life, LVEF,
and survival and to decrease hospitalizations in patients with
persistently symptomatic HF undergoing optimal medical
therapy who have cardiac dyssynchrony (as evidenced by a
prolonged QRS duration). The use of an ICD in combination
with CRT should be based on the indications for ICD therapy.
With few exceptions, resynchronization trials have enrolled
patients in normal sinus rhythm. Although the entry criteria
specified QRS duration only over 120 ms, the average QRS
duration in the large trials was more than 150 ms, with less
information demonstrating benefit in patients with lesser
prolongation of QRS. Two small studies, one randomized
(375) and the other observational (376), evaluated the poten-
tial benefit of CRT in HF patients with ventricular dyssyn-
chrony and atrial fibrillation. Although both studies demon-
strated the benefit of CRT in these patients, the total number
of patients examined (fewer than 100) precludes a recom-
mendation for CRT in otherwise eligible patients with atrial
fibrillation. To date, only a small number of patients with
“pure” right bundle-branch block have been enrolled in CRT
trials. The effect of CRT in these patients is currently
unknown. Similarly, the prolonged QRS duration associated
with right ventricular pacing has also been associated with
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physical conditioning in patients with HF (392), and in that
trial, exercise training was associated with a reduction in the
risk of hospitalization and death. Little work has been con-
ducted to identify patients most likely to respond favorably
to training and to define optimal exercise protocols.
Recommendations Concerning Exercise Training.
Exercise training should be considered for all stable outpa-
tients with chronic HF who are able to participate in the pro-
tocols needed to produce physical conditioning. Exercise
training should be used in conjunction with drug therapy.
4.3.1.4. Drugs and Interventions Under 
Active Investigation
Several drugs and other interventions are undergoing active
evaluation in long-term large-scale trials because they
showed promise in pilot studies that involved small numbers
of patients. Until the results of definitive trials are available,
none of these interventions can be recommended for use in
patients with HF. Several drugs that showed promise in pilot
studies and were included in this section in the 2001 guide-
lines failed to live up to their promise in long-term, large-
scale trials and are no longer included as “promising” in this
update. Several remain under or have begun active investi-
gation. Investigational drug therapies currently in phase III
evaluation for the treatment of chronic HF include vaso-
pressin receptor antagonists, intermittent nesiritide infusions,
and oral phosphodiesterase III inhibitors. In addition, newer
devices and technologies, such as implantable hemodynamic
monitors and internal cardiac support devices, external coun-
terpulsation, treatment for sleep-disordered breathing,
myocardial growth factors and stem cell transplantation, and
devices to achieve intravascular volume reduction, as well as
novel surgical approaches, including surgical ventricular
restoration, are under active investigation. Several of these
are discussed below.
4.3.1.4.1. TECHNIQUES FOR RESPIRATORY SUPPORT. Patients
with HF frequently exhibit abnormal respiratory patterns,
including Cheyne-Stokes breathing and sleep-disordered
breathing (398). In the Sleep Heart Health Study, the pres-
ence of sleep-disturbed breathing was associated with a 2.38
relative risk of HF independent of other known risk factors
(399). This risk of HF exceeded that for all other cardiovas-
cular disease syndromes evaluated, including hypertension,
stroke, and coronary artery disease. The use of nocturnal
oxygen and devices that provide continuous positive airway
pressure has been reported to produce symptomatic improve-
ment (400, 401). Although there is no direct evidence that
treatment of sleep-disturbed breathing prevents incident HF,
treatment of established LV dysfunction with continuous
positive airway pressure breathing has been shown to
improve LV structure and function in patients with either
obstructive or central sleep apnea disturbed-breathing syn-
drome (402). Additional studies are in progress to evaluate
the efficacy of these interventions. It is hoped that such stud-
ies will provide information about the efficacy and safety of
this approach and help identify patients most likely to bene-
fit from treatment.
4.3.1.4.2. EXTERNAL COUNTERPULSATION. The technique of
external counterpulsation involves the use of a device with
inflatable cuffs that surround the lower limbs and inflate and
deflate in synchronization with the cardiac cycle. The device
is designed to reduce loading conditions in systole while
increasing coronary perfusion pressures in diastole (403).
External counterpulsation has been shown to reduce the fre-
quency and severity of anginal attacks in patients with symp-
tomatic coronary artery disease (404). A possible mechanism
of action for this observed clinical effect may be an improve-
ment in endothelial function of the coronary vascular bed
(405, 406). Early trials of this therapy in patients with HF
and low EF have been encouraging, and a randomized trial
has been completed recently (407, 408). Until more data are
available, routine use of this therapy cannot be recommend-
ed for the management of patients with symptomatic reduced
LVEF.
4.3.1.4.3. VASOPRESSIN RECEPTOR ANTAGONISTS. Arginine
vasopressin is a peptide hormone with significant cardiovas-
cular and renal effects. These effects are mediated through at
least 2 receptor subtypes: the V1A receptor, which is found on
vascular smooth muscle cells and in the myocardium, and the
V2 receptors, which are found in the kidney. Vasopressin lev-
els are often elevated in patients with HF and LV dysfunc-
tion, and they appear to be associated with adverse outcomes
in the setting of low EF after MI (409).
Early studies with 2 different vasopressin receptor antago-
nists have shown favorable changes in hemodynamics and
urine output without a significant change in blood pressure
or heart rate. The drugs appear to reduce body weight and
edema, and they normalized serum sodium in patients with
hyponatremia, but the duration and significance of these clin-
ical effects are not clear (410, 411). Currently, longer-term
clinical trials are under way to determine the role, if any, of
these vasopressin antagonists in patients with chronic HF
(412, 413).
4.3.1.4.4. IMPLANTABLE HEMODYNAMIC MONITORS. Several
implantable systems are in development for the chronic,
remote, outpatient monitoring of ventricular filling pressures
and other hemodynamic and clinical variables in HF patients.
One such system has completed phase I and II study and is
currently being evaluated in a phase III randomized out-
comes trial. The hypothesis underlying this approach sug-
gests that changes in therapy to optimize LV filling pressure
may improve outcomes in HF patients (414, 415).
4.3.1.4.5. CARDIAC SUPPORT DEVICES. There is developing
experience with surgical devices that are designed to alter
physical stresses on the LV; theoretically, the devices may
improve performance or attenuate further ventricular dilata-
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ishment of documented deficiencies, randomized trials have
failed to demonstrate benefit for routine vitamin, nutritional,
or hormonal supplementation (430).
In most data or other literature regarding nutraceuticals,
there are issues, including outcomes analyses, adverse
effects, and drug-nutraceutical interactions, that remain unre-
solved. No clinical trials have demonstrated improved sur-
vival in users of nutritional or hormonal therapy. Some stud-
ies have suggested a possible effect for coenzyme Q10 in
reduced hospitalization rates, dyspnea, and edema in patients
with HF, but these benefits have not been seen uniformly
(431-434). Because of possible adverse effects and drug
interactions of nutritional supplements and their widespread
use, physicians caring for patients with HF should routinely
inquire about their use. Until more data are available, nutri-
tional supplements or hormonal therapies are not recom-
mended for the treatment of HF. The ACCF Clinical Expert
Consensus Document on the Integration of Complementary
Medicine Into Cardiovascular Medicine (in press ) will pro-
vide more details regarding cardiovascular issues with alter-
native and complementary medicine.
4.3.1.5.2. INTERMITTENT INTRAVENOUS POSITIVE INOTROPIC
THERAPY. Although positive inotropic agents can improve
cardiac performance during short- and long-term therapy
(435, 436), long-term oral therapy with these drugs has not
improved symptoms or clinical status (292, 437-447) and has
been associated with a significant increase in mortality, espe-
cially in patients with advanced HF (445, 448-453). Despite
these data, some physicians have proposed that the regularly
scheduled intermittent use of intravenous positive inotropic
drugs (e.g., dobutamine or milrinone) in a supervised outpa-
tient setting might be associated with some clinical benefits
(41-43, 454).
However, there has been little experience with intermittent
home infusions of positive inotropic agents in controlled
clinical trials. Nearly all of the available data are derived
from open-label and uncontrolled studies or from trials that
have compared one inotropic agent with another, without a
placebo group (41-43, 454). Most trials have been small and
short in duration and thus have not been able to provide reli-
able information about the effect of treatment on the risk of
serious cardiac events. Much if not all of the benefit seen in
these uncontrolled reports may have been related to the
increased surveillance of the patient’s status and intensifica-
tion of concomitant therapy and not to the use of positive
inotropic agents. Only one placebo-controlled trial of inter-
mittent intravenous positive inotropic therapy has been pub-
lished (455), and its findings are consistent with the results
of long-term studies with continuous oral positive inotropic
therapy in HF (e.g., with milrinone), which showed little effi-
cacy and were terminated early because of an increased risk
of death. 
Because of lack of evidence to support their efficacy and
concerns about their toxicity, physicians should not utilize
intermittent infusions of positive inotropic agents (at home,
in an outpatient clinic, or in a short-stay unit) in the long-
tion. One such device now being evaluated clinically is a car-
diac wrapping device made from a bidirectional woven poly-
ester that allows for shortening but resists circumferential
expansion beyond the limits of the wrap (416). Clinical trials
in Europe (417) and the United States are currently under
way to evaluate the safety and efficacy of this device in
patients. Other ventricular constraint or support devices are
also under investigation in Europe and the United States.
4.3.1.4.6. SURGICAL APPROACHES UNDER INVESTIGATION. A
number of surgical approaches have emerged as potentially
beneficial in patients with ischemic HF. The goals of such
procedures generally include revascularization, reduction in
“geometric” or functional mitral regurgitation, and restora-
tion of a more normal LV geometry and function. In this con-
text, the so-called surgical ventricular restoration procedure
is one of the most extensively studied and applied techniques
for reshaping or excluding anteroapical and septal regions of
asynergy (418-420). The surgical ventricular restoration pro-
cedure, although extensively applied to the treatment of LV
asynergy, is now being studied prospectively in a random-
ized trial comparing standard medical therapy versus surgi-
cal therapy (coronary artery bypass grafting) alone versus
surgical ventricular restoration plus coronary artery bypass
grafting in patients with ischemic HF. The National Heart,
Lung, and Blood Institute’s multicenter, international, ran-
domized STICH (Surgical Treatment for Ischemic Heart
Failure) trial began enrolling patients with coronary artery
disease and HF in the Spring of 2002. The goal of this study
is to determine whether a benefit over medical therapy can be
found for coronary revascularization and whether this bene-
fit can be enhanced by ventricular restoration surgery.
4.3.1.4.7. NESIRITIDE. Natriuretic peptides are novel com-
pounds that promote diuresis and natriuresis, have vasodila-
tory properties, lead to an indirect increase in cardiac output,
and suppress neurohormonal activation; they have been
approved for use in the management of acute HF (421-423).
In this setting, nesiritide has been shown to improve symp-
toms of acute HF, but the effect on morbidity and mortality
has not been clear from available clinical trials (423a-423b). 
They are currently under investigation as adjunctive thera-
py, administered on an intermittent outpatient basis, for
advanced HF. Unless a definitive study does demonstrate
safety and efficacy, intermittent or continuous outpatient
infusion of nesiritide and other natriuretic peptides is not rec-
ommended.
4.3.1.5. Drugs and Interventions of Unproved Value
and Not Recommended
4.3.1.5.1. NUTRITIONAL SUPPLEMENTS AND HORMONAL
THERAPIES. Patients with HF, particularly those treated with
diuretics, may become deficient in vitamins and micronutri-
ents. Several nutritional supplements (e.g., coenzyme Q10,
carnitine, taurine, and antioxidants) and hormonal therapies
(e.g., growth hormone or thyroid hormone) have been pro-
posed for the treatment of HF (424-429). Aside from replen-
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term treatment of HF, even in its advanced stages. The use of
continuous infusions of positive inotropic agents as palliative
therapy in patients with end-stage disease (Stage D) is dis-
cussed later in this document.
4.3.2. Patients With HF and Normal LVEF
RECOMMENDATIONS
Class I
1. Physicians should control systolic and diastolic hyper-
tension in patients with HF and normal LVEF, in
accordance with published guidelines. (Level of
Evidence: A)
2. Physicians should control ventricular rate in patients
with HF and normal LVEF and atrial fibrillation.
(Level of Evidence: C)
3. Physicians should use diuretics to control pulmonary
congestion and peripheral edema in patients with HF
and normal LVEF. (Level of Evidence: C)
Class IIa
Coronary revascularization is reasonable in patients
with HF and normal LVEF and coronary artery dis-
ease in whom symptomatic or demonstrable myocar-
dial ischemia is judged to be having an adverse effect
on cardiac function. (Level of Evidence: C)
Class IIb
1. Restoration and maintenance of sinus rhythm in
patients with atrial fibrillation and HF and normal
LVEF might be useful to improve symptoms. (Level of
Evidence: C)
2. The use of beta-adrenergic blocking agents, ACEIs,
ARBs, or calcium antagonists in patients with HF and
normal LVEF and controlled hypertension might be
effective to minimize symptoms of HF. (Level of
Evidence: C)
3. The usefulness of digitalis to minimize symptoms of
HF in patients with HF and normal LVEF is not well
established. (Level of Evidence: C)
Table 8 summarizes the recommendations for treatment of
patients with HF and normal LVEF.
4.3.2.1. Identification of Patients
For many years, the syndrome of HF was considered to be
synonymous with diminished contractility of the LV, or
reduced LVEF. Over the past few years, however, there has
been a growing appreciation that a large number of patients
with HF have a relatively normal EF, or preserved EF. The
pathophysiology of this type of HF has been reviewed in
depth (456), and a large, randomized study that enrolled
patients with HF and normal EF has been completed (235).
Currently, a number of investigators are seeking to clarify the
epidemiology, clinical characteristics, and prognosis of
patients with HF and a normal LVEF (457).
Depending on the criteria used to delineate HF and the
accepted threshold for defining preserved LVEF, it is esti-
mated that as many as 20% to 60% of patients with HF have
a relatively (or near) normal LVEF and, in the absence of
valvular disease, are believed to have reduced ventricular
compliance as a major contributor to the clinical syndrome
(458-462). Some investigators have found that in a signifi-
Table 8. Recommendations for Treatment of Patients With Heart Failure and Normal Left Ventricular Ejection
Fraction
Recommendation Class Level of Evidence
Physicians should control systolic and diastolic hypertension, I A
in accordance with published guidelines. 
Physicians should control ventricular rate in patients with I C
atrial fibrillation.
Physicians should use diuretics to control pulmonary congestion I C
and peripheral edema. 
Coronary revascularization is reasonable in patients with IIa C
coronary artery disease in whom symptomatic or demonstrable 
myocardial ischemia is judged to be having an adverse effect 
on cardiac function. 
Restoration and maintenance of sinus rhythm in patients with atrial  IIb C
fibrillation might be useful to improve symptoms.
The use of beta-adrenergic blocking agents, angiotensin converting IIb C
enzyme inhibitors, angiotensin II receptor blockers, or calcium 
antagonists in patients with controlled hypertension might be effective 
to minimize symptoms of heart failure. 
The use of digitalis to minimize symptoms of heart failure is not IIb C
well established.
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cant number of patients, a tendency to fluid retention and
reduced vascular compliance, rather than myocardial stiff-
ness, represent the principal abnormalities (463). Regardless,
abnormal renal sodium handling and arterial stiffness, in
addition to myocardial stiffness, are likely to play important
pathophysiologic roles in many patients. Diastole is that peri-
od in the cardiac cycle during which the myocardium loses
its ability to generate force and shorten and returns to an
unstressed length and force, and diastolic dysfunction occurs
when these events are prolonged, slowed, or are incomplete
(456). It should also be recognized that diastolic function is
abnormal in patients with HF and reduced LVEF, as well as
those with preserved LVEF. Several recognized myocardial
disorders are associated with HF and a normal LVEF, includ-
ing restrictive cardiomyopathy, obstructive and nonobstruc-
tive hypertrophic cardiomyopathy, and infiltrative cardiomy-
opathies. The vast majority of patients with HF and relative-
ly preserved LVEF have a history of hypertension, and many,
if not most, of these patients have evidence of LVH on
echocardiography. However, some patients who present with
HF and relatively preserved LVEF have no identifiable
myocardial pathology. Because these patients usually present
with symptoms typical of HF, they should be classified as
Stage C. Indeed, most patients will have some detectable
structural abnormality of the heart, including LVH, atrial
dilation, mitral annular calcification, aortic sclerosis, or
myocardial scar.
Heart failure associated with relatively preserved LVEF is
most prevalent among elderly women, most of whom have
hypertension, diabetes mellitus, or both and often coronary
artery disease or atrial fibrillation as well (459). This obser-
vation may be related to the fact that aging has a greater
impact on ventricular filling characteristics than on EF (464).
Aging is associated with decreases in the elastic properties of
the heart and great vessels, which leads to an increase in sys-
tolic blood pressure and an increase in myocardial stiffness.
The rate of ventricular filling decreases in part because of
structural changes in the heart (due to fibrosis) and because
of a decline in relaxation and compliance. These deleterious
effects on diastolic function are exacerbated by a decrease in
beta-adrenergic receptor density and a decline in peripheral
vasodilator capacity, both of which are characteristic of eld-
erly patients. In addition, elderly patients commonly have
associated disorders (e.g., coronary artery disease, diabetes
mellitus, aortic stenosis, atrial fibrillation, or obesity), which
can adversely affect the diastolic properties of the heart or
decrease the time available for ventricular filling. There may
also be sex-specific responses to hypertension and diabetes
mellitus that make women more susceptible than men to the
cumulative effects of aging on diastolic function (465). 
A number of recent investigations have focused on the dif-
ferences between HF with preserved EF and that with low
LVEF (27, 28, 457). Myocardial infarction or other evidence
of atherosclerotic disease appears to be less common in HF
with normal LVEF, but hypertension is at least as common in
this subgroup. The morbidity and mortality associated with
HF and a relatively preserved LVEF may be nearly as pro-
found as that with low LVEF; frequent and repeated hospi-
talizations characterize the patient with HF and a normal
LVEF (466, 467). Most, but not all, series of patients with
HF and relatively preserved LVEF have shown better sur-
vival than is seen in patients with HF and reduced LVEF;
however, these comparisons are difficult to interpret, because
it is difficult to be certain that such series do not contain at
least some patients in whom the diagnosis of HF is erro-
neous.
4.3.2.2. Diagnosis 
There have been several proposed criteria by which clini-
cians and investigators may define HF with a relatively pre-
served LVEF (468-471). In general, a definitive diagnosis
can be made when the rate of ventricular relaxation is
slowed; this physiological abnormality is characteristically
associated with the finding of an elevated LV filling pressure
in a patient with normal LV volumes and contractility. In
practice, the diagnosis is generally based on the finding of
typical symptoms and signs of HF in a patient who is shown
to have a normal LVEF and no valvular abnormalities (aortic
stenosis or mitral regurgitation, for example) on echocardio-
graphy. Every effort should be made to exclude other possi-
ble explanations or disorders that may present in a similar
manner (462, 473) (Table 9). 
Noninvasive methods (especially those that rely on
Doppler echocardiography) have been developed to assist in
the diagnosis of HF with normal LVEF, but these tests have
significant limitations, because cardiac filling patterns are
readily altered by nonspecific and transient changes in load-
ing conditions in the heart and by aging, changes in heart
rate, or the presence of mitral regurgitation (474-480). The
analysis of BNP levels in association with echocardiograph-
ic filling patterns can improve diagnostic accuracy, e.g., a
normal BNP level along with completely normal diastolic
filling parameters makes HF much less likely; however, HF
does remain a strictly clinical diagnosis (481).
Table 9. Differential Diagnosis in a Patient With Heart Failure and
Normal Left Ventricular Ejection Fraction
Incorrect diagnosis of HF
Inaccurate measurement of LVEF
Primary valvular disease
Restrictive (infiltrative) cardiomyopathies
Amyloidosis, sarcoidosis, hemochromatosis
Pericardial constriction
Episodic or reversible LV systolic dysfunction
Severe hypertension, myocardial ischemia
HF associated with high metabolic demand (high-output states)
Anemia, thyrotoxicosis, arteriovenous fistulae
Chronic pulmonary disease with right HF
Pulmonary hypertension associated with pulmonary vascular disorders
Atrial myxoma
Diastolic dysfunction of uncertain origin
Obesity
HF indicates heart failure; LV, left ventricular; and LVEF, left ventricular ejection fraction.
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blockers) can provide symptomatic relief in patients with HF
and normal LVEF. Similarly, patients with HF and preserved
LVEF may be particularly sensitive to loss of atrial kick,
which supports a potential benefit for restoration of sinus
rhythm in patients with atrial fibrillation. The benefits of
restoring sinus rhythm in these individuals are less clear, and
the large trials of rhythm versus rate control in atrial fibrilla-
tion published recently have excluded patients with HF.
Moreover, the presence of systolic or diastolic dysfunction
may diminish the efficacy and enhance the toxicity of drugs
used to achieve and maintain sinus rhythm. 
Circulating blood volume is a major determinant of ven-
tricular filling pressure, and the use of diuretics may improve
breathlessness in patients with HF and normal LVEF as well
as those with reduced LVEF. Other possible agents used to
reduce diastolic filling pressures are nitrates or agents that
block neurohumoral activation. Hypotension may be a sig-
nificant problem in this population, especially in the very
elderly, because they can be quite sensitive to preload reduc-
tion.
4.4. Patients With Refractory End-Stage HF
(Stage D)
RECOMMENDATIONS
Class I
1. Meticulous identification and control of fluid reten-
tion is recommended in patients with refractory end-
stage HF. (Level of Evidence: B)
2. Referral for cardiac transplantation in potentially eli-
gible patients is recommended for patients with
refractory end-stage HF. (Level of Evidence: B)
3. Referral of patients with refractory end-stage HF to
an HF program with expertise in the management of
refractory HF is useful. (Level of Evidence: A)
4. Options for end-of-life care should be discussed with
the patient and family when severe symptoms in
patients with refractory end-stage HF persist despite
application of all recommended therapies. (Level of
Evidence: C)
5. Patients with refractory end-stage HF and
implantable defibrillators should receive information
about the option to inactivate defibrillation. (Level of
Evidence: C)
Class IIa
Consideration of an LV assist device as permanent or
“destination” therapy is reasonable in highly selected
patients with refractory end-stage HF and an estimat-
ed 1-year mortality over 50% with medical therapy.
(Level of Evidence: B)
Class IIb
1. Pulmonary artery catheter placement may be reason-
able to guide therapy in patients with refractory end-
stage HF and persistently severe symptoms. (Level of
Evidence: C)
4.3.2.3. Principles of Treatment
In contrast to the treatment of HF due to reduced LVEF, few
clinical trials are available to guide the management of
patients with HF and relatively preserved LVEF. Although
controlled studies have been performed with digitalis,
ACEIs, ARBs, beta-blockers, and calcium channel blockers
in patients with HF who had a relatively preserved LVEF, for
the most part, these trials have been small or have produced
inconclusive results (113, 482-485). Nevertheless, many
patients with HF and normal LVEF are treated with these
drugs because of the presence of comorbid conditions (i.e.,
atrial fibrillation, hypertension, diabetes mellitus, and coro-
nary artery disease). A large, randomized trial recently com-
pleted included patients with HF and normal LVEF, which
demonstrates that studies in such patients can be accom-
plished (235). In that trial, the addition of candesartan to the
treatment regimen for patients with symptomatic HF and rel-
atively preserved LVEF significantly reduced morbidity but
did not reach the primary end point.
In the absence of other controlled clinical trials, the man-
agement of these patients is based on the control of physio-
logical factors (blood pressure, heart rate, blood volume, and
myocardial ischemia) that are known to exert important
effects on ventricular relaxation (462). Likewise, diseases
that are known to cause HF with normal LVEF should be
treated, such as coronary artery disease, hypertension, or aor-
tic stenosis. Clinically, it seems reasonable to target symptom
reduction, principally by reducing cardiac filling pressures at
rest and during exertion (456). Recommendations regarding
the use of anticoagulation and antiarrhythmic agents apply to
all patients with HF, irrespective of LVEF.
POTENTIAL TREATMENT STRATEGIES. Hypertension exerts a
deleterious effect on ventricular function by causing both
structural and functional changes in the heart. Increases in
systolic blood pressure have been shown to slow myocardial
relaxation (486), and the resulting hypertrophy may adverse-
ly affect passive chamber stiffness. Physicians should make
every effort to control both systolic and diastolic hyperten-
sion with effective antihypertensive therapy in accordance
with published guidelines (61). Consideration should at least
be given to achieving target levels of blood pressure lower
than those recommended for patients with uncomplicated
hypertension (e.g., less than 130 mm Hg systolic and less
than 80 mm Hg diastolic) (61, 485, 487). Because myocar-
dial ischemia can impair ventricular relaxation, coronary
revascularization should be considered in patients with coro-
nary artery disease in whom symptomatic or demonstrable
myocardial ischemia is believed to be exerting a deleterious
effect on cardiac function [for more information, see the
ACC/AHA 2004 Guideline Update for Coronary Artery
Bypass Graft Surgery (29)]. 
Because tachycardia can shorten the time available for ven-
tricular filling and coronary perfusion, drugs that slow the
heart rate or the ventricular response to atrial arrhythmias
(e.g., beta-blockers, digoxin, and some calcium channel
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has a complementary mode of action (e.g., metolazone) (169,
171). If the patient continues to exhibit evidence of volume
overload despite these measures, hospitalization is generally
required for further adjustment of therapy (168, 488), possi-
bly including intravenous dopamine or dobutamine. This
strategy can elicit a marked increase in urine volume, but
such a diuresis is frequently accompanied by worsening
azotemia, especially if patients are also being treated with an
ACEI. Provided that renal function stabilizes, small or mod-
erate elevations of blood urea nitrogen and serum creatinine
should not lead to efforts to minimize the intensity of thera-
py; however, if the degree of renal dysfunction is severe or if
the edema becomes resistant to treatment, ultrafiltration or
hemofiltration may be needed to achieve adequate control of
fluid retention (489, 490). The use of such mechanical meth-
ods of fluid removal can produce meaningful clinical benefits
in patients with diuretic-resistant HF and may restore respon-
siveness to conventional doses of loop diuretics. 
In general, patients should not be discharged from the hos-
pital until a stable and effective diuretic regimen is estab-
lished, and ideally, not until euvolemia is achieved. Patients
who are sent home before these goals are reached are at high
risk of recurrence of fluid retention and early readmission
(491), because unresolved edema may itself attenuate the
response to diuretics (164-166). Once euvolemia is achieved,
the patient’s dry weight can be defined and used as a contin-
uing target for the adjustment of diuretic doses. Many
patients are able to modify their own diuretic regimen in
response to changes in weight that exceed a predefined
range. The restriction of dietary sodium (to 2 g daily or less)
can greatly assist in the maintenance of volume balance.
Patients with persistent or recurrent fluid retention despite
sodium restriction and high-dose diuretic use may benefit
from review of fluid intake and restriction to 2 liters daily.
The ongoing control of fluid retention may be enhanced by
enrollment in an HF program, which can provide the close
surveillance and education needed for the early recognition
and treatment of volume overload (143-146).
4.4.2. Utilization of Neurohormonal Inhibitors
Controlled trials suggest that patients with advanced HF
respond favorably to treatment with both ACEIs and beta-
blockers in a manner similar to those with mild to moderate
disease (195-197, 199-201, 204, 209-220, 247-255, 260-263,
492). However, because neurohormonal mechanisms play an
important role in the support of circulatory homeostasis as
HF progresses, neurohormonal antagonism may be less well
tolerated by patients with severe symptoms than by patients
with mild symptoms. Patients who are at the end stage of
their disease are at particular risk of developing hypotension
and renal insufficiency after the administration of an ACEI
and of experiencing worsening HF after treatment with a
beta-blocker. As a result, patients with refractory HF may
tolerate only small doses of these neurohormonal antagonists
or may not tolerate them at all.
Consequently, physicians should exercise great care when
considering the use of both ACEIs and beta-blockers in
2. The effectiveness of mitral valve repair or replace-
ment is not established for severe secondary mitral
regurgitation in refractory end-stage HF. (Level of
Evidence: C)
3. Continuous intravenous infusion of a positive inotrop-
ic agent may be considered for palliation of symptoms
in patients with refractory end-stage HF. (Level of
Evidence: C)
Class III
1. Partial left ventriculectomy is not recommended in
patients with nonischemic cardiomyopathy and
refractory end-stage HF. (Level of Evidence: C)
2. Routine intermittent infusions of positive inotropic
agents are not recommended for patients with refrac-
tory end-stage HF. (Level of Evidence: B)
Most patients with HF due to reduced LVEF respond favor-
ably to pharmacological and nonpharmacological treatments
and enjoy a good quality of life and enhanced survival; how-
ever, some patients do not improve or experience rapid recur-
rence of symptoms despite optimal medical therapy. Such
patients characteristically have symptoms at rest or on mini-
mal exertion, including profound fatigue; cannot perform
most activities of daily living; frequently have evidence of
cardiac cachexia; and typically require repeated and/or pro-
longed hospitalizations for intensive management. These
individuals represent the most advanced stage of HF and
should be considered for specialized treatment strategies,
such as mechanical circulatory support, continuous intra-
venous positive inotropic therapy, referral for cardiac trans-
plantation, or hospice care. 
Before a patient is considered to have refractory HF, physi-
cians should confirm the accuracy of the diagnosis, identify
any contributing conditions, and ensure that all conventional
medical strategies have been optimally employed. Measures
listed as Class I recommendations for patients in stages A, B,
and C are also appropriate for patients in end-stage HF (also
see Section 5). When no further therapies are appropriate,
careful discussion of the prognosis and options for end-of-
life care should be initiated (see Section 7).
4.4.1. Management of Fluid Status
Many patients with advanced HF have symptoms that are
related to the retention of salt and water and thus will
respond favorably to interventions designed to restore sodi-
um balance. Hence, a critical step in the successful manage-
ment of end-stage HF is the recognition and meticulous con-
trol of fluid retention.
In most patients with chronic HF, volume overload can be
treated adequately with low doses of a loop diuretic com-
bined with moderate dietary sodium restriction; however, as
HF advances, the accompanying decline in renal perfusion
can limit the ability of the kidneys to respond to diuretic ther-
apy (148, 161). In such patients, the control of fluid retention
may require progressive increments in the dose of a loop
diuretic and frequently the addition of a second diuretic that
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and reduce the subsequent risk of deterioration. Assessment
of the adequacy and tolerability of orally based strategies
may necessitate observation in the hospital for at least 48
hours after the infusions are discontinued (497).
Patients who cannot be weaned from intravenous to oral
therapy despite repeated attempts may require placement of
an indwelling intravenous catheter to allow for the continu-
ous infusion of dobutamine or milrinone, or as has been used
more recently, nesiritide. Such a strategy is commonly used
in patients who are awaiting cardiac transplantation, but it
may also be used in the outpatient setting in patients who
otherwise cannot be discharged from the hospital. The deci-
sion to continue intravenous infusions at home should not be
made until all alternative attempts to achieve stability have
failed repeatedly, because such an approach can present a
major burden to the family and health services and may ulti-
mately increase the risk of death. However, continuous intra-
venous support can provide palliation of symptoms as part of
an overall plan to allow the patient to die with comfort at
home (498, 499). The use of continuous intravenous support
to allow hospital discharge should be distinguished from the
intermittent administration of infusions of such agents to
patients who have been successfully weaned from inotropic
support.
4.4.4. Mechanical and Surgical Strategies
Cardiac transplantation is currently the only established sur-
gical approach to the treatment of refractory HF, but it is
available to fewer than 2500 patients in the United States
each year (500, 501). Current indications for cardiac trans-
plantation focus on the identification of patients with severe
functional impairment or dependence on intravenous
inotropic agents (Table 10). Less common indications for
cardiac transplantation include recurrent life-threatening
ventricular arrhythmias or angina that is refractory to all cur-
rently available treatments (502).  
Alternate surgical and mechanical approaches for the treat-
ment of end-stage HF are under development. Clinical
improvement has been reported after mitral valve repair or
replacement in patients who have a clinically important
degree of mitral regurgitation that is secondary to LV dilata-
tion (120). However, no controlled studies have evaluated
the effects of this procedure on ventricular function, clinical
status, or survival. One recent single-center report of a non-
randomized series of patients considered appropriate candi-
dates for mitral valve repair did not demonstrate a survival
advantage (503).
Although both cardiomyoplasty and left ventriculectomy
(Batista procedure) at one time generated considerable
excitement as potential surgical approaches to the treatment
of refractory HF (504, 505), these procedures failed to result
in clinical improvement and were associated with a high risk
of death (506). A variant of the aneurysmectomy procedure
is now being developed for the management of patients with
ischemic cardiomyopathy (420), but its role in the manage-
ment of HF remains to be defined. None of the current sur-
patients with refractory HF. Treatment with either type of
drug should not be initiated in patients who have systolic
blood pressures less than 80 mm Hg or who have signs of
peripheral hypoperfusion. In addition, patients should not be
started on a beta-blocker if they have significant fluid reten-
tion or if they recently required treatment with an intra-
venous positive inotropic agent. Treatment with an ACEI or
beta-blocker should be initiated in very low doses, and
patients should be monitored closely for signs or symptoms
of intolerance. If low doses are tolerated, further dosage
increments may be considered but may not be tolerated.
However, clinical trials with lisinopril and carvedilol suggest
that even low doses of these drugs may provide important
benefits (272, 493). 
Alternative pharmacological treatments may be considered
for patients who cannot tolerate ACEIs or beta-blockers. A
combination of nitrates and hydralazine has been reported to
have favorable effects on survival in patients with mild to
moderate symptoms who were not taking an ACEI or a beta-
blocker (354), but the utility of this vasodilator combination
in patients with end-stage disease who are being given these
neurohormonal antagonists remains unknown. In addition,
many patients experience headaches or gastrointestinal dis-
tress with these direct-acting vasodilators, which can prevent
patients from undergoing long-term treatment. Spiron-
olactone has been reported to prolong life and reduce the risk
of hospitalization for HF in patients with advanced disease
(141); however, the evidence supporting the use of the drug
has been derived in patients who have preserved renal func-
tion, and the drug can produce dangerous hyperkalemia in
patients with impaired renal function. Finally, although
ARBs (224) are frequently considered as alternatives to
ACEIs because of the low incidence of cough and angioede-
ma with these medications, it is not clear that ARBs are as
effective as ACEIs, and they are as likely as ACEIs to pro-
duce hypotension or renal insufficiency (196, 494).
4.4.3. Intravenous Peripheral Vasodilators and
Positive Inotropic Agents
Patients with refractory HF are hospitalized frequently for
clinical deterioration, and during such admissions, they com-
monly receive infusions of both positive inotropic agents
(dobutamine, dopamine, or milrinone) and vasodilator drugs
(nitroglycerin, nitroprusside, or nesiritide) in an effort to
improve cardiac performance, facilitate diuresis, and pro-
mote clinical stability. Some physicians have advocated the
placement of pulmonary artery catheters in patients with
refractory HF, with the goal of obtaining hemodynamic
measurements that might be used to guide the selection and
titration of therapeutic agents (495). However, the logic of
this approach has been questioned, because many useful
drugs for HF produce benefits by mechanisms that cannot be
evaluated by measuring their short-term hemodynamic
effects (280, 496). Regardless of whether invasive hemody-
namic monitoring is used, once the clinical status of the
patient has stabilized, every effort should be made to devise
an oral regimen that can maintain symptomatic improvement
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occasionally be followed by sufficient recovery of myocar-
dial function to allow explantation of the device (509).
Improvements in ventricular mechanics, myocardial energet-
ics, histology, and cell signaling have been reported with LV
assist device support. However, the frequency and duration
of myocardial recovery have been variable (510), and suffi-
cient recovery to permit device explantation is rare except in
a few patients with acute onset of HF and the absence of
coronary artery disease. Coupling of device therapy with cell
transplantation and a variety of angiogenesis or myocardial
growth factors are approaches planned for future investiga-
tion.
5. TREATMENT OF SPECIAL POPULATIONS
RECOMMENDATIONS
Class I
1. Groups of patients including (a) high-risk ethnic
minority groups (e.g., blacks), (b) groups underrepre-
sented in clinical trials, and (c) any groups believed to
be underserved should, in the absence of specific evi-
dence to direct otherwise, have clinical screening and
therapy in a manner identical to that applied to the
broader population. (Level of Evidence: B)
2. It is recommended that evidence-based therapy for
HF be used in the elderly patient, with individualized
consideration of the elderly patient’s altered ability to
metabolize or tolerate standard medications. (Level of
Evidence: C)
Class IIa
The addition of isosorbide dinitrate and hydralazine
to a standard medical regimen for HF, including
ACEIs and beta-blockers, is reasonable and can be
effective in blacks with NYHA functional class III or
IV HF. Others may benefit similarly, but this has not
yet been tested. (Level of Evidence: A)
Many patients with HF are members of subpopulations
who are likely to exhibit unique responses that accelerate the
development or progression of HF or complicate the man-
agement of HF.
5.1. Women and Men
Many physicians regard HF primarily as a disease of men,
because coronary risk factors are common in men and pri-
marily men are enrolled in clinical trials of treatments for
HF; however, the majority of patients with HF in the gener-
al population are women (particularly elderly women), who
frequently have HF associated with a normal LVEF (27).
Even HF due to reduced LVEF may be different in women
than in men. Yet, most large, multicenter trials have not
included sufficient numbers of women to allow conclusions
about the efficacy and safety of their treatment. Several stud-
ies have documented a lower use of ACEIs in women with
HF than in men (511), and another study reported that
gical reconstruction techniques offer “rescue therapy” to
patients with critical hemodynamic compromise. 
The use of mechanical circulatory assist devices in end-
stage HF is an area of intense investigation. Extracorporeal
devices can be used for short-term circulatory support in
patients who are expected to recover from a major cardiac
insult (e.g., myocardial ischemia, postcardiotomy shock, or
fulminant myocarditis). Left ventricular assist devices pro-
vide similar degrees of hemodynamic support; many are
implantable and thus allow for long-term support, patient
ambulation, and hospital discharge (507). Most clinical
experience with these devices has been derived from their
use in patients being “bridged” to transplant. The completion
of the Randomized Evaluation of Mechanical Assistance for
the Treatment of Congestive Heart Failure (REMATCH) trial
investigated the use of these devices as permanent or “desti-
nation” therapy in selected non–transplant-eligible patients.
This trial enrolled 129 patients, for whom 2-year survival
was 23% in the 68 patients treated with the device and 8% in
the 61 patients who received medical therapy (508). Device-
related adverse events were numerous and included bleeding,
infection, thromboembolic events, and device failure. This
trial established the efficacy of device therapy for end-stage
HF. Improvements in newer generations of devices will
hopefully permit even further prolongation of survival.
Presently, destination device therapy is anticipated to benefit
those patients predicted to have a 1-year survival of less than
50%. One such group could be the population of non–trans-
plant-eligible patients requiring continuous intravenous
inotropic infusions. Some reports have suggested that pro-
longed mechanical decompression of the failing heart may
Table 10. Indications for Cardiac Transplantation
Absolute indications in appropriate patients
For hemodynamic compromise due to HF
• Refractory cardiogenic shock
• Documented dependence on IV inotropic support to maintain 
adequate organ perfusion
• Peak VO2 less than 10 mL per kg per min with achievement of 
anaerobic metabolism
Severe symptoms of ischemia that consistently limit routine activity
and are not amenable to coronary artery bypass surgery or 
percutaneous coronary intervention
Recurrent symptomatic ventricular arrhythmias refractory to all 
therapeutic modalities
Relative indications
Peak VO2 11 to 14 mL per kg per min (or 55% of predicted) and 
major limitation of the patient’s daily activities
Recurrent unstable ischemia not amenable to other intervention
Recurrent instability of fluid balance/renal function not due to
patient noncompliance with medical regimen
Insufficient indications
Low left ventricular ejection fraction
History of functional class III or IV symptoms of HF
Peak VO2 greater than 15 mL per kg per min (and greater than 55%
of predicted) without other indications
HF indicates heart failure; IV, intravenous; and VO2, oxygen consumption per unit time.
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the diagnosis is made, HF progresses more rapidly in black
than in white patients, as evidenced by a higher risk of initial
and recurrent hospitalizations (520-522). This risk cannot be
explained by the presence of epicardial coronary artery dis-
ease or documented MI, both of which are less common in
black than in nonblack patients with HF. The data are not
clear as to whether a definitive increase in mortality risk
exists (520-522). 
The literature is mixed on whether blacks with HF more
frequently receive suboptimal inpatient care for their HF
(523, 524). However, deficiencies in cardiovascular risk fac-
tor evaluation and disease detection and treatment as well as
in access to quality outpatient care may contribute to the
increased incidence and morbidity of blacks with HF (525-
527).
Blacks and other racial minorities with HF are underrepre-
sented in most clinical trials of HF, which compromises the
extrapolation of results from major clinical trials to ethnic
subgroup populations. To date, there are no data to suggest
that any significant treatment variance from standard care for
HF should be acceptable in any particular group. Clinical
experience suggests that Asian patients have a higher than
average risk of cough during treatment with an ACEI.
Retrospective analysis of subgroup data has suggested that,
as in the treatment of hypertension, black patients with HF
may experience less efficacy than nonblacks from the use of
ACEIs (528). A recent analysis of a large ACEI HF trial that
used a matched-cohort design confirmed that black patients
had a greater number of hospitalizations for HF than
matched white patients (529). However, rates of death in that
trial were similar between black and nonblack patients with
HF (529). Interestingly, the results of 2 trials evaluating the
effects of different beta-blockers in black patients have been
discordant: bucindolol caused a nonsignificant increase in
the risk of a serious clinical event in black patients, but it
reduced deaths and hospitalizations in nonblack patients
(530). Thus, bucindolol may represent a decidedly different
beta-blocker than those already approved for the treatment of
HF. Conversely, the benefit of carvedilol in a separate series
of trials was apparent and of a similar magnitude in both
black and nonblack patients with HF (531). There may be
race-based differences in the outcome of cardiac transplanta-
tion as well (532). Further study is needed to clarify these
issues. 
The emerging field of genomic medicine has begun to sug-
gest that important variances in the expression of certain
high-risk, single-nucleotide polymorphisms may be evident
along racial lines and may provide a physiological basis for
differences in the natural history of HF and differences in
drug responsiveness (533-536). Data from these early inves-
tigations are not yet definitive; racial groupings are neces-
sarily heterogenous, and data will need to be interpreted cau-
tiously. 
A prospective, double-blind randomized trial conducted
specifically in blacks with NYHA class III/IV HF has been
completed (356) . The patient population was characterized
by a much higher likelihood of a nonischemic cause of HF
women are given fewer cardiovascular medications after an
MI than men (510, 512, 513). These findings may explain
why women have been noted to rate their quality of inpatient
care lower than men and why they have less improvement in
physical health status after an episode of HF (510). Some
analyses have suggested that women with HF, particularly
with asymptomatic reduced LVEF, may not show survival
benefits from ACE inhibition (514, 515). Women may also
have a different safety profile than men, as evidenced by
their higher risk of ACEI-induced cough (516). The conflict-
ing data regarding the efficacy of digoxin in women suggests
that if it is prescribed, particular attention should be paid to
dosing and renal function (314). Currently, great efforts are
being made (and mandated) to include a higher proportion of
women in government-sponsored trials. 
Because HF is frequently accompanied by erectile dys-
function, men may express interest in the use of a phospho-
diesterase type 5 inhibitor (e.g., sildenafil) as a means of
enhancing sexual performance. Few patients with HF were
enrolled in controlled trials with sildenafil, and thus, the effi-
cacy and safety of this drug in patients with HF are not
known. Nevertheless, recent studies suggest that sildenafil
may produce hemodynamic benefits in patients with coro-
nary artery disease and may act to improve some of the
peripheral vascular abnormalities that characterize patients
with HF (517). Although patients with HF appear to tolerate
short-term administration of the drug without difficulty,
sildenafil should not be given to patients taking nitrates, who
may experience profound hypotension due to its ability to
potentiate the systemic vasodilator effects of drugs that
increase intracellular levels of cyclic guanosine monophos-
phate (518).
5.2. Ethnic Considerations
Race is an imprecise concept that has largely become a social
and political construct, with more limited biological signifi-
cance (519). The concept of racial “minorities” may be rele-
vant to large populations, especially those in clinical trials,
but is clearly not a concept applicable in many demographic
areas and clinical practices. However, it is useful to review
epidemiological and clinical trial evidence to raise awareness
of potential areas of concern and guide socioeconomic and
clinical remedies. This has become especially pertinent in the
evaluation of HF as it affects blacks, although much more
information is also needed about the effects of current and
new therapies in the Hispanic population. Heart failure is a
major public health problem in blacks. Heart failure is more
common in the black population, affecting approximately
3% of all black adults. This reflects a 50% higher incidence
of HF in the black population than is seen in the general pop-
ulation. 
Black patients develop symptoms of HF at an earlier aver-
age age than nonblacks, possibly because black patients are
more likely to have hypertension and diabetes mellitus than
nonblacks and because they more frequently exhibit sodium
retention, ventricular hypertrophy, and vascular injury. Once
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2. Physicians should control systolic and diastolic hyper-
tension and diabetes mellitus in patients with HF in
accordance with recommended guidelines. (Level of
Evidence: C)
3. Physicians should use nitrates and beta-blockers for
the treatment of angina in patients with HF. (Level of
Evidence: B)
4. Physicians should recommend coronary revascular-
ization according to recommended guidelines in
patients who have both HF and angina. (Level of
Evidence: A)
5. Physicians should prescribe anticoagulants in patients
with HF who have paroxysmal or persistent atrial fib-
rillation or a previous thromboembolic event. (Level
of Evidence: A)
6. Physicians should control the ventricular response
rate in patients with HF and atrial fibrillation with a
beta-blocker (or amiodarone, if the beta-blocker is
contraindicated or not tolerated). (Level of Evidence:
A)
7. Patients with coronary artery disease and HF should
be treated in accordance with recommended guide-
lines for chronic stable angina. (Level of Evidence: C)
8. Physicians should prescribe antiplatelet agents for
prevention of MI and death in patients with HF who
have underlying coronary artery disease. (Level of
Evidence: B)
Class IIa
1. It is reasonable to prescribe digitalis to control the
ventricular response rate in patients with HF and atri-
al fibrillation. (Level of Evidence: A)
2. It is reasonable to prescribe amiodarone to decrease
recurrence of atrial arrhythmias and to decrease
recurrence of ICD discharge for ventricular arrhyth-
mias. (Level of Evidence: C)
Class IIb
1. The usefulness of current strategies to restore and
maintain sinus rhythm in patients with HF and atrial
fibrillation is not well established. (Level of Evidence:
C)
2. The usefulness of anticoagulation is not well estab-
lished in patients with HF who do not have atrial fib-
rillation or a previous thromboembolic event. (Level
of Evidence: B)
3. The benefit of enhancing erythropoiesis in patients
with HF and anemia is not established. (Level of
Evidence: C)
Class III
1. Class I or III antiarrhythmic drugs are not recom-
mended in patients with HF for the prevention of ven-
tricular arrhythmias. (Level of Evidence: A)
2. The use of antiarrhythmic medication is not indicated
as primary treatment for asymptomatic ventricular
and of a history of hypertension and obesity. In this trial, the
adjunctive use of a proprietary formulation of isosorbide
dinitrate and hydralazine along with a standard HF regimen
resulted in a 43% decrease in total mortality, which led to
premature termination of the trial. Additionally, time to first
hospitalization and quality of life were both improved. The
mechanism of benefit of this regimen may be related to an
improvement in nitric oxide bioavailability, but this regimen
had a small (but significant) effect on blood pressure lower-
ing. The effect of this combination of isosorbide dinitrate and
hydralazine in other patients with HF who are undergoing
standard therapy is not known because the population stud-
ied was limited to blacks, but there is no reason to believe
that this benefit is limited to blacks (356).
5.3. Elderly Patients
Heart failure is particularly common in elderly patients. The
prevalence of HF rises from 2% to 3% at age 65 to more than
80% in persons over 80 years of age (537), and HF is the
most common reason for hospitalization in elderly patients
(538-541). The high prevalence of HF in the elderly may be
associated with age-related changes in ventricular function
(particularly diastolic function) and to the cumulative effects
of hypertension and other chronic risk factors (542-546). In
addition, risk factors for HF (e.g., hypertension, diabetes
mellitus, and hyperlipidemia) are generally not treated
aggressively in the elderly, yet elderly patients commonly
take medications that can exacerbate the syndrome of HF
(e.g., nonsteroidal anti-inflammatory drugs) (132). 
Heart failure in elderly patients is inadequately recognized
and treated (547). Both patients and physicians frequently
attribute the symptoms of HF to aging, and noninvasive car-
diac imaging commonly fails to reveal impaired systolic
function because HF with a preserved LVEF is frequently
found in the elderly. In addition, some reports suggest that
elderly patients may have diminished responses to diuretics,
ACEIs, and positive inotropic agents (548, 548-550) com-
pared with younger patients and may experience a higher
risk of adverse effects attributable to treatment (513, 551-
555). Uncertainties regarding the relation of risk to benefit
are exacerbated by the fact that very old individuals are poor-
ly represented in large-scale clinical trials designed to evalu-
ate the efficacy and safety of new treatments for HF. 
Some multidisciplinary HF programs have been successful
in decreasing the rate of readmission and associated morbid-
ity in elderly patients (143, 556). Managed care organiza-
tions continue to struggle to find improved ways to imple-
ment these pathways (557, 558).
6. PATIENTS WITH HF WHO HAVE
CONCOMITANT DISORDERS
RECOMMENDATIONS
Class I
1. All other recommendations should apply to patients
with concomitant disorders unless there are specific
exceptions. (Level of Evidence C)
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in patients with NYHA functional class III to IV symptoms
of HF. Clinical experience has shown that one side effect of
newer oral agents of the thiazolidinedione class is weight
gain, which is due in part to fluid retention. This effect may
have the potential to precipitate or exacerbate HF in patients
with reduced cardiac reserve. Thiazolidinediones probably
should be used with caution in such patients (572, 573).
Recommendations Concerning Management.
Little is known about the benefits of treating hypertension,
hypercholesterolemia, or diabetes mellitus in patients with
established reduced LVEF and symptoms of HF. The lack of
such data is noteworthy, both because the progression of HF
is frequently associated with decreases in blood pressure
(due to deterioration of cardiac performance) and decreases
in serum lipids (due to development of cardiac cachexia)
(564) and because the benefits of drugs used to lower blood
pressure or blood lipids may be seen only during prolonged
periods of treatment, i.e., those that exceed the expected life
span of many patients with HF (55, 56, 564, 565).
Nevertheless, it is prudent to manage hypertension, hyperc-
holesterolemia, and diabetes mellitus in patients with HF as
if the patients did not have HF. This may be particularly true
in patients with HF and preserved LVEF, whose symptoms
may respond particularly well to treatments that lower blood
pressure (574, 575). Renal artery stenosis should be consid-
ered in patients with hypertension and HF, because renal
artery stenting can treat both conditions.
Drugs that can both control blood pressure and treat HF
should be preferred in patients with both conditions; this
includes the use of diuretics, ACEIs, and beta-blockers. In
contrast, physicians should avoid the use of most calcium
channel blockers, because of their cardiodepressant effects,
or potent direct-acting vasodilators such as minoxidil,
because of their sodium-retaining effects. 
The drugs routinely used in the management of HF in non-
diabetic patients should be administered to those with dia-
betes mellitus. Angiotensin converting enzyme inhibitors
and beta-blockers prevent the progression of HF in diabetic
and nondiabetic patients (193, 260, 576). Physicians should
not avoid the use of beta-blockers in diabetic patients despite
fears that these drugs may mask symptoms of hypoglycemia
produced by antidiabetic therapy or may exacerbate glucose
intolerance or insulin resistance.
6.1.2. Coronary Artery Disease
Approximately two thirds of patients with HF have underly-
ing coronary artery disease, which may limit exercise toler-
ance by causing angina pectoris or may lead to further
myocardial injury by causing an MI. Therefore, physicians
should manage both the symptomatic and prognostic conse-
quences of the patient’s underlying coronary artery disease in
accordance with contemporary guidelines.
arrhythmias or to improve survival in patients with
HF. (Level of Evidence: A)
Patients with reduced LVEF frequently have associated
cardiovascular and noncardiovascular disorders, the course
or treatment of which may exacerbate the syndrome of HF.
In many patients, appropriate management of these con-
comitant illnesses may produce symptomatic and prognostic
benefits that may be as important as the treatment of the HF
condition itself. 
6.1. Cardiovascular Disorders
6.1.1. Hypertension, Hyperlipidemia, and 
Diabetes Mellitus
Approximately two thirds of patients with HF have a past or
current history of hypertension, and approximately one third
have diabetes mellitus (559). Both disorders can contribute
to the development of systolic or diastolic dysfunction (560,
561), either directly or by contributing (together with hyper-
lipidemia) to the development of coronary artery disease
(562, 563). Long-term treatment of both hypertension and
hyperlipidemia decrease the risk of developing HF (55, 56,
564, 565). In a large-scale trial, the administration of a lipid-
lowering agent to patients with hypercholesterolemia and a
history of MI reduced all-cause mortality and the risk of
developing HF (564). In 2 large-scale multicenter studies, the
treatment of hypertension reduced both the risk of death and
the risk of HF; this was true regardless of whether the eleva-
tion of blood pressure was primarily systolic or diastolic (55,
56, 565). The benefits of lowering blood pressure may be
particularly marked in patients with diabetes mellitus (63,
66, 566). 
Heart failure may complicate the management of both
hypertension and diabetes mellitus. Some antihypertensive
agents should be avoided in patients with HF because of their
ability to depress cardiac function or to lead to salt and water
retention. In addition, HF itself is associated with resistance
to the actions of insulin (567, 568), and the resulting hyper-
insulinemia may promote both cardiac and vascular hyper-
trophy (569-571) and thus may hasten the progression of HF.
These mechanisms may compound the deleterious effects of
accelerated atherosclerosis and altered energy metabolism on
cardiac function and may help to explain why diabetic
patients with HF have a worse prognosis than their nondia-
betic counterparts (75). 
Thiazolidinediones have been associated with increased
peripheral edema and symptomatic HF in patients with
underlying risk factors or known cardiovascular disease. The
risk of developing edema with thiazolidinediones is dose
related and is higher in diabetic patients who are taking con-
comitant insulin therapy. However, the incidence of thiazo-
lidinedione-related fluid retention is low in patients with
NYHA functional class I to II symptoms, in whom these
drugs can be administered safely with careful monitoring for
fluid retention. Initiation of these drugs is not recommended
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Aspirin has been shown to reduce the risk of major
ischemic events in patients without HF. The role of aspirin in
patients with HF has not been established (595), and con-
cerns have been raised that it may attenuate the hemody-
namic and survival benefits of ACEIs (202, 205, 206). For
these reasons, the role of aspirin in preventing ischemic
events in patients with chronic HF is controversial (see
Section 4.3.1.2.2.1). Alternative antiplatelet agents (e.g.,
clopidogrel) may not interact adversely with ACEIs (204)
and may have superior effects in preventing clinical events
(211), but their ability to favorably affect outcomes in HF has
not been demonstrated (see Section 4.3.1.2.2.1). 
Surgical revascularization has been recommended for a
certain subset of patients in other guidelines (29). Some
physicians recommend the use of coronary revascularization
in patients with HF and coronary artery disease who do not
have symptoms of angina. Advocates of this approach have
suggested that surgical reperfusion can improve cardiac
function and relieve symptoms of HF in patients with
myocardium that appears on imaging to be viable but not
contracting normally (601-603) and may also reduce the risk
of a fatal coronary occlusion in patients with established
multivessel disease (602). Despite these theoretical possibil-
ities, however, coronary revascularization has not been
shown to improve cardiac function or symptoms or to pre-
vent reinfarction or death in patients with HF and no angina
(21, 604).
6.1.3. Supraventricular Arrhythmias
The course of patients with HF is frequently complicated by
supraventricular tachyarrhythmias, which may occur when
the myocardial disease process affects the atria or when the
atria are distended as a result of pressure or volume overload
of the right or left ventricles. The most common treatable
atrial arrhythmia is atrial fibrillation, which affects 10% to
30% of patients with chronic HF and is associated with a
reduction in exercise capacity and a worse long-term prog-
nosis (605-607). 
Supraventricular tachyarrhythmias may exert adverse
effects by 4 different mechanisms: 1) the loss of atrial
enhancement of ventricular filling may compromise cardiac
output; 2) the rapid heart rate may increase demand and
decrease coronary perfusion (by shortening ventricular fill-
ing time); 3) the rapidity of ventricular response may dimin-
ish both cardiac contraction (by aggravating abnormalities of
the force-frequency relation) (608, 609) and cardiac relax-
ation (610, 611); and 4) the stasis of blood in the fibrillating
atria may predispose patients to pulmonary or systemic
emboli. In most patients with an ischemic or nonischemic
dilated cardiomyopathy, the rapidity of ventricular response
is more important than the loss of atrial support, because
restoration of sinus rhythm does not result in predictable
clinical benefits (612). Rapid supraventricular arrhythmias
may actually cause a cardiomyopathy (even in patients with-
out an underlying contractile abnormality) or may exacerbate
a cardiomyopathy caused by another disorder (115, 116).
Hence, the control of ventricular rate and the prevention of
Recommendations Concerning Management of
Patients With Angina Pectoris.
In general, patients who have both angina pectoris and HF
should be given drugs that relieve angina along with drugs
that are appropriate in the management of HF (577). Both
nitrates and beta-blockers can improve anginal symptoms
and may produce hemodynamic and clinical benefits in
patients with reduced LVEF, and thus, they are preferred if
these conditions coexist (255, 260, 262, 578, 579). Yet, the
combination of the 2 drugs may produce little improvement
in anginal pain unless fluid retention is adequately controlled
with diuretics. It is therefore noteworthy that the decrease in
ventricular volume and pressures produced by diuretics may
exert independent antianginal effects (580). 
Some have suggested that the systemic and coronary
vasodilator actions of calcium channel blockers might
improve cardiac performance and relieve myocardial
ischemia, but these theoretical advantages have not been
translated into clinical benefits in controlled clinical trials in
HF (581-583). These drugs have not improved symptoms of
HF or enhanced exercise tolerance (580-584), and short- and
long-term treatment with these drugs (even the use of sus-
tained-release or vasoselective preparations) has increased
the risk of worsening HF and death in patients with LV dys-
function (114, 585-593). Therefore, most calcium channel
blockers should be avoided in patients with HF, even when
used for the treatment of angina or hypertension. Of avail-
able agents, only amlodipine has been shown not to adverse-
ly affect survival, although experience with the drug exists
largely in patients who are not taking beta-blockers (594). 
In patients with both HF and angina pectoris, strong con-
sideration should be given to the use of coronary revascular-
ization. Coronary revascularization can relieve symptoms of
myocardial ischemia (595, 596), and coronary artery bypass
surgery has been shown to lessen angina and reduce the risk
of death in patients who have multivessel disease, reduced
LVEF, and stable angina (597) [see the ACC/AHA/ACP-
ASIM Guidelines for the Management of Patients With
Chronic Stable Angina (598) or the ACC/AHA 2004
Guideline Update for Coronary Artery Bypass Graft Surgery
(29)].
Recommendations Concerning Management of
Patients Without Angina.
In patients with a prior MI but without HF or angina, 4 types
of interventions have been used to reduce the risk of rein-
farction and death: neurohormonal antagonists such as
ACEIs and beta-blockers (66, 103, 104, 109); drugs to
address dyslipidemia, such as statins; antiplatelet drugs such
as aspirin and clopidogrel (209, 211); and coronary revascu-
larization (595). In patients who have had an MI and who
have HF but not angina, the use of ACEIs and beta-blockers
can also decrease the risk of reinfarction and death (106-108,
599, 600), but it is less clear whether such patients benefit
from the use of aspirin or revascularization. 
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aggressive rhythm control. The trial populations did not
include patients with HF symptoms associated with their
atrial fibrillation. However, the rate-control strategy was
associated with fewer hospitalizations and fewer side effects
from drug therapy. Most patients who had thromboembolic
events, regardless of the strategy used, were in atrial fibrilla-
tion at the time of the event and were either not undergoing
anticoagulation therapy or were undergoing therapy at sub-
therapeutic levels . There was a subset analysis of patients
with HF and atrial fibrillation that suggested better outcomes
for those in whom sinus rhythm could be maintained. A fur-
ther study is in progress (621). Until more definitive data are
available, treatment must be individualized.
6.1.4. Prevention of Thromboembolic Events
Patients with chronic HF are at increased risk of throm-
boembolic events due to stasis of blood in dilated hypokinet-
ic cardiac chambers and in peripheral blood vessels (622,
623) and perhaps due to increased activity of procoagulant
factors (624). However, in large-scale studies, the risk of
thromboembolism in clinically stable patients has been low
(1% to 3% per year), even in those with very depressed EFs
and echocardiographic evidence of intracardiac thrombi
(625-629). These rates are sufficiently low to limit the
detectable benefit of anticoagulation in these patients. 
In several retrospective analyses, the risk of thromboem-
bolic events was not lower in patients with HF taking war-
farin than in patients not treated with antithrombotic drugs
(625, 627, 628). The use of warfarin was associated with a
reduction in major cardiovascular events and death in
patients with HF in one retrospective analysis but not in
another (630-632). A randomized trial comparing the out-
come of patients with HF and low EF assigned to aspirin,
warfarin, or clopidogrel was completed recently.
Unfortunately, low enrollment in the trial precluded defini-
tive conclusions about efficacy, but no therapy appeared to
be superior. Another trial is currently under way comparing
aspirin with warfarin in patients with reduced LVEF and may
provide more definitive data upon which to base recommen-
dations.
Recommendations Concerning Management.
In the absence of definitive trials, it is not clear how antico-
agulants should be prescribed in patients with HF. Despite
the lack of supportive data, some physicians prescribe anti-
coagulants to all patients with markedly depressed EFs and
dilated hearts (622). Others would advocate the use of war-
farin in patients who are known to harbor a cardiac thrombus
(623), even though many thrombi detected by echocardiog-
raphy do not embolize and many embolic events are proba-
bly related to thrombi that are not visualized (179, 633).
Anticoagulation with warfarin is most justified in patients
with HF who have experienced a previous embolic event or
who have paroxysmal or persistent atrial fibrillation (614).
Anticoagulation should also be considered in patients with
underlying disorders that may be associated with an
thromboembolic events are essential elements of the treat-
ment of HF in patients with an underlying supraventricular
arrhythmia (613, 614). Specific care and initially low doses
should be used when beta blockers are instituted to control
heart rate in patients with clinical evidence of HF decom-
pensation.
The agent most commonly used in clinical practice to slow
the ventricular response in patients with HF and atrial fibril-
lation is digoxin, but the cardiac glycoside slows atrioven-
tricular conduction more effectively at rest than during exer-
cise (299, 615). Hence, digitalis does not block the excessive
exercise-induced tachycardia that may limit the functional
capacity of patients with HF (297-299, 615). Beta-blockers
are more effective than digoxin during exercise (297, 299)
and are preferred because of their favorable effects on the
natural history of HF (255, 260, 262). The combination of
digoxin and beta-blockers may be more effective than beta-
blockers alone for rate control. Although both verapamil and
diltiazem can also suppress the ventricular response during
exercise, they can depress myocardial function and increase
the risk of HF and thus should be avoided (588, 590). If beta-
blockers are ineffective or contraindicated in patients with
atrial fibrillation and HF, amiodarone may be a useful alter-
native (616). Atrioventricular nodal ablation may be needed
if tachycardia persists despite pharmacological therapy
(325). Catheter intervention for pulmonary vein isolation has
been most effective in patients without structural heart dis-
ease; the benefit for patients with established HF is not
known. Regardless of the intervention used, every effort
should be made to reduce the ventricular response to less
than 80 to 90 beats per min at rest and less than 110 to 130
beats per min during moderate exercise. Anticoagulation
should be maintained in all patients with HF and a history of
atrial fibrillation, regardless of whether sinus rhythm is
achieved, because of the high rate of silent recurrence of atri-
al fibrillation with its attendant embolic risk (614). 
Should patients with HF and atrial fibrillation be converted
to and maintained in sinus rhythm? Although atrial fibrilla-
tion increases the risk of embolic events, the benefits of
restoring sinus rhythm remain unclear (614), and the diffi-
culties and risks of doing so should not be underestimated.
Most patients who are electrically converted to sinus rhythm
will revert to atrial fibrillation within a short time unless they
are treated with a Class I or III antiarrhythmic drug (605).
However, patients with HF are not likely to respond favor-
ably to Class I drugs and may be particularly predisposed to
their cardiodepressant and proarrhythmic effects (127, 326),
which can increase the risk of death (323, 324, 327). Class III
antiarrhythmic agents (e.g., sotalol, dofetilide, and amio-
darone) can maintain sinus rhythm in some patients, but
treatment with these drugs is associated with an increased
risk of organ toxicity (amiodarone) (617, 618) and proar-
rhythmia (dofetilide) (619). The efficacy and safety of restor-
ing and maintaining sinus rhythm in patients with atrial fib-
rillation was recently evaluated in a total of 5032 patients in
4 separate trials (620). These trials consistently showed no
improvement in mortality or morbidity using a strategy of
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ACEIs may be inappropriately stopped in patients with pul-
monary causes of cough. Therefore, physicians should seek
a pulmonary cause in all patients with HF who complain of
cough, whether or not they are taking an ACEI. The cough
should be attributed to the ACEI only if respiratory disorders
have been excluded and the cough disappears after cessation
of ACEI therapy and recurs after reinstitution of treatment.
Because the ACEI-related cough does not represent any seri-
ous pathology, many patients can be encouraged to tolerate it
in view of the important beneficial effects of ACEIs.
Beta-blockers can aggravate bronchospastic symptoms in
patients with asthma; however, many patients with asympto-
matic or mild reactive airways disease tolerate beta-blockers
well. Also, most patients with chronic obstructive pulmonary
disease do not have a bronchospastic component to their ill-
ness and remain reasonable candidates for beta-blockade
(639). Of note, both metoprolol tartrate and bisoprolol may
lose their beta-1 selectivity when prescribed in doses that
have been associated with an improvement in survival in
patients with HF.
6.2.3. Patients With Cancer
Patients with cancer are particularly predisposed to the
development of HF as a result of the cardiotoxic effects of
many cancer chemotherapeutic agents, especially the anthra-
cyclines (640), high-dose cyclophosphamide (641-645), and
trastuzumab (646). Trastuzumab is a monoclonal antibody
recently approved for therapy of metastatic breast cancer
(647) that has a significant potential to cause HF, especially
when combined with anthracyclines. Mediastinal radiation
can also cause acute and chronic injury to the pericardium,
myocardium, cardiac valves, and coronary arteries, particu-
larly when used in conjunction with cardiotoxic chemother-
apy (648). 
Patients undergoing potentially cardiotoxic treatments for
cancer should be monitored closely for the development of
cardiac dysfunction. Heart failure may appear many years
after anthracycline exposure, particularly in association with
another stress, such as tachycardia. Although noninvasive
assessments of LV function and endomyocardial biopsy have
been advocated by some investigators (649), many cases
escape early detection despite close surveillance.
Dexrazoxane may confer some cardioprotection in patients
undergoing anthracycline-based chemotherapy and may
allow for higher doses of the chemotherapy to be given (650,
651). Heart failure due to chemotherapeutic agents is man-
aged similarly to HF due to other causes, although it is not
clear whether patients with cancer respond similarly to
patients with other causes of HF. Nevertheless, because most
patients with anthracycline-induced cardiomyopathy have
striking degrees of tachycardia, many experts believe that
beta-blockers play a particularly important role in the man-
agement of these patients. Although once thought to progress
inexorably, HF related to chemotherapy often improves in
response to therapy, even when it appears late after exposure.
increased thromboembolic risk (e.g., amyloidosis or LV non-
compaction) and in patients with familial dilated cardiomy-
opathy and a history of thromboembolism in first-degree rel-
atives.
6.2. Noncardiovascular Disorders
6.2.1. Patients With Renal Insufficiency
Patients with HF frequently have impaired renal function as
a result of poor renal perfusion, intrinsic renal disease, or
drugs used to treat HF. Patients with renal hypoperfusion or
intrinsic renal disease show an impaired response to diuret-
ics and ACEIs (161, 634) and are at increased risk of adverse
effects during treatment with digitalis (304). Renal function
may worsen during treatment with diuretics or ACEIs (160,
488), although the changes produced by these drugs are fre-
quently short-lived, generally asymptomatic, and reversible.
Persistent or progressive renal functional impairment often
reflects deterioration of the underlying renal disease process
and is associated with a poor prognosis (19, 635). The symp-
toms of HF in patients with end-stage renal disease may be
exacerbated by an increase in loading conditions produced
both by anemia (636) and by fistulas implanted to permit
dialysis. In addition, toxic metabolites and abnormalities of
phosphate, thyroid, and parathyroid metabolism associated
with chronic renal insufficiency can depress myocardial
function. 
Despite the potential for these adverse interactions, most
patients with HF tolerate mild to moderate degrees of func-
tional renal impairment without difficulty. In these individu-
als, changes in blood urea nitrogen and serum creatinine are
generally clinically insignificant and can usually be managed
without the withdrawal of drugs needed to slow the progres-
sion of HF. However, if the serum creatinine increases to
more than 3 mg per dL, the presence of renal insufficiency
can severely limit the efficacy and enhance the toxicity of
established treatments (161, 304, 634). In patients with a
serum creatinine greater than 5 mg per dL, hemofiltration or
dialysis may be needed to control fluid retention, minimize
the risk of uremia, and allow the patient to respond to and
tolerate the drugs routinely used for the management of HF
(490, 637).
6.2.2. Patients With Pulmonary Disease
Because dyspnea is the key symptom in both HF and pul-
monary disease, it is important to distinguish the 2 diseases
and to quantify the relative contribution of cardiac and pul-
monary components to the disability of the patient when
these disorders coexist. Exercise testing with simultaneous
gas exchange or blood gas measurements may be helpful in
this regard, particularly when used in conjunction with right
heart catheterization (638). 
Some drugs used to treat HF can produce or exacerbate
pulmonary symptoms. Angiotensin converting enzyme
inhibitors can cause a persistent nonproductive cough that
can be confused with a respiratory infection, and conversely,
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events may be increased. This therapy is undergoing further
investigation.
7. END-OF-LIFE CONSIDERATIONS
RECOMMENDATIONS
Class I
1. Ongoing patient and family education regarding
prognosis for functional capacity and survival is rec-
ommended for patients with HF at the end of life.
(Level of Evidence: C)
2. Patient and family education about options for for-
mulating and implementing advance directives and
the role of palliative and hospice care services with re-
evaluation for changing clinical status is recommend-
ed for patients with HF at the end of life. (Level of
Evidence: C)
3. Discussion is recommended regarding the option of
inactivating ICDs for patients with HF at the end of
life. (Level of Evidence: C)
4. It is important to ensure continuity of medical care
between inpatient and outpatient settings for patients
with HF at the end of life. (Level of Evidence: C)
5. Components of hospice care that are appropriate to
the relief of suffering, including opiates, are recom-
mended and do not preclude the options for use of
inotropes and intravenous diuretics for symptom pal-
liation for patients with HF at the end of life. (Level of
Evidence: C)
6. All professionals working with HF patients should
examine current end-of-life processes and work
toward improvement in approaches to palliation and
end-of-life care. (Level of Evidence: C)
Class III
Aggressive procedures performed within the final
days of life (including intubation and implantation of
a cardioverter-defibrillator in patients with NYHA
functional class IV symptoms who are not anticipated
to experience clinical improvement from available
treatments) are not appropriate. (Level of Evidence:
C)
Although issues surrounding end-of-life care deserve atten-
tion for all chronic terminal diseases, several general princi-
ples merit particular discussion in the context of chronic HF.
Education of both patient and family regarding the expected
or anticipated course of illness, final treatment options, and
planning should be undertaken before the patient becomes
too ill to participate in decisions. Discussions regarding treat-
ment preferences, living wills, and advance directives should
encompass a variety of likely contingencies that include
responses to a potentially reversible exacerbation of HF, a
cardiac arrest, a sudden catastrophic event such as a severe
cerebrovascular accident, and worsening of major coexisting
noncardiac conditions. In reviewing these issues with fami-
lies, short-term intervention in anticipation of rapid recovery
should be distinguished from prolonged life support without
6.2.4. Patients With Thyroid Disease
Patients with both hyperthyroidism and hypothyroidism are
prone to develop HF. Special vigilance is required for
patients who are taking amiodarone, who may develop either
hyperthyroidism or hypothyroidism. New atrial fibrillation
or exacerbation of ventricular arrhythmias should trigger re-
evaluation of thyroid status.
6.2.5. Patients With Hepatitis C and HIV
Hepatitis C viral infection can be a cause of cardiomyopathy
and myocarditis. It appears that the virus can cause both
dilated cardiomyopathy and hypertrophic cardiomyopathy
(474, 475). The relatively high prevalence of this virus in
Japanese populations compared with those in North America
and Europe suggests that there may be a genetic predisposi-
tion to this type of viral myocarditis (476, 652). A small
study showed that hepatitis C virus myocarditis might
respond favorably to immunosuppressive therapy with pred-
nisone and azathioprine (653, 654). Preliminary data also
suggest that this type of myocarditis might respond well to
interferon therapy (475), although there is concern that inter-
feron can also depress myocardial function. 
Human immunodeficiency virus has been recognized as a
probable occasional cause of dilated cardiomyopathy. The
presence of reduced LVEF in patients with HIV infection
appears to correlate with decreased survival (655). Reduced
LVEF is often seen in association with a significantly
reduced CD4 count, although progression of cardiomyopa-
thy does not appear to be related to falling CD4 levels (656).
Drug therapy for HIV with zidovudine has also been impli-
cated as a cause of cardiomyopathy, possibly through its
effect on cardiac myocyte mitochondrial function (657).
Heart failure in patients with HIV infection may also be
caused or exacerbated by pericardial effusion or pulmonary
hypertension. Interferon-alpha therapy for HIV-related
Kaposi’s sarcoma has also been associated with reversible
reduction in LVEF. Because of the occurrence of complex
opportunistic infections, autoimmune responses to the viral
infection, and drug cardiotoxicity, it is difficult to determine
how therapies influence the development and control of car-
diomyopathy with HIV (658).
6.2.6. Patients With Anemia
Anemia is seldom the cause of HF in the absence of under-
lying cardiac disease. To be the sole cause of high-output HF,
anemia must be severe (e.g., hemoglobin levels less than 5 g
per deciliter). On the other hand, patients with HF frequent-
ly have anemia for a variety of reasons. The severity of ane-
mia may contribute to the increasing severity of HF. Several
studies have demonstrated worse outcomes in patients with
HF and anemia (659, 660). It is unclear whether anemia is
the cause of decreased survival or a result of more severe dis-
ease.
Several small studies have suggested benefit from use of
erythropoietin and iron for treatment of mild anemia in HF
(661-663). There is concern, however, that thromboembolic
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recommendations for procedures being done within the final
days of life that do not add to the hope of recovery or
improvement in life quality. Finally, greater attention and
research need to be devoted to the provision of comfort
measures in the final days of life, including relief of pain and
dyspnea.
Hospice services have only recently been extended to
patients dying of HF. Originally developed for patients with
end-stage cancer, the focus of hospice care has now been
expanded to include the relief of symptoms other than pain
(670). This is appropriate because the suffering of patients
with HF is characteristically linked to symptoms of breath-
lessness, and thus, compassionate care may require the fre-
quent administration of intravenous diuretics and, in some
cases, the continuous infusion of positive inotropic agents
rather than only the use of potent analgesics. However, many
patients dying of HF do describe pain during the final days
(671, 672). Physicians caring for these patients should
become familiar with the prescription of anxiolytics, sleep-
ing medications, and narcotics to ease distress during the last
days. 
Traditionally, the utilization of hospice care has required a
prediction by a physician of death within 6 months, but this
operational policy may be difficult to apply, because health-
care providers are generally unable to accurately predict the
end of life in patients with HF. In a large US study on the
experience of patients hospitalized in intensive care units
with terminal stages of disease, the majority of patients who
were identified by broad criteria for hospice care survived
the next 6 months despite a prediction to the contrary (673).
This discrepancy between predicted and actual survival may
be particularly great for patients with HF, which more often
than other chronic illnesses is characterized by periods of
good quality of life despite the approaching end and which is
likely to be terminated by sudden death despite a recent
remission of symptoms. Current guidelines and policies
(674) are being revised to allow patients with HF to benefit
from the type of care that can be provided through hospice
services. 
Ultimately, the decisions regarding when end of life is
nearing reflect a complex interaction between objective
information and subjective information, emotions, and
patient and family readiness. Ideally, these decisions would
be made in conjunction with the individual or team most
experienced in caring for advanced HF or in collaboration
and/or consultation with such an expert. In reality, however,
this does not occur often. The Writing Committee recom-
mends that all those involved with HF care make it a priori-
ty to improve recognition of end-stage disease and provide
care to patients and families approaching this stage. As we
become more familiar with the steps in progression to end-
stage HF in this era, the current abrupt transition from
aggressive intervention to comfort and bereavement care will
be softened by a gradual and progressive emphasis on palli-
ation until it dominates the final days of care (672).
reasonable expectation of a return to good functional capac-
ity. 
Most patients hospitalized with severe HF indicate a pref-
erence that resuscitation be performed in the event of a car-
diopulmonary arrest. In the largest study of patients hospital-
ized with HF, only 23% stated they did not wish resuscita-
tion, and 40% of these patients subsequently changed their
minds after the hospitalization (664). These frequencies are
higher than those seen in other chronic diseases (665), per-
haps because patients with HF are more likely to experience
extended periods of stability with good quality of life after
hospitalization for intensive care. Hospitals in the United
States are required by the Patient Self-Determination Act
(666) to seek and record information regarding advance
directives at the time of admission. Yet, when these have not
been addressed in advance, forced contemplation of resusci-
tation options at the time of admission for worsening HF
may heighten patient and family anxiety without revealing
true preferences (667). The majority of patients with HF who
had not discussed resuscitation during hospitalization indi-
cated that they had not desired such an interaction (664).
Furthermore, in one study, the impact of resuscitation prefer-
ences on in-hospital outcome was minimal even for patients
with HF in intensive care, of whom only 4% experienced
unexpected cardiac arrests compared with more than 25% of
patients in intensive care units who had other chronic ill-
nesses (668). 
When the limitations imposed by HF alone or in combina-
tion with other severe conditions become intolerable, how-
ever, resuscitation may no longer be desired by the patient.
At this time, it is important to understand which aspects of
further care the patient wishes to forego. In some cases, the
patient may want full supportive care while conscious, other
than actual resuscitation; in other circumstances, hospitaliza-
tion may no longer be desired for any intervention. Any deci-
sion to forego resuscitation should lead to possible deactiva-
tion of the life-saving function of an implanted defibrillation
device; the poor functional status of any patient should also
influence the decision regarding implantation of such a
device in the first place (669). To observe both the intent and
the directives of the patient and family, it is highly desirable
that outpatient, inpatient, and crisis management be super-
vised by the same team to diminish the hazards of fragment-
ed care during this period. The patient should be encouraged
to choose in advance a person to assume legal authority (i.e.,
designated power of attorney or healthcare proxy) for health-
care matters when the patient cannot be involved in deci-
sions. That individual should serve as the contact point for
the team. Rapid communications with this team will reduce
the conflicts and uncertainties that may arise when patients
are first seen in an emergent setting by physicians not nor-
mally involved in their care. The standing-care plans for each
patient need to be quickly accessible to all personnel likely
to be involved in the patient’s care. Professionals caring for
patients with advanced HF should have realistic expectations
for survival and communicate those accurately to patients
and families. Also, the professionals should provide realistic
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implementing practice guidelines for patients with HF can be
divided into 3 areas: isolated provider interventions, disease-
management systems, and use of performance measures.
8.1. Isolated Provider Interventions
A recent controlled trial has shown that the simple dissemi-
nation of an HF guideline followed by written and verbal
reminders about recommended actions was unable to change
the treatment of HF in the intensive care unit (681). Indeed,
an extensive literature has documented how difficult it is to
produce appropriate changes in physician behavior (682-
684). Basic physician education and passive dissemination of
guidelines alone are generally insufficient to sustain quality
improvement. Chart audit and feedback of results, reminder
systems to consider use of specific medicines or tests, and
the use of local opinion leaders have had variable results.
Multifactorial interventions that simultaneously attack dif-
ferent barriers to change tend to be more successful than iso-
lated efforts. For example, academic detailing, which
involves intensive educational outreach visits that incorpo-
rate communication and behavioral change techniques, has
been effective and is commonly used by pharmaceutical
companies (685). Thus, dissemination of a practice guideline
must be accompanied by more intensive educational and
behavioral interventions to maximize the chances of improv-
ing physician practice patterns.
8.2. Disease-Management Systems
The disease-management approach views HF as a chronic
illness that spans the home as well as outpatient and inpatient
settings. Most patients have multiple medical, social, and
behavioral challenges, and effective care requires a multidis-
ciplinary systems approach that addresses these various dif-
ficulties. Heart failure disease-management programs vary in
their content, but in general, they include intensive patient
education, encouragement of patients to be more aggressive
participants in their care, close monitoring of patients
through telephone follow-up or home nursing, careful review
of medications to improve adherence to evidence-based
guidelines, and multidisciplinary care with nurse case man-
agement directed by a physician. High-risk patients have
usually been chosen for such programs. 
Observational studies and randomized controlled trials
have shown that disease-management programs can reduce
the frequency of hospitalization and can improve quality of
life and functional status (146, 686). Patients at high risk for
clinical deterioration or hospitalization are likely to benefit
from disease-management programs and represent those for
whom such interventions are most likely to be cost-effective
(687). The largest successful randomized controlled trial of
disease management targeted elderly patients who had been
hospitalized for HF, had a prior history of HF, had 4 or more
hospitalizations within 5 years, or had an HF exacerbation
caused by an acute MI or uncontrolled hypertension (143).
Patients randomized to the disease-management program
had significantly fewer hospitalizations and a reduced cost of
8. IMPLEMENTATION OF
PRACTICE GUIDELINES
RECOMMENDATIONS
Class I
1. Academic detailing or educational outreach visits are
useful to facilitate the implementation of practice
guidelines. (Level of Evidence: A)
2. Multidisciplinary disease-management programs for
patients at high risk for hospital admission or clinical
deterioration are recommended to facilitate the
implementation of practice guidelines, to attack dif-
ferent barriers to behavioral change, and to reduce
the risk of subsequent hospitalization for HF. (Level of
Evidence: A)
Class IIa
1. Chart audit and feedback of results can be effective to
facilitate implementation of practice guidelines. (Level
of Evidence: A)
2. The use of reminder systems can be effective to facili-
tate implementation of practice guidelines. (Level of
Evidence: A)
3. The use of performance measures based on practice
guidelines may be useful to improve quality of care.
(Level of Evidence: B)
4. Statements by and support of local opinion leaders
can be helpful to facilitate implementation of practice
guidelines. (Level of Evidence: A)
Class IIb
Multidisciplinary disease-management programs for
patients at low risk for hospital admission or clinical
deterioration may be considered to facilitate imple-
mentation of practice guidelines. (Level of Evidence:
B)
Class III
1. Dissemination of guidelines without more intensive
behavioral change efforts is not useful to facilitate
implementation of practice guidelines. (Level of
Evidence: A)
2. Basic provider education alone is not useful to facili-
tate implementation of practice guidelines. (Level of
Evidence: A)
Despite the publication of evidence-based guidelines (147,
675), the current care of patients with HF remains subopti-
mal. Numerous studies document underutilization of key
processes of care, such as use of ACEIs in patients with
decreased systolic function and the measurement of LVEF
(513, 676, 677). The overall quality of inpatient care for HF
as judged by both explicit and implicit standards is variable,
with lower quality associated with higher readmission rates
and mortality (491, 678, 679). Many HF admissions may be
prevented with good outpatient care (680). The literature on
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care compared with patients in the control group. However,
it is not clear which elements of disease-management pro-
grams are crucial for success. In addition, it is not known
whether such interventions are feasible in settings with lim-
ited resources and personnel and among diverse patient pop-
ulations.
8.3. Performance Measures
Performance measures are standards of care for a particular
illness or condition that are designed to assess and subse-
quently improve the quality of medical care. Performance
measures are chosen on the basis of the knowledge or
assumption that the particular item is linked to improved
patient outcomes. In the field of HF, such measures might
include documentation of the level of LV function, medica-
tions used, or patient education measures. These measures
can be used either internally within an organization or pub-
licly to compare the performance of providers, hospitals, and
healthcare organizations. In theory, performance measures
could improve care by encouraging providers to compete on
the basis of quality as opposed to cost, empowering con-
sumers to make informed choices in the marketplace, pro-
viding incentives to providers to concentrate on certain dis-
eases or processes of care, and supplying information to aid
with internal quality improvement. The evidence is mixed,
but some studies indicate that performance measures can
improve health outcomes (688).
The ACC and AHA are collaborating with a variety of
organizations to develop and implement performance meas-
ures. ACC/AHA practice guidelines are useful starting points
for performance measures, but several considerations apply:
1) ACC/AHA practice guidelines are designed for improving
the care of individual patients. Performance measures are
generally used for improving the care of populations of
patients. Although significant overlap exists in these goals,
performance measures need to take into account additional
factors, such as ease of data collection, simplicity of stan-
dards, calculation of sufficient numbers of patients for whom
the measure would apply, and provision of flexibility for
clinically diverse situations. 2) In general, most performance
measures should be chosen from Class I and Class III prac-
tice guideline recommendations; however, given the addi-
tional factors involved in improving the care of populations
of patients, Class IIa recommendations may be suitable in
selected situations. 3) Opportunities should be given for cli-
nicians to describe why a particular performance measure
may not be appropriate for an individual patient.
8.4. Roles of Generalist Physicians and
Cardiologists
Insufficient evidence exists to allow for recommendations
about the most appropriate roles for generalist physicians
and cardiologists in the care of patients with HF. Several
studies indicate that primary care physicians as a group have
less knowledge about HF and adhere to guidelines less close-
ly than cardiologists (689-691). Some studies have noted bet-
ter patient outcomes in patients cared for by cardiologists
than in those cared for by generalist physicians (692, 693),
whereas another study reported that cardiologists deliver
more costly care that is accompanied by a trend toward
improved survival (694). Despite these observations, pri-
mary care physicians with knowledge and experience in HF
should be able to care for most patients with uncomplicated
HF. By contrast, patients who remain symptomatic despite
basic medical therapy may benefit from care directed by con-
sulting physicians who have special expertise and training in
the care of patients with HF. 
Do generalist physicians and cardiologists provide similar
levels of care for the noncardiac comorbid conditions fre-
quently present in patients with HF? What is the optimal time
for referral to a specialist? What is the most effective system
of comanagement of patients by generalists and cardiolo-
gists? What is the most cost-effective entry point into a dis-
ease-management program? Regardless of the ultimate
answers to these questions, all physicians and other health-
care providers must advocate and follow care practices that
have been shown to improve patient outcomes. If a physician
is not comfortable following a specific recommendation
(e.g., the use of beta-blockers), then the physician should
refer the patient to someone with expertise in HF. A collabo-
rative model in which generalist and specialist physicians
work together to optimize the care of patients with HF is
likely to be most fruitful. 
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EF = ejection fraction
HF = heart failure
HIV = human immunodeficiency virus 
ICD = implantable cardioverter-defibrillator
LV = left ventricular; left ventricle
LVEF = left ventricular ejection fraction
LVH = left ventricular hypertrophy
MI = myocardial infarction
NYHA = New York Heart Association
VT = ventricular tachycardia
APPENDIX 3. ABBREVIATIONS
ACC = American College of Cardiology
ACE = angiotensin converting enzyme
ACEI = angiotensin converting enzyme 
inhibitor
AHA = American Heart Association
ARB = angiotensin II receptor blocker
ATPase = adenosine triphosphatase
BNP = B-type natriuretic peptide*
CRT = cardiac resynchronization therapy
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